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Abstract
Mutations in the gene encoding parkin (PARK2) result in familial early onset forms of
Parkinson’s disease (PD) as a result of loss of E3 ubiquitin ligase function. Protein
misfolding is a common molecular feature of most neurodegenerative diseases, including
PD. To test whether parkin misfolding also plays a role in the more common spontaneous
PD, we established and functionally characterized a parkin yeast model. We found that
oxidative and protein folding stress, parkin point mutations and truncations, and parkin’s
interaction with the PD-associated kinase PINK1 profoundly alter parkin’s subcellular
localization and toxicity. Notably, these conditions also induce parkin fragmentation,
degradation, and potential misfolding, all of which may contribute to PD pathogenesis.
Future research presents great potential to establish parkin misfolding as a promising new
therapeutic target for PD.
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Chapter One: Introduction
Neurodegenerative diseases are a broad spectrum of disorders with a wide variety
of symptoms and clinical presentations that are all caused by degeneration or death of
neuronal cells. The most common neurodegenerative disorders include Alzheimer’s
disease (AD), which can be attributed to the majority of dementia cases, Huntington’s
disease (HD), a heritable disease that results in loss of cognitive function and sporadic jerky
movements, and Parkinson’s disease (PD), which is the second most common cause of
neurodegeneration resulting in loss of motor control. In general, neuronal cell death occurs
in the brain, but these diseases can also affect motor neurons in the periphery as seen in
Amyotrophic Lateral Sclerosis (ALS). Unlike many other cell types, neurons are postmitotic during life and cannot regenerate, thus making these conditions permanent and
mostly incurable. Neurodegenerative diseases are usually late onset, as they are often
associated with aging that leads to the gradual accumulation of toxic molecules, for
example, reactive oxygen species (ROS) within neurons that damage cellular components
over time. Human cells, including neurons, contain multiple cellular pathways that act to
prevent accumulation of cytotoxic proteins. These processes can be generally classified as
protein quality control machinery.

1.1

Protein Quality Control
In order to maintain cellular homeostasis and overall cell health, protein quality

control machinery must ensure accurate protein production, maintenance, and turnover.
One of the main causes of cell damage is the accumulation of damaged or misfolded
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proteins, which are often toxic to the cell. Protein damage or protein misfolding can occur
in response to many factors, particularly oxidative stress.
1.1.1

Oxidative Stress
ROS play a vital role in maintaining normal cellular processes, including cell

growth, immune response, and the synthesis of biological molecules (1,2). However, ROS
are also associated with aging and many diseases, including cancer and neurodegenerative
disorders. They are highly reactive and thus have the potential to cause major cellular
damage to proteins, nucleic acids, and lipids. In healthy cells, there is a balance of pro- and
anti-oxidants that maintain healthy levels of ROS, but an imbalance of these reagents can
lead to excessive accumulation of ROS, which is often seen in aging. Mitochondria are one
of the major sources of ROS because superoxide anions (O2●-) are a natural byproduct of
cellular respiration (3). Normally, superoxide anions are reduced to hydrogen peroxide
(H2O2) by manganese superoxide dismutase (SOD1) which can be further reduced to water
and oxygen by catalase (4), but the failure of SOD1 or catalase can lead to the accumulation
of O2●- or H2O2, respectively. Because of its single unpaired electron, superoxide is highly
reactive and can generate other ROS including hydroxide radicals (OH●) and hypochlorous
acid (HClO). The accumulation of excessive amounts of ROS can damage cellular proteins
by causing them to lose proper function. This often leads to misfolding as a result of
changes in the protein’s hydrophobic properties, consequently leading to protein
aggregation (5). Due to the gradual accumulation of ROS over time, oxidative stress has
been strongly implicated in many age related diseases, including neurodegeneration (6).
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Oxidative damage to proteins occurs when amino acids of proteins are posttranslationally modified by ROS. There are many ways ROS can modify proteins, and the
most common type of modification is to the thiol group of cysteine residues which are
highly sensitive to oxidative damage (7). While they are coded for much less frequently
than other amino acids (8), cysteines play an important role in maintaining protein structure
and function. When the thiol groups of two cysteines are in close proximity, it is possible
for them to form a disulfide bond whereby two free thiol groups form a covalent bond with
one another (7). This process can occur between two cysteines within the same protein
(intramolecular) or between cysteines of two separate proteins (intermolecular). These
interactions are required for proper tertiary or quaternary protein structure, respectively.
Due to their polar nature, cysteines are also capable of coordinating metal ions within
proteins that are also required for maintaining proper three-dimensional structure, which
involves the free thiol side chain.
Under normal cellular conditions, cysteines can freely revert between their free
thiol and disulfide forms, but the presence of excessive amounts of ROS can forcibly
convert these residues from one form to another, preventing proper function. This often
results in the formation of aberrant disulfide bonds within or between proteins, which
disrupts their three-dimensional conformation. Additionally, ROS are capable of
converting thiols to sulfur based acids, which are incapable of performing either of the
normal functions of cysteines. In the presence of low amounts of ROS, free thiols (-SH)
can be converted to sulfenic acid (-SOH), which can be reverted back to a free thiol and
resume normal function when ROS levels are reduced (7). Alternatively, if ROS levels are
much higher, -SOH is converted sulfinic acid (-SO2H) and subsequently, sulfonic acid
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(-SO3H), both of which occur irreversibly. In this situation, the proteins are damaged
beyond repair and are typically targeted for degradation (7).
1.1.2

Protein Quality Control Machinery
As mentioned above, protein structure and function are closely linked. When

proteins are unable to form their native confirmation (misfold), which can occur naturally
as a result of mutation or in response to protein damage, they often lose their ability to
function properly and have an increased propensity to aggregate. The processing of
damaged or misfolded proteins is essential in maintaining protein homeostasis, and the
failure of this process can result in cellular dysfunction or cell death, which is associated
with many diseases. Cells have two major systems for eliminating damaged and misfolded
proteins (Figure 1-1):
1) The molecular chaperone machinery. Most proteins require the assistance of
molecular chaperones during and after translation to attain their accurate three-dimensional
structure (9, 10). This process either occurs in the cytosol or proteins can be directed to the
endoplasmic reticulum, mitochondria, or other cellular organelles, for further processing
(11, 12). By changing the immediate local chemical and physical environment surrounding
misfolded proteins, chaperones promote refolding, thus facilitating proper folding and
reducing the accumulation of damaged proteins. Not surprisingly, dysfunction of the
molecular

chaperone

machinery

has

been

strongly

implicated

in

multiple

neurodegenerative disorders (13) and has also been identified as a target for therapeutic
intervention (10, 15, 16).
2) The ubiquitin proteasome system (UPS). UPS is the second system that is
essential for protein homeostasis, which is shown in Figure 1-2. The addition of ubiquitin
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to a substrate protein (ubiquitination) plays a large role in protein regulation by altering
cellular localization, effecting interactions with other proteins, and with particular
relevance to this study, targeting damaged proteins for degradation. The UPS acts to
transfer ubiquitin successively through E1, E2, and E3 enzymes to build mono- or polyubiquitin chains on substrate proteins (17). Following ubiquitination, substrate proteins are
directed to the 26S proteasome where they are degraded. Humans contain nine genes
encoding E1 ubiquitin activating enzymes, two of which are involved in ubiquitin
conjugation in the UPS (18–20), about 40 genes for E2 ubiquitin conjugating enzymes, and
over 600 genes for E3 ubiquitin ligases (21). Each class of enzyme contains structural
similarities that are required to facilitate ubiquitin transfer, but they also have differences
that affect their regulation and it is this diversity that differentiates substrate recognition.
Dysregulation of the UPS is a highly studied field and research has shown its involvement
in cancer (22, 23), cardiovascular disease (24, 25), and neurodegenerative diseases (26,
27).
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Figure 1-1. Cellular protein quality control. 1) Following transcription, mRNA is
directed to the ribosome for translation which often required co-translational assistance
from molecular chaperones like HSP40s and HSP70s. 2) Fully translated proteins mature
and obtain their proper functional three-dimensional conformation. 3) The buildup of
damaging molecules over time as a result of aging, environmental exposure, or cellular
dysfunction causes protein damage leading to misfolding whereby the protein can no
longer function properly. 4-5) Molecular chaperones can recognize damaged proteins and
assist in their refolding which will cause them to re-attain their proper three-dimensional
conformation and resume normal function. 6) Proteins that are damaged beyond repair are
recognized by the UPS and ubiquitinated to target them for degradation by the 26S
proteasome. 7) Failure of one or both of these cellular protein quality control mechanisms
can lead to the accumulation of misfolded proteins leading to protein aggregation which
can be toxic to the cell or even cause cell death.
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Figure 1-2. The ubiquitin proteasome system (UPS).

Figure 1-2. The ubiquitin proteasome system (UPS). 1) Unmodified ubiquitin is
activated with the use of ATP and bonded to an E1, ubiquitin activating enzyme. 2)
Activated ubiquitin is transferred from an E1 to an E2, ubiquitin conjugating enzyme. 3)
An E2 ubiquitin conjugate interacts or docks with an E3, ubiquitin ligase. 4) The E2-E3ubiquitin complex comes in contact with a protein substrate which is properly oriented by
the E3. 5) A poly-ubiquitin chain is built on the substrate protein either by direct transfer
of ubiquitin from the E2 enzyme, or through a sequential transfer of ubiquitin from E2 to
E3 to substrate. 6) The ubiquitinated substrate is directed to the 26S proteasome where the
substrate protein is degraded into proteolytic fragments. 7) Ubiquitin is recycled and is
ready for use in the UPS or other cellular pathways.
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1.2

Neurodegenerative Disease
Many neurodegenerative diseases are caused by genetic mutations. These genetic

or familial forms often present a more severe phenotype and an earlier onset than sporadic
cases. Notably, neurodegenerative-associated genes and proteins have distinct functions
and structures, cause dysfunction and cell death in distinct sets of neurons, and cause
distinct symptoms. That being said, there are several features that are common and central
to many, if not all neurodegenerative diseases.
One common feature of neurodegenerative diseases, that can also cause other
human diseases, is loss of function (LOF) mutations, whereby an inherited mutation in a
specific gene causes a protein to lose its proper function, leading to cell death. Examples
of neurodegenerative diseases caused by heritable loss of function mutations include nonsense mutations causing premature transcriptional termination of the glutamine superoxide
dismutase (SOD1) protein causing ALS (28), and any of the several heritable mutations of
in the PARK gene family causing PD (29).
The second common feature of neurodegenerative diseases is toxic gain of function
(GOF) mutations. Similar to LOF mutations, GOF mutations can be genetically inherited
or acquired over time. Instead of losing their proper function, GOF mutations often cause
proteins to misfold and aggregate, dragging other essential proteins into large insoluble
protein aggregates that can be cytotoxic (30). The accumulation of protein aggregates
overloads the protein quality control machinery, causing further stress to the cell by
disrupting normal cellular processes. An example of neurodegeneration caused by toxic
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GOF mutations is α-synuclein mutations causing the formation of Lewy Bodies leading to
PD (31, 32).
Another hallmark of neurodegenerative disorders is the accumulation of damaged
or misfolded proteins into insoluble plaques or aggregates. The accumulation of aggregated
of misfolded proteins has been proposed to be cytotoxic. Recent studies have suggested,
however, that protein aggregation can indeed play a protective role in cells by sequestering
potentially toxic protein species, thereby reducing their potential to damage the cell (33).
Some well-established examples of disease-associated protein aggregates include
neurofibrillary tangles made of the protein tau and plaques made of amyloid fibrils of the
Aβ peptide in AD (34), nuclear and cytosolic aggregates made of polyglutamine repeat
proteins in HD and Spinocerebellar Ataxia Type 1 (36), and Lewy Bodies made primarily
of α-synuclein in PD (37). As stated above, the major cellular systems that neutralize or
eliminate misfolded proteins are 1) refolding via molecular chaperones and 2) degradation
via the UPS or autophagy.
Although research over the past decades has discovered the genetic cause of many
of these diseases, the underlying mechanisms of how they cause neuronal damage and cell
death are still widely unknown. Furthermore, there is even less understanding of what
causes the much more common sporadic cases of neurodegenerative diseases and their
underlying mechanisms.
1.2.1

Alzheimer’s Disease
AD is the most common neurodegenerative disorder and the most common cause

of dementia, accounting for 60-70% of all cases of dementia (38). Like most
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neurodegenerative disorders, this disease generally has a late age of onset, usually
presenting after 65 years of age. Patients experience progressive neurological deterioration
with the most common symptom being memory loss. There are cases of early onset AD
which are more frequently seen in cases of familial inheritance. Pathology of Alzheimer’s
patients presents with the classical protein aggregates, referred to as plaques, which
overload the protein quality control machinery. Alzheimer’s plaques are predominantly
made of Aβ, a short amino acid peptide made of fragments of the amyloid precursor protein
(APP). The tau protein, whose normal function is to stabilize microtubules, can also been
found in Alzheimer’s protein aggregates, but this is likely due to mis-sorting of the protein
caused by Aβ. Although environmental exposure and lifestyle choices, such as smoking,
can increase the risk of developing Alzheimer’s disease, there is no evidence that there is
any way to prevent disease development (38,39). There is currently no cure for Alzheimer’s
disease and no available treatment to slow or prevent disease progression. Treatment
options, which consist of five different compounds, are only intended to manage
neurological symptoms (41).
1.2.2

Huntington’s Disease
Unlike most other neurodegenerative diseases, HD is solely caused by one protein

known as huntingtin (Htt). HD occurs as a result of the expansion of a polyglutamine
(polyQ) region within Htt, which causes the protein to misfold and form aggregates, again
stressing the protein quality control machinery. The regular function of the Htt protein is
still unknown, but it is expressed at the highest levels in the brain and testes (42). HD
generally presents between 35 and 45 years of age, but symptoms can begin during infancy
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or late in life depending on the size of the polyQ expansion. The wild-type Htt protein
contains less than 36 glutamine repeats and expansion of the polyQ track causes increased
disease severity and leads to an earlier age of onset which is directly correlated to the length
of the polyQ expansion. HD heritability is dominant, where one mutant copy of the gene
can drag normal copies of the protein into Htt aggregates. There are currently no treatments
available to prevent or eliminate Htt aggregates, but several treatments have been used to
manage symptoms which include jerky, random, and uncontrollable movements known
as chorea.
1.2.3

Amyotrophic Lateral Sclerosis
ALS, made famous by the baseball player Lou Gehrig, is different than most other

neurodegenerative diseases as it affects motor neurons in the periphery rather than in the
brain. ALS is progressive, with neurons in the extremities being affected first which leads
to movement difficulties that gradually causes paralysis of the arms and legs. Patients
generally do not experience any cognitive symptoms but they eventually lose the ability to
speak, chew, or swallow, and typically succumb to respiratory failure after cell death
occurs to motor neurons controlling the diaphragm. This condition is also different from
most other neurodegenerative diseases because of its rapid progression. After onset,
patients typically survive for only three to four years. ALS can be heritable, whereby
mutations in the genes encoding SOD1 (43), FUS, TDP-43 (44), C9Orf72 (45), the recently
discovered RGNEF (46, 47), and more can cause ALS, but these only account for a small
proportion of all ALS cases. Pathology of ALS patients is a proteinopathy where proteins
form potentially toxic aggregate as seen in other neurodegenerative diseases. There is
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currently no cure for the disease and the only available treatment is a drug called riluzole,
which only extends patients’ lifespan by approximately three months.

1.3

Parkinson’s Disease
PD is the second most common neurodegenerative disease affecting more than 100

000 Canadians and typically has a late age of onset, which occurs around 70 years of age
(48). Patients experience progressive neurodegeneration that results in a variety of physical
manifestations including resting tremors, rigidity, postural instabilities, and staggered gait.
PD cases can be classified into two categories: familial and non-familial, also referred to
as sporadic or idiopathic PD; in both cases, patients experience loss of dopaminergic
neurons in the substantia nigra resulting in decreased dopamine uptake at neural synapses
(49). Inherited forms of PD have been linked to seven genes with various functions (Table
1-1). One of the most common pathologies seen in PD patients is the formation of Lewy
Bodies composed primarily of -synuclein which can be inherited in an autosomal
dominant manner (50). Although inherited PD is associated with one or more mutations in
the PARK family of genes, these only account for approximately 10% of all cases of PD.
In cases of idiopathic PD, which account for the remaining 90% of PD cases, the
relationships between these proteins is extremely complex. Although pathogenic mutations
in single genes have been identified in familial PD (51), it is plausible to speculate that
there is an intricate interplay between these genes that cause cases of sporadic PD (52–54).
This study focuses predominantly on the role of parkin (PARK2) in idiopathic PD and how
dysregulation of the protein quality control machinery may also be involved.
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Table 1-1. PARK family of genes involved in inherited Parkinson’s disease.
Gene

Protein

Inheritance

Function

PARK1

-synuclein

Dominant

Presynaptic protein

PARK2

parkin

Recessive

Ubiquitin E3 ligase

PARK5

UCH-L1

Dominant

Ubiquitin hydrolase

PARK6

PINK1

Recessive

Mitochondrial kinase

PARK7

DJ-1

Recessive

Chaperone

PARK8

LRRK2

Dominant

Kinase

PARK13

HTRA2

Unknown

Serine proteinase

1.3.1

Parkin – An E3 Ubiquitin Ligase
Research on parkin began in 1998 with the discovery of a mutation in the PARK2

gene, which is located on the long arm of chromosome 6, by Tohru Kitada et al. in a
Japanese family (55). This study showed that parkin contains amino acid similarity to
ubiquitin from residues 1-76 and high cysteine content in the remainder of the protein.
They also established, based on exon deletions found in five patients, that parkin is linked
to Autosomal Recessive Juvenile Parkinsonism (AR-JP), an early onset form of PD that
affects individuals less than 40 years of age. AR-JP is pathologically very similar to PD,
as patients exhibit the same decreased sensitivity to dopamine in the substantia nigra and
experience the same progressive neurodegeneration and loss of motor control at a much
younger age. Also similar to PD, AR-JP mutations are often inherited in an autosomal
recessive manner, many of which map to the PARK2 gene encoding parkin (Figure 1-3).
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Figure 1-3. Mutations and deletions in the PARK2 gene causing Parkinson’s disease.
(56, 57)

Figure 1-3. Mutations and deletions in the PARK2 gene causing Parkinson’s disease.
A) Schematic representation of the PARK2 gene showing known exon deletions, frameshift
mutations, non-sense mutations, and splicing mutations causing Parkinson’s disease. B)
Schematic representation of the parkin protein encoded by the PARK2 gene and its
functional domains showing known nonsense mutations causing Parkinson’s disease. The
highlighted red missense mutations in B) were used in this study to assess parkin
misfolding. Modified from (55, 56).
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Figure 1-4. Parkin is an E3 ubiquitin ligase involved in the UPS.

Figure 1-4. Parkin is an E3 ubiquitin ligase involved in the UPS. (A) Schematic
representation of parkin domains based on structural determination by NMR containing an
N-terminal Ubl domain, which acts to auto-inhibit parkin activity, and a C-terminal
Rcat/RING2 domain required for catalytic transfer of ubiquitin. (B) The role of parkin as
an E3 ligase in UPS which acts to transfer ubiquitin from E2 to target substrate.
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Following its initial discovery in the context of AR-JP, work by several groups
focused on deciphering parkin’s regular function and its altered function that causes PD
development. Initially, sequence homology was used to define the functional domains
within parkin where, in addition to the N-terminal ubiquitin-like domain, three additional
domains were proposed based on sequence homology, which included two Really
Interesting New Gene (RING) domains (58). Since its discovery, a fifth domain (RING0)
has also been described within parkin, and our understanding of its function has vastly
increased (59).
We now know that human parkin is a 465 residue protein made up of five domains
and functions as an E3 ubiquitin ligase in the UPS (Figure 1-4). Parkin is classified as an
RBR (RING1-BRcat-Rcat, formerly known as RING1-inBetweenRING-RING2) E3 ligase
(60). Its functions are twofold during the process of ubiquitin transfer: 1) it acts as a
scaffold to orient the E2 enzyme for the transfer of ubiquitin to substrate proteins, and 2)
parkin accepts ubiquitin onto a catalytic cysteine located in the Rcat/RING2 domain before
transferring it to the substrate protein. This action differs from the RING class E3 enzymes
that only act as a scaffold between the E2 and protein substrate (61) and from homologous
to the E6-AP carboxyl terminus (HECT) E3 ligases that accept activated ubiquitin onto a
catalytic site before interacting with and subsequently ubiquitinating substrate proteins
(62). Parkin can therefore be classified as a RING/HECT hybrid. Previous work in our lab,
in addition to work by several other groups, has studied parkin structure, exploring its
regulation and the dynamics involved in ubiquitin transfer using nuclear magnetic
resonance (NMR) spectroscopy and other methods (63–65). These studies have shown that
the N-terminal Ubl domain of parkin acts to inhibit parkin ubiquitination by folding back
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on itself, blocking surfaces of the protein required for ubiquitin transfer and E2 docking.
They have also shown that this inhibition can be regulated through phosphorylation of the
Ubl domain and ubiquitin, both at Serine 65 by PTEN-induced putative kinase 1 (PINK1),
a PD-associated kinase. Structural studies have also established that the four C-terminal
domains of parkin each coordinate two Zn2+ ions that are essential for structural stability
of the protein (59).
In addition to the extensive research aimed at understanding parkin at a structural
level, there have also been significant efforts made to understand parkin function at a
cellular level. Prior to the recent discovery of the connection between parkin and PINK1,
which will be discussed below, the majority of parkin related research was focused on its
role as an E3 ligase. AR-JP causing loss-of-function mutations are found across the entire
length of the PARK2 gene. These mutations are comprised of point mutations (missense,
nonsense or frame shift) and deletions across one or more exons, resulting in early
termination or truncation (66, 67). Functional studies have implied the ubiquitination and
subsequent degradation of many different proteins by parkin, including CDrel-1, a GTPase
expressed in the nervous system, and Pael-R, a G-protein coupled transmembrane protein
expressed in dopaminergic neurons. The literature also describes hundreds of potential
parkin substrates that have been detected by high throughput screens (68) and in vitro
testing (69). Most of these substrates have not been confirmed independently and it remains
to be determined whether there are changes in the levels of these proteins upon
dysregulation of parkin.
Although many studies associate parkin to PD through its inability to prevent the
accumulation of damaged protein, work by several groups suggest that pathogenic parkin
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mutants induce parkin misfolding and aggregation. Schlehe et. al have shown that the ARJP causing R42P is actively degraded by the proteasome upon expression (70). Similar
aggregation patterns have been shown by Wen-Jie et. al using mutations of two cysteine
residues that normally co-ordinate binding of structural zinc ions. They show that these
mutants not only form perinuclear aggregates, but also disrupt the co-localization of parkin
with two different E2 enzymes, UbcH7 and UbcH8 (71). 1-methyl-4-phenylpyridinium
(MPP+) is a positively charged molecule that induces ROS accumulation by inhibiting
complex I, interfering with oxidative respiration. Parkin has been found in insoluble
fractions of SH-SY5Y cells experiencing excess accumulation of MMP+ induced ROS and
in non-familial PD patient brain samples (72). In addition to these results, the proposed
association of parkin with alpha-synuclein within Lewy bodies (73, 74) gives additional
support to the claim that aggregation of insoluble mutants or oxidatively damaged parkin
plays an important role in the pathogenesis of idiopathic PD. Overall, it remains mostly
unclear how parkin is oxidized under stress conditions and how missense mutations cause
misfolding and subsequent PD.
1.3.2

Parkin’s Role in Mitophagy
Parkin has been implicated in the degradation and turnover of damaged

mitochondrial proteins and entire mitochondria (mitophagy, (75, 76)), and it is suggested
that this activity is induced by PINK1 mediated phosphorylation (77, 78). PINK1 is a
serine/threonine kinase that contains an N-terminal mitochondrial targeting sequence
(MTS) that is used to direct and anchor PINK1 to the mitochondria and a C-terminal kinase
domain (79). Currently there is not a clear consensus on where PINK1 is anchored to the
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mitochondria as some studies suggest that it undergoes processing and cleavage at the inner
mitochondrial membrane (80), while others propose that PINK1 is directed to and interacts
with the outer membrane in response to loss of membrane potential, leaving the C-terminal
kinase lobe facing the cytosol to interact with ubiquitin, parkin, or other proteins (77, 81).
There are over 50 recessive mutations to PINK1 that can cause PD and studies suggest that
these mutations inhibit parkin meditated protein degradation by inhibiting PINK1
phosphorylation and recruitment of parkin, or by preventing PINK1 translocation to the
mitochondria, also preventing parkin activation (82).
Narendra et. al have shown that PINK1 is normally degraded in the cytosol in
HeLa cells, but upon mitochondrial damage following carbonyl cyanide m-chlorophenyl
hydrazone (CCCP) treatment, damaged mitochondria lose their membrane potential.
CCCP damages mitochondria by uncoupling the proton gradient established by the electron
transport chain during oxidative respiration (83). This study showed that the loss
mitochondrial membrane potential causes PINK1 to be selectively recruited and anchored
to the outer mitochondrial membrane. They further showed that parkin only localizes to
mitochondria of CCCP treated cells when PINK1 is present (84). Although this study
provides strong evidence that PINK1 is required for parkin recruitment, this does not
explain the mechanism by which this recruitment of parkin to mitochondria and the ensuing
mitophagy occurs. Figure 1-5 shows one potential model of how PINK1 recruits and
activates parkin. Previous studies suggest that parkin recruitment is activated by: 1)
phosphorylation of free ubiquitin to activate parkin (85), 2) by phosphorylation of one of
several mitochondrial proteins, such as TOM20 or mitofusin 2, to recruit parkin
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Figure 1-5. Activation of parkin mediated mitophagy of damaged mitochondria by
PINK1.

Figure 1-5. Activation of parkin mediated mitophagy of damaged mitochondria by
PINK1. 1) Following its transport to damaged mitochondria, 2) PINK1 phosphorylates
parkin and ubiquitin. 3) Phospho-parkin undergoes a closed-to-open conformational
change and becomes more active, 4) directing it to damaged mitochondria, while PINK1
phosphorylation of ubiquitin is required to activate parkin. 5) While at the mitochondrial
membrane, activated phospho-parkin ubiquitinates damaged mitochondrial proteins
leading to 6) their degradation by the 26S proteasome or lysosomal degradation of damaged
mitochondria (mitophagy).
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for ubiquitination (86, 87), or 3) direct phosphorylation of S65 in the ubiquitin-like domain
of parkin by PINK1, which converts parkin to an open or “active” conformation, priming
it for ubiquitination (88). Ultimately, the recruitment of parkin to damaged mitochondria
causes ubiquitination of damaged mitochondrial proteins, and subsequently, lysosomal
degradation. Notably, these models are highly controversial because the published
experimental data has not allowed researchers to draw a definite conclusion regarding the
mechanism of parkin activation by PINK1. Additionally, a direct interaction between
PINK1 and parkin has yet to be demonstrated.

1.4

Yeast Models
Saccharomyces cerevisiae, commonly known as baker’s or brewer’s yeast, is a

model organism that has many advantages that make that it an excellent model system to
study human diseases. Yeast is a single celled eukaryote that contains membrane bound
organelles found in higher order eukaryotes and as a result, many key cellular pathways
and processes relevant to human disease are conserved. As a unicellular organism, yeast
can be grown in isolation as they do not require the release of growth factors from
neighboring cells, which is often required for mammalian systems. In the laboratory, yeast
is relatively easy to handle and has extremely short generation times, but the greatest power
of the system comes from the ease of genetic manipulation. The yeast genome is
considerably smaller than that of humans, with about 25% of the total number of genes
found in humans (89). This smaller size has enabled the identification and characterization
of each and every yeast gene to test whether they are essential and identify any phenotypes
associated with deletion or over-expression. To this end, comprehensive deletion and over-
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expression libraries have been generated that allow for high-throughput screening for
genetic interactions, which is not possible in any model other organism. Furthermore, yeast
can exist in both a diploid and haploid state, so it can be used to study the effects of
heterozygous deletions or mutations.
1.4.1

Yeast Models of Neurodegeneration
Many established yeast models have been and are currently used to study human

disease and one prominent class of human diseases studied in yeast are neurodegenerative
disorders. One of the best-established yeast models of neurodegeneration is the polyglutamine expansion causing HD. Yeast HD models have established that polyQ expanded
Htt exhibits tendencies to aggregate that are reminiscent of those found in human cells and
have also shown the same toxicity associated with polyQ expansion (90, 91). Since its
establishment, this model has been used to study how protein misfolding and aggregation
can be modulated by molecular chaperones like heat shock protein (HSP) 70 and has
identified this class of proteins as a potential for therapeutic intervention (92, 93). Other
established yeast models for neurodegenerative diseases include Aβ models of Alzheimer’s
disease (94–96), and ALS models investigating SOD1, FUS, and TDP-43 aggregation and
toxicity (97, 98).
1.4.1.1 Parkinson’s Disease Yeast Models
There are also several established yeast models for PD associated genes and
mutations. Of these genes, α-synuclein is the most well characterized model (99–101).
Yeast models of α-synuclein, like yeast Htt models, closely mimic α-synuclein behavior in
mammalian cells, showing transport of α-synuclein to the cell membrane under normal
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levels of expression (102) and following accumulation (mimicked by overexpression), αsynuclein forms cytoplasmic inclusion that are similar to Lewy Bodies in human patients
(103). With this established model, researchers have been able to further characterize the
effects of specific point mutants (100), clearance of α-synuclein aggregates (104), and the
effects of the ribosomal chaperone RPS3A (105). Yeast models have also been used to
characterize the PD associated chaperone DJ-1. Under normal conditions in human cells,
DJ-1 is a redox sensitive chaperone that acts to prevent α-synuclein aggregation (106, 107).
Yeast models frequently use the Saccharomyces cerevisiae protein HSP31, which is a
member of the DJ-1 superfamily of chaperones. Although HSP31 deletion strains do not
exhibit a phenotype compared to wild-type yeast under normal conditions, they do have an
increased sensitivity to oxidative stress (108). There has also been one recent parkin yeast
model published in 2015 (109).
It must be noted that because yeast is a simple model system, results obtaining using
this model may not always directly translate into human cells, therefore, they must be
carefully interpreted and validated in other system. Nevertheless, yeast models can give
new insight into protein function and potential therapeutics by focusing on conserved
pathways including protein quality control, UPS, and protein misfolding, making it a highly
versatile and capable model system.

25

Figure 1-6. Parkin truncation variants and point mutants.

Figure 1-6. Parkin truncation variants and point mutants. Schematic representation of
generated parkin (A) truncation variants and (B) point mutants used in this study.
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1.5

Rationale, Hypothesis, Objectives, and Significance

1.5.1

Rationale

Parkin dysfunction can cause PD, but the underlying mechanisms causing disease
development and progression remain unresolved. Independent evidence suggests that
regulation by PINK1, loss of function caused by mutations, and misfolding can all
contribute to PD development. Additionally, there currently is not an effective animal
model that has clarified the role of parkin misfolding and ensuing cellular outcomes that
lead to PD.
1.5.2

Hypotheses

1) Parkin truncations and point mutations alter cell growth and disrupt normal
parkin localization.
2) Parkin is involved in genetic interactions with genes required for oxidative stress
management and preventing protein misfolding.
3) Oxidative stress damages parkin resulting in misfolding and altered cellular
localization.
4) PINK1 interacts with parkin to disrupt parkin localization and stability
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1.5.3

Objectives

1) Establish a functional parkin yeast model
A yeast model expressing parkin and several parkin mutants (Figure 1-6) was established.
The system was used to identify how dysregulation of parkin affected growth, and altered
localization with the use of growth assays and fluorescence microscopy, respectively.
Parkin variants bearing N- and C-terminal truncations allowed mapping and
characterization of results based on functional knowledge of each domain. Additionally,
two parkin point mutants were selected that have an increased propensity to misfold. These
mutants were used to compare oxidative stress induced misfolding to aggregation caused
by pathogenic AR-JP mutants. Two additional mutations to S65, the serine residue
phosphorylated by PINK1 (88), were used to monitor how parkin aggregation and toxicity
changed in the absence of PINK1-mediated phosphorylation.
2) Identify genetic interactions that alter parkin misfolding and toxicity
We tested how parkin localization is affected by the deletion of key genes involved in
managing oxidative stress and protein misfolding by performing a pilot screen using yeast
deletion libraries. Changes in growth and parkin localization were examined by spotting
assays and fluorescence microscopy, respectively.
3) Assess how oxidative stress alters folding and localization of parkin
The effects of oxidative stress treatment towards parkin localization, toxicity and stability
were examined in yeast by fluorescent microscopy, growth assays, and Western blot
analysis following treatment with stress inducing chemicals.
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4) Identify how PINK1 modifies parkin stability and cell toxicity
We tested how parkin toxicity, localization, and stability were altered by co-expression of
PINK1 in yeast using growth assays, fluorescent microscopy, and Western blot analysis.
1.5.4

Significance

The use of genetic screens gave insight into alternate cellular pathways that parkin may be
involved in that contribute to PD. This built a strong rational to conduct a high throughput
screen using the entire deletion and over-expression yeast libraries, which may uncover
previously unidentified genetic interactions with parkin and elucidate previously
undescribed pathways that may modulate parkin localization and function. By assessing
how mutations, truncations, oxidative stress, and PINK1 co-expression, altered parkin
localization, toxicity, and stability, we also established that parkin misfolding and
regulation contribute to its dysfunction. Continuing research on these aspects of parkin
dysregulation will certainly provide a better understanding of how parkin contributes to
PD.
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Chapter Two: Materials and Methods
2.1 Materials
2.1.1 Escherichia coli Strains - DH5α Genotype F–Φ80lacZΔM15 Δ(lacZYA-argF) 169
recA1 endA1 hsdR17 (rK–, mK+) phoA supE44 λ– thi-1 gyrA96 relA1
2.1.2

Bacterial Media

2.1.2.1 Luria-Bertani (LB) - 10 g/L NaCl (Sigma Aldrich), 10 g/L tryptone (Sigma
Aldrich) and 5 g/L yeast extract (Sigma Aldrich), supplemented with antibiotics: 100
g/mL ampicillin (Amresco) or 50 g/mL kanamycin (Amreseco).
2.1.2.2 2xYT - Full nutrient media for non-selective bacterial growth in liquid culture.
16 g/L tryptone, 10 g/L yeast extract (Sigma Aldrich) and 5 g/L NaCl.
2.1.3

Saccharomyces cerevisiae Strains - W303 MAT a (genotype: leu2-3,112 trp1-1

can1-100 ura3-1 ade2-1 his3-11,15) were used in all growth assays and protein work.
BY4742 MAT a (Genotype his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0) were used in all fluorescence
microscopy experiments. BY4741 MATα (Genotype his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0) were
used for screening genetic deletion strains.
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2.1.4

Yeast Media

2.1.4.1 Yeast Peptone Dextrose (YPD) - Full nutrient media for non-selective yeast
growth in either liquid or agar plates. 10 g/L yeast extract (Amresco), 20 g/L peptone
(Sigma-Aldrich), and 20 g/L dextrose (Sigma-Aldrich).
2.1.4.2 Selective Dextrose (SD) - Media lacking essential amino acids required for growth
of yeast deficient in amino acid biosynthesis in liquid media or on agar plates. 2% Glucose,
YNB (Sigma-Aldrich) as nitrogen source, and amino acid powder as required for selection.
100X general amino acid solutions (6 g/L l-isoleucine, 2 g/L L-arginine, 4g/L L-lysine
HCl, 6 g/L L phenylalanine, 1 g/L L-threonine, and 1g/L L-methionine); 100X selective
amino acids (4g/L L-tryptophan, 6g/L L-leucine, 2 g/L L-histidine-monohydrate); 0.2%
(w/v) adenine hemisulfate in 0.1 M NaOH; 0.4% (w/v) uracil in 0.1M NaOH.
2.1.4.3 Selective Galactose/Raffinose (SGal/Raff) - Media lacking essential amino acids
required for growth of yeast deficient in amino acids biosynthesis; used to induce genes
carried on vectors under control of Gal promoter. 2% Galactose (Sigma-Aldrich), 2%
Raffinose (Sigma Aldrich), YNB as nitrogen source, and amino acid powder as required
for selection.
2.1.5

Mammalian Cell Lines – Cervical cancer derived HeLa cells, human embryonic

kidney (HEK) 293 cells stably expressing transfected FLAG-Parkin, and neuroblastoma
derived SH-SY5Y cells were used in this study.
2.1.6

Cell Culture Media - Dulbecco's Modified Eagle Medium (DMEM, Corning) with

4.5 g/L or 1 g/L glucose was supplemented with 10% fetal bovine serum (FBS, Gibco),
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100 I.U./mL penicillin (Corning Cellgro), 100 µg/mL streptomycin (Corning) and 1x
glutamine (Sigma Aldrich).
2.1.7

Sources of DNA used for Cloning - Human parkin DNA used to clone parkin and

parkin truncation variants was acquired from Dr. Shaw (Western). Yeast specific PINK1
DNA used in cloning and human PINK1 and kinase dead PINK1 DNA used for expression
in mammalian was provided by was generously provided by Dr. Endo (Kyoto Sangyo
University)
2.1.8

Chemicals

2.1.8.1 General Chemicals
All chemicals were purchased from Sigma Aldrich unless stated otherwise.
2.1.8.2 Protease Inhibitors
Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific)
SIGMAFAST™ Protease Inhibitor Tablets (Sigma Aldrich)
N-Ethylmaleimide (NEM, Sigma Aldrich)
Phenylmethanesulfonyl fluoride (PMSF, Sigma Aldrich)
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2.1.9

Antibodies

Table 2-1. Antibodies used in this study.
Antigen

Epitope

Supplier

Use

Concentration

Parkin

Ubl

Novus

WB

1-1000

IF

1-200

WB

1-1000

IF

1-500

WB

1-10000 (Yeast)

WB

1-2000 (Mam)

IF

1-200

Parkin

Parkin

RING1

RING2

Abcam

Cell Signaling

Parkin

Unknown

Santa Cruz

IF

1-200

PGK1

N/A

Antibodies-online

WB

1-10000 – 1-20000

Tubulin

N/A

Abcam

WB

1-5000

FLAG

N/A

Sigma Aldrich

WB

1-1000 – 1-2000

Polyubiquitin

N/A

Enzo

WB

1-2000

PS65-Ubiquitin

N/A

Boston Biochem

WB

1-500
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2.2

Methods

2.2.1

Cloning

2.2.1.1 Polymerase Chain Reaction (PCR) – PCR is a technique used to create parkin
variant templates to be used in Gateway® recombination cloning. Reaction mixtures
included: 10 mM dNTPs (2 μL), variable concentration template (1 μL), 100 mM forward
primer (2 μL), 100 mM reverse primer (2 μL), Q5 polymerase (1μL) (New England
Biolabs), 5x buffer (20 μL) (New England Biolabs), and ddH2O (72 μL). Samples were run
for 25 cycles with denaturing, annealing, and extension temperatures of 95°C, 58°C, and
72°C respectively. DNA products were resolved by agarose gel electrophoresis (See Table
2-2 for primer design).
2.2.1.2 Agarose Gel Electrophoresis - 1% agarose powder was dissolved in TAE (40 mM
Tris, 20 mM acetic acid and 1 mM ethylenediaminetetraacetic acid (EDTA)) buffer with
1ug/mL ethidium bromide (Sigma Aldrich) and allowed to solidify at room temperature.
2.2.1.3 Gel Purification of DNA - AccuPrep® Gel Purification Kit (Bioneer) was used to
purify DNA products from agarose gel. DNA bands were excised from the agarose gel and
purified as described in the supplier instruction manual.
2.2.1.4 Mini Prep - High Speed Plasmid Mini Kit (Geneaid) uses standard alkaline lysis
followed by neutralization and ethanol wash on DNA binding columns to extract dsDNA
plasmids from E. coli. E. coli were grown in 3 mL cultures of LB supplemented with
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ampicillin or kanamycin. Cells were lysed and DNA was extracted following the protocol
described in the supplier instruction manual.
2.2.1.5 Midi/Maxi Prep - PureLink® HiPure Plasmid Midi/Maxiprep Kits provided by
Invitrogen were used to prepare DNA for transfection of HeLa cells. 250-500 mL LB Amp
cultures of E. coli were grown and isolated as per the instruction manual.

Table 2-2. Custom designed primers used to generate constructs for use in
Gateway® cloning.
Clone and Orientation

Sequence (5’ to 3’)

Parkin/Ubl Fw

ggggacaagtttgtacaaaaaagcaggctatgatagtgtttgtcaggttcaact

141C/141-409 Fw

ggggacaagtttgtacaaaaaagcaggctatgtcaatctacaacagcttttatgtgt

321-465 Fw

ggggacaagtttgtacaaaaaagcaggctatggaggagtgtgtcctgcagatggggg

Parkin/141C/321-465
Rv w/ Stop

ggggaccactttgtacaagaaagctgggtctacacgtcgaaccagtggtccccc

Parkin/141C/321-465
Rv No Stop

ggggaccactttgtacaagaaagctgggtccacgtcgaaccagtggtcccccatg

141-409 Rv w/ Stop

ggggaccactttgtacaagaaagctgggtctaaaatacggcactgcactccccttca

141-409 RV No Stop

ggggaccactttgtacaagaaagctgggtcaaatacggcactgcactccccttca

Ubl Rv w/ Stop

ggggaccactttgtacaagaaagctgggtctaaccttttctccacggtctctgcaca

Ubl Rv No Stop

ggggaccactttgtacaagaaagctgggtcaccttttctccacggtctctgcaca

PINK1 Fw

ggggacaagtttgtacaaaaaagcaggctatggtcagagaacagaaggccaag

PINK1 Rv w/ Stop

ggggaccactttgtacaagaaagctgggttcacttatcatcatcatccttata
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2.2.1.6 Preparation of Competent DH5 Cells – Two mL 2xYT culture of DH5 were
inoculated and incubated for six hours at 37°C during the day. Ten μl of culture was
transferred into 2 mL fresh 2xYT and incubated overnight at 37°C. The culture was diluted
1:100 in 1xYT media and incubated at 37°C. During this time, the culture OD600 was
checked 30 minutes after the first 2 hours and every 15 minutes after that. Cultures were
grown to OD600 0.4-0.5. All the following steps occurred on ice. Cultures were chilled on
ice 10 minutes by pouring equal volumes into two 50 mL conical PP centrifuge tubes.
Samples were spun at 2,000xg for 15 minutes at 4°C in RT6000 Sorvall centrifuge with
Swinging Bucket Rotor and resuspended with a 10mL pipet in 10 mL of CaCl2 solution
(60 mM CaCl2.2H2O, 10 mM PIPES pH 7.0 and 15% glycerol) per 50 mL tube with a 10
mL disposable pipet. Samples were spun again at 2,000xg for 10 minutes at 4°C in RT6000
Sorvall centrifuge with Swinging Bucket Rotor and resuspended with 10 mL pipet in 10
mL total volume of CaCl2 solution before incubating on ice for 30 minutes. Following the
incubation on ice, samples were spun at <2,000xg for 10 minutes at 4°C in RT6000 Sorvall
centrifuge with Swinging Bucket Rotor and resuspended with 5 mL pipet into 1 mL volume
of CaCl2 Solution per 50 mL volume starting culture. Using P1000 pipet solutions were
aliquoted in 100 µL volumes into chilled tubes and quickly frozen to -80°C.
2.2.1.7 Gateway® Cloning – Gateway® Cloning is technique that utilizes homologous
recombination to selectively insert the desired gene product into one of several destination
vectors (110). After isolating PCR generated dsDNA constructs, the BP recombination
reaction was first used transfer PCR template DNA into an intermediate cloning vector.
Reaction mixtures included BP Clonase (1μL) (Invitrogen), pDONR vector (1μL)
(Invitrogen), gel purified PCR DNA (3 μL). The reaction was incubated at 37°C overnight.
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Following the overnight incubation, the reaction was quenched with 1 μL Proteinase K
(Invitrogen) and incubated for 10 minutes at 37°C. Three μL of reaction mixture was
transformed into competent DH5α cells via E. coli transformation protocol (see below) and
plated on LB agar plates containing 50 µg/ml Kan. Single colonies were isolated and grown
in liquid LB Kan media overnight at 37°C. DNA was isolated from the E. coli using the
High Speed Plasmid Mini Kit (Geneaid) and sequenced using the sequencing services
provided by Robarts Research Institute at Western University to verify successful
incorporation of the DNA into the pDONR201 vector.
After successfully isolating the desired construct in the pDONR backbone, the LR
recombination reaction was used to transfer from the intermediate vector to one of several
possible destination vectors. Reaction mixtures included: LR Clonase (4 μL) (Invitrogen),
destination vector (2 μL), pDONR vector as source of recombinant DNA (2 μL), and TE
(10mM Tris pH 8.0, and 1 mM EDTA) buffer (12 μL). The reaction was incubated at 37°C
overnight followed by quenching with 2 μL Proteinase K, which was incubated for 10
minutes at 37°C. Ten μL of the reaction was transformed into competent DH5α cells via
E. coli transformation protocol and plated on LB agar plates containing 100 µg/mL
ampicillin (Amp). Again, single colonies were isolated, grown in LB AMP overnight at
37°C and the DNA was extracted and sequenced to verify successful recombination into
the destination vector. A list of constructs and destination vectors used in this study can be
found in Table 2-3.
2.2.1.8 Bacterial Transformation – Transformation is a protocol for introducing double
stranded plasmid DNA into E. coli cells for replication/expression. One hundred μL
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aliquots of competent DH5 cells were removed from -80°C and allowed to thaw on ice
for five minutes. 1-5 μL of plasmid DNA was added and samples were left to incubate on
ice for 30 minutes. Samples were heat shocked at 42°C for 100 seconds followed by a two
minutes incubation on ice. 900 μL of 2xYT was added to each sample to make to total
volume of 1mL. Samples were then incubated at 37°C shaking for at least one hour. After
recover, cells were pelleted at 15 000xg for one minute and the supernatant was removed.
The pellet was resuspended in 100 μL LB or 2xYT and plated on LB agar plates with
antibiotic.

Table 2-3. List of constructs and expression vectors used in this study.
Construct

Vector

Expression Control

Expression System

Parkin (WT)

pRS423

Galactose Induced

Yeast

Parkin (WT)

pRS423-YFP

Galactose Induced

Yeast

Parkin (WT)

pcDNA3.1

Constitutive

Mammalian

Parkin S65A

pRS423

Galactose Induced

Yeast

Parkin S65A

pRS423-YFP

Galactose Induced

Yeast

Parkin S65A

pcDNA3.1

Constitutive

Mammalian

Parkin S65E

pRS423

Galactose Induced

Yeast

Parkin S65E

pRS423-YFP

Galactose Induced

Yeast

Parkin S65E

pcDNA3.1

Constitutive

Mammalian

Parkin C289G

pRS423

Galactose Induced

Yeast

Parkin C289G

pRS423-YFP

Galactose Induced

Yeast

Parkin C289G

pcDNA3.1

Constitutive

Mammalian

Parkin C418R

pRS423

Galactose Induced

Yeast
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Parkin C418R

pRS423-YFP

Galactose Induced

Yeast

Parkin C418R

pcDNA3.1

Constitutive

Mammalian

141C

pRS423

Galactose Induced

Yeast

141C

pRS423-YFP

Galactose Induced

Yeast

141C

pcDNA3.1

Constitutive

Mammalian

141-409

pRS423

Galactose Induced

Yeast

141-409

pRS423-YFP

Galactose Induced

Yeast

141-409

pcDNA3.1

Constitutive

Mammalian

321C

pRS423

Galactose Induced

Yeast

321C

pRS423-YFP

Galactose Induced

Yeast

321C

pcDNA3.1

Constitutive

Mammalian

Ubl

pRS423

Galactose Induced

Yeast

Ubl

pRS423-YFP

Galactose Induced

Yeast

Ubl

pcDNA3.1

Constitutive

Mammalian

PINK1 (WT)

pRS416

Galactose Induced

Yeast

PINK1 (WT)

pDENTIG

Constitutive

Mammalian

Kinase Dead PINK1

pRS416

Galactose Induced

Yeast

Kinase Dead PINK1

pDENTIG

Constitutive

Mammalian

2.2.2

Yeast Culturing Techniques

2.2.2.1 Yeast Transformation - Yeast cells were inoculated in 3 mL YPD or SD media
and grown overnight at 30°C. Starter cultures were used to inoculate a 30ml culture in YPD
or SD to an OD600 = 0.200. Cells were grown for 4-5 hours at 30°C to OD600 = 0.500. Equal
volumes of the culture were poured into two 50mL sterile centrifuge tubes and centrifuge
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for 5 minutes at 2000xg at 4°C. Supernatant was discarded and cell pellets were
resuspended in 5 mL sterile H2O per 50 mL tube. Samples were centrifuged again for 5
minutes at 2000xg at 4°C after which the supernatant was aspirated and cell pellets were
resuspended in 2 mL of 100 mM Li-Acetate/TE and incubate for 10 minutes at 30°C.
Samples were once again centrifuged for 5 minutes at 2000xg at 4°C and the supernatant
was removed. One hundred mM Li-Acetate/TE was used to resuspend cells in the
necessary volume for the number of transformations + 1 (100 μl/transformation). One
hundred μl of yeast cell suspension was aliquoted into labeled tubes and to each tube add
in order: 250 μl transformation buffer (1 X TE, 40% polyethylene glycol and 100 mM LiAcetate), 12 μl salmon sperm DNA, 1 μl mini-prep cDNA and 25 μl DMSO (SigmaAldrich). After resuspension, samples were heat shocked for 20 minutes at 42°C shaking.
Samples were chilled on ice for 5 minutes before centrifuging for 1 minute at 1000xg, after
which the supernatant was aspirated. Cells were then resuspended in 50 μl TE. The entire
suspension was plated onto selective agar plates.
2.2.2.2 Protein Induction – Yeast cells maintained on selective agar plates were used to
inoculate liquid cultures in SD media. Cultures were incubated overnight at 30°C with
constant shaking. After approximately 16 hours of growth, cultures were spun at 3000xg
to pellet cells. The supernatant was aspirated and the cells were resuspended in sterile
ddH2O. This process was repeated and cells were washed a second time with ddH2O before
spinning one more time at 3000xg and aspirating the supernatant. The cells were then
resuspended in SGal/Raff media to induce expression of constructs under control of the
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Gal promoter. Cells were allowed to incubate in inducing media for 8-10 hours at 30°C
before analysis or preparation for protein extraction.
2.2.3

Growth Assays

2.2.3.1 Spotting Assays - Yeast cells were inoculated into 3 mL liquid cultures of SD
media and incubated with constant shaking overnight at 30°C. These cultures were diluted
1:10 in water and the OD600 was measured as a proxy for cell density. In 96 well plates,
yeast cultures were diluted in sterile ddH2O to 200 μl with an OD600 = 1.0. The subsequent
five wells were filled with 120 μl of ddH2O. Serial dilution of 1:4 volume from top well
into subsequent 5 wells were prepared by transferring 30 μl from well to well. Equal
volumes of each well were transferred onto agar plates using a 48 prong spotting tool
(“frogger”). Samples were plated on YPD media to ensure equal cell concentrations as well
as SGal/Raff plates to detect affects caused by protein induction. Plates were dried for 1015 minutes prior to spotting to prevent samples from running. After spotting the plates were
incubated at 30°C for 2-5 days. Pictures were taken to document growth differences
between samples at the indicated incubation times.
2.2.3.2 Growth Curves – Yeast cultures were inoculated in SD media and grown
overnight at 30° C with constant shaking. After approximately 12-16 hours, cultures were
spun at 3000xg for 5 minutes and washed twice with sterile ddH2O after removing the
supernatant. Following the wash step, protein expression was induced by resuspending the
cells in SGal/Raff media. Culture density was measured at a 600nm wavelength using a
spectrophotometer. After measuring the OD600, cultures were diluted to an OD600 = 0.2 in
SGal/Raff media and 300 μL of the culture was added to each well of a honeycomb plate.
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Plates were incubated for 2-3 days in a Bioscreen C instrument (Oy Growth Curves Ab
Ltd) at 30°C. OD600 measurements were taken every 15 minutes after the plates were
agitated for 15 seconds prior to reading.
2.2.3.2.1

Quantification of Growth Curves – Means of OD600 measurements at mid-log

growth were compared using GraphPad Prism 6 software to calculate statistical
significances. Means and standard deviations were compared using either an unpaired Ttest for experiments with two samples or a One-way ANOVA for experiments containing
three or more samples. All sample means were compared to a vector control at an
equivalent time point to assess growth inhibition.
2.2.4

Fluorescent Microscopy - Imaging of YFP (yellow fluorescent protein) tagged

parkin variants expressed in BY 4742 MAT a following 10 hours of galactose induction
were performed on a Leica TCS SP5 II Confocal microscope using a HCX PL APO 63x
oil objective. Images were captured using an equipped CCD camera using Leica
Application Suite Advance Fluorescence Life V2.6.0 software.
2.2.5

Cell Lysis

2.2.5.1 Yeast - Following 10 hours of induction in SGal/Raff media at 30°C, yeast cultures
were spun at 3000xg for 5 minutes to pellet cells. After aspirating the supernatant, the
pellets were washed with sterile ddH2O. These steps were repeated to wash the cells a
second time, after which, the cells were spun one more time. Again the supernatant was
aspirated and cell pellets were put through one freeze thaw cycle at -20°C to assist with
lysis. Cells were resuspended in equal volumes cold lysis buffer (50 mM Hepes pH 7.5,
150 mM NaCl, 5 mM EDTA, 1% Triton X-100, SIGMAFAST™ Protease Inhibitor
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(Sigma), and 50 mM NEM or 2 mM PMSF) and glass beads. Yeast cells were lysed by
vortexing in a Disruptor Genie (Scientific Industries) 6 times for 30 seconds with 1 minute
incubations on ice between vortexes. After lysis, samples were spun at 20000xg for 10
minutes at 4°C. The supernatant was collected and the protein concentration of each sample
was determined and normalized using the bicinchoninic acid (BCA) kit (Promega) using
bovine serum albumin (BSA) as a standard.
2.2.5.2 Mammalian - Cells were washed with cold PBS which was then aspirated off. A
cell scraper was used to detach cells into cold lysis buffer (50 mM Hepes pH 7.5, 150 mM
NaCl, 5 mM EDTA, 1% (v/v) Triton X-100, and SIGMAFAST™ Protease Inhibitor) after
which, extracts were frozen at -20°C. After thawing on ice, extracted were lysed using a
Branson Sonifier® ultrasonic cell disruptor for two 3-5 second pluses. Lysed samples were
centrifuged at 20000xg for 10 minutes at 4°C. The supernatant was collected and protein
concentrations were determined using the BCA kit (Promega) using BSA as a standard.
2.2.5.3 NaOH Based Yeast Lysis – NaOH based lysis is an alternative method of yeast
lysis used to address post lysis protease dependent protein degradation. The protocol was
followed as described by Von der Haar T. (111) with adaptions made using 5ml cultures
and adapting total volumes accordingly.
2.2.6

Western Blotting – Thirty µg of normalized protein samples in 1x sample buffer

(2% sodium dodecyl sulphate (SDS), 5% glycerol, 50 mM EDTA, 200mM Tris-HCl pH
6.8) with or without reducing agents (1% β-mercaptoethanol (BME) and 100 mM
dithiolthreitol (DTT)) were loaded onto 12% or 15% acrylamide gels. Once resolved, the
protein samples were transferred to nitrocellulose membranes (Bio Rad) using the Trans
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Blot Turbo Transfer System (Bio Rad) following the manufacturer’s instructions.
Membranes were blocked with blocking buffer (PBST 0.01% Tween-20, 2% BSA (Sigma
Aldrich), and 2% goat serum) for 1 hour at room temperature and then incubated with
primary antibodies (concentrations can be found in Table 2-1) in PBST with 2% BSA
overnight at 4°C. Primary antibodies solutions were removed and membranes were washed
with PSBT for 10 minutes 6 times before adding secondary antibody solutions and
incubating at room temperature for 1 hour. After removing secondary antibody solutions,
the membranes were again washed 6 times with PBST. Samples were imaged at infrared
wavelengths using the LiCor system (Odyssey) using Odyssey V3.0 software.
2.2.7

SYTOX® Green Cell Death Assay - Yeast cells maintained on selective agar plates

were used to inoculate liquid cultures in SD media. Cultures were incubated overnight at
30°C with constant shaking. After approximately 16 hours of growth, cultures were spun
at 3000xg to pellet cells. The supernatant was aspirated and the cells were resuspended in
ddH2O. This process was repeated and cells were washed a second time with ddH2O before
spinning one more time at 3000xg and aspirating the supernatant. The cells were then
resuspended in SGal/Raff media to induce expression of constructs under control of the
Gal promoter. Cells were allowed to incubate in inducing media for 8-10 hours at 30°C
before adding 5 µL of SYTOX® Green Nucleic Acid Stain (Thermo-Fisher) to 1 mL of
culture to a final concentration of 25 µM. The cultures were vortexed and allowed to
incubate at room temperature for ten minutes. Three 200 µL aliquots of the SYTOX®
treated culture were added to 96 well plates followed by analysis using the Victor3V Plate
Reader using the Perkin Elmer 2030 Manager Software. SYTOX® emission were read at
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535nm and culture density was measured at 595nm. STYOX® measurements were
corrected to culture density and values used for analysis.

2.2.8

Semi Denaturing Detergent Agarose Gel Electrophoresis (SDD AGE) – SDD AGE

is a technique used to resolve amyloid-like protein aggregates using mild detergents.
Protein expression in yeast was performed, as described above. After 10 hours of protein
induction, cells were washed twice in ddH2O before resuspending in equal volumes of cold
SDD PAGE lysis buffer (100 mM Tris pH 7.5, 200 mM NaCl, 1mM EDTA, 5% glycerol,
1 mM PMSF, 50mM NEM, Phosphatase and Protease Inhibitor Cocktail (Sigma Aldrich),
and SIGMAFAST™ Protease Inhibitor) and glass beads. Yeast cells were lysed by
vortexing in a Disruptor Genie (Scientific Industries) 6 times for 30 seconds with 30 second
incubations on ice between vortexes. After lysis, samples were spun at 1000xG for 10
minutes to pellet insoluble debris. The supernatant was collected and protein extracts were
normalized by BCA assay (Pierce) using BSA as a standard. Sample buffer (1x TAE, 5%
glycerol, and 0.2% SDS) was added to protein extracts and 30 µg total protein was loaded
into each lane. Sampled were resolved by electrophoresis through a 1.8% agarose gel
containing 0.1% SDS. After rinsing the gel in TBS (10 mM Tris pH 7.5, and 150 mM
NaCl) samples were transferred to a nitrocellulose membrane (Bio Rad) through capillary
force using pre-assembled TurboBlotter™ Rapid Downward Transfer System packs (GE
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Healthcare). Once samples were transferred to the nitrocellulose membrane, samples were
treated and imaged in the same way as standard Western blots (described above).
2.2.9

Cell Culture

2.2.9.1 Cell Maintenance and Passaging - Cervical cancer derived HeLa, human
embryonic kidney (HEK 293) stably expressing FLAG-Parkin, and neuroblastoma derived
SH-SY5Y cell lines were used in this study. Cells were continually passaged on culturing
plastics (Starsted) in Dulbecco's Modified Eagle Medium (DMEM) containing 4.5g\L
glucose supplemented with 10% fetal bovine serum (FBS), 100 I.U./mL penicillin
(Corning Cellgro), 100 µg/mL streptomycin (Corning Cellgro), and 1x glutamine (Sigma
Aldrich) at 37°C with ~5% CO2. Cell lines were passaged using standard 0.25% trypsin
with 2.21 mM EDTA incubation followed by washing with fresh DMEM and re-seeding
to new sterile culture plastics.
2.2.9.2 Transfection - Cells were grown to approximately 90% confluency in DMEM
before transfecting cells using Lipofectamine® 2000 (Thermo Fisher) following the
supplier recommended concentrations in Opti-MEM® low serum media. Transfections
were incubated for 16-20 hours at 37°C before washing with PBS. Cells were returned to
DMEM media to recover for 24 hours before passaging into 6 well plates or 8 chamber
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microscopy slides. Cells were allowed to recover for 24 hours after passaging before
further treatment or analysis.
2.2.10 Chemical Stress Treatment
2.2.10.1.1 Yeast - Spotting assays and Bioscreen growth curve experiments were
performed with selective agar or liquid media, respectively, containing 50 µM H2O2, 100
µM H2O2, 1 mM H2O2, 500 µM azetidine-2-carboxylic acid (AZC, Sigma-Aldrich), 10 µM
peroxynitrite (Enzo), 2 mM DTT, 25 µM radicicol (Sigma-Aldrich), or 50 µM antimycin
A (Sigma Aldrich). Spotting assays were grown for 3-5 days at 30°C under stress
conditions where as Bioscreen growth experiments were incubated for 2-3 days at 30°C
with agitation every 15 minutes
2.2.10.1.2 Mammalian - Mammalian cells were treated with either 75 µM H2O2, 10 µM
MG132, 1 mM LAZC, 50 µM antimycin-A, or 10 µM peroxynitrite for either 8 hours or
16 hours in DMEM at 37°C with 5% CO2. Following treatment, cells were washed with
PBS and used for Western Blotting or Immunofluorescence microscopy (IF).
2.2.11 Viability Assay – SH-SY5Y cells expressing endogenous parkin and PINK1, HEK
293 cells stably expressing FLAG-parkin but no PINK1, or HeLa cells transiently
transfected with parkin, various parkin mutants, wild-type (WT) PINK1, and/or a kinase
dead (KD) mutant PINK1 were used to perform viability assays. Following transfection or
standard passaging, cells were given either 1 or 4 days to recover in rich media (DMEM
with 10% FBS and 4.5 g/L glucose) or minimal media (DMEM with 1% FBS and 1 g/L
glucose) before performing the luminescence based Cell Titer-Glo® Luminescent Cell
Viability Assay (Promega). Samples were prepared as recommended by the supplier and
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loaded into 96 well plates. Plates were then measured using the Victor3V Plate Reader
(Perkin Elmer) using the Perkin Elmer 2030 Manager Software.
2.2.12 Immunofluorescence Microscopy - 8 well chamber slides (Lab-Tex) were coated
with Poly-L-Lysine (Sigma Aldrich) before passaging cells into wells. Culturing media
was removed after a 24 hour recovery period and cells were fixed with 4%
paraformaldehyde in PBS pH 7.4 for 20 minutes at room temperature. Cell were rinsed
with PBS every 5 minutes for 30 minutes followed by permeabilization with 0.1% Triton
X-100 (Sigma Aldrich) in PBS for 10 minutes. The Triton X-100 solution was removed
and cells were washed 6 times with PBS before blocking in PBST (PBS + 0.01% Tween
20) with 6% BSA and 2% goat serum for 1.5 hours at room temperature. Following
blocking, cells were incubated in primary antibody solution for 1 hour at room temperature
with antibody titers corresponding to Table 2-1 in section 2.1.9. Cells were then washed
with PSBT every 5 minutes for 30 minutes. This was followed by incubation with
secondary antibody solution for 1 hour at room temperature. Cells were washed again for
30 minutes at 5 minutes intervals with PBST before mounting with SlowFade® Gold antifade reagent with DAPI (Life Technologies) mounting media. Samples were then
visualized using a Zeiss Axio Vert A1 Inverted fluorescent microscope using a 40x
objective. Images were captured using an Axiocam Icc5 camera operating on the Zen 2
Lite software.
2.2.13 Shutoff
2.2.13.1 Yeast – After ten hours of protein induction, glucose was added to the cultures to
a final concentration of 2% to quench expression under control of the gal promoter. At the
point of glucose addition, 50µM MG132 or an equivalent volume of DMSO were added to
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cultures. Δerg1, Δerg3 W303 MAT a yeast strains were used in these experiments to inhibit
export of MG132 from the cells. Aliquots of the culture were taken at various time points
following expression inhibition, and frozen at -80°C until all time points were collected.
All time points were then lysed as described above, used to perform western blots, and
band intensities were quantified using Odyssey V3.0 software.
2.2.13.2 Mammalian – Following transfection or normal passaging, mammalian cells were
treated with 200 µg/mL cycloheximide (Sigma Aldrich) and 10 µM MG132 or an
equivalent volume of DMSO in fresh culturing media (DMEM with 10% FBS and 4.5 g/L
glucose). Cells were harvest as described above at various time points and kept at -20°C
until all time points were collected. Samples were then lysed as previously described, used
for western blotting, and band intensities were quantified using Odyssey V3.0 software.
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Chapter Three: Results
3.1 Parkin Sequence Analysis
To gain a better understanding how the amino acid composition of parkin affects
its sensitivity to damage by oxidation, which can lead to altered parkin function, we
performed an amino acid sequence analysis. Using sequence files obtained from
Uniprot.org, we conducted a comprehensive analysis, aligning the parkin sequences of 38
difference species (Appendix 2). For clarity, a representative alignment of four species
(Homo sapiens, Mus musculus, Drosophila melanogaster, and Caenorhabditis elegans) is
shown in Figure 3-1. These four species cover a wide spectrum of species divergence from
roundworm to insects and mammals. Amino acids C431, H433, and E444, which make up
the catalytic triad involved in human parkin’s E3 ubiquitin conjugation activity (112), are
highly conserved in these species. C431 and H433 are completely conserved across all four
species, and E444 is substituted for an acidic aspartate residue in C. elegans.
Analysis of the human parkin amino acid sequence revealed that 35 of the 465
residues are cysteines, equating to 7.52% of the total protein. This proportion of cysteines
is approximately two times higher than the calculated random incorporation of 3.28%
based on the two of 61 possible sense codons encoding cysteine residues and, more
importantly, nearly three times higher than the average for all analyzed human proteins,
which is 2.26% (8). Twenty-nine of parkin’s 35 cysteines (82.8%) are conserved between
all four species and all of these residues are located within the boundaries of structurally
determined functional domains. When C. elegans is excluded from this analysis, this
number increases to 32 of the possible 35 cysteines (91.4%).
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Figure 3-1. Parkin sequence alignment. (A) Schematic representation of parkin domains
based on structural determination by NMR. (B) Amino acid sequences acquired from
UniProt were aligned using Clustal Omega software. Cysteine residues are in red and
amino acid residues of the functional domains in the human sequence are highlighted in
the corresponding colour as shown in panel A. Asterisks (*) indicate positions with fullyconserved residues; colons (:) indicate conservation between groups of strongly similar
properties, and periods (.) indicate conservation between groups of weakly similar
properties.
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Figure 3-1
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Many of these cysteines are known to be involved in coordinating Zn2+ ions, which is
required for proper folding and stability of parkin (59). However, this unusually high
cysteine content also suggests a high susceptibility to oxidative damage and disulfide
formation caused by exposure to reactive oxygen species (ROS) in vivo.

3.2

The Parkin Yeast Model
The yeast genome does not contain a PARK2 orthologue. We therefore used human

parkin to establish a yeast model to study how parkin is affected by truncations, point
mutations, PINK1 meditated phosphorylation, or various types of chemical stress including
oxidative, nitrogenous, or membrane stress. Recombination-based cloning (Gateway) was
used to generate yeast expression vectors for human parkin: one expressing the unmodified
wild-type protein, and one containing a carboxy-terminal (C-terminal) yellow fluorescent
protein (YFP) fusion protein (parkin-YFP) to visualize cellular localization by fluorescence
microscopy. These parkin expression vectors contain a galactose inducible promoter
(GAL1) to allow controlled expression of parkin. Unlike many constitutive promoters used
in many mammalian systems, yeast enables the use of various promoters that can be
selectively induced. This allows yeast to be grown on media containing glucose as a
primary carbon source which causes them to grow and divide like wild-type yeast, but
switching to a galactose based media induces parkin translation, allowing for controlled
expression. Additionally, yeast expressing parkin can be switched back to glucose based
media to selectively inhibit parkin expression without altering transcription of all other
cellular proteins. Both the YFP-tagged and untagged parkin expression vectors were
transformed into yeast. We first assessed whether the expression of human parkin has an
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effect on the growth of yeast cultures under normal conditions. Spotting assays on agar
plates and growth curves in liquid media showed an extremely mild growth defect
associated with the over expression of untagged human parkin (Figure 3-2 A and B).
Notably, control yeast (transformed with empty vector) and those over-expressing parkin
had a similar growth rate during exponential growth phase as documented by a similar
maximum slope of the curve during the first 12-18 hours of growth (Figure 3-2 B). Cells
expressing parkin took two to three hours longer to enter logarithmic growth, indicating a
prolonged lag phase.
We next assessed parkin localization of parkin-YFP by fluorescent microscopy.
After ten hours of inducing parkin-YFP expression, parkin-YFP was diffusely localized
throughout the yeast cytosol (Figure 3-2 C) as previously reported in mammalian systems
(113, 114). A minor proportion of yeast cells showed small cytosolic foci of increased
signal intensity which could indicate subcellular accumulation of parkin (data not shown).
Western blots showed that after ten hours of galactose induction, parkin was stably
expressed in the transformed yeast (Figure 3-2 D). These data established our yeast parkin
model and set the baseline to determine how cellular stress conditions and genetic
modifications alter parkin toxicity, localization, stability, and degradation.
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Figure 3-2. Establishing a parkin yeast model. (A) Liquid cultures of W303 were grown
to stationary phase in non-inducing selective media and diluted to OD600 = 1.0 and serial
diluted 1:5 before spotting on selective inducing agar media and incubated at 30°C for 2-4
days before imaging to assess the effects of parkin expression on wild type W303. (B)
Liquid cultures grown to stationary phase in non-inducing selective media were washed
twice with sterile H2O and resuspended in inducing selective media before diluting to
OD600 = 0.2 and incubating at 30°C. OD600 measurements were taken every 15 minutes and
plotted to generate a growth curve. Standard deviations did not exceed a maximum OD600
= 0.02. At mid-log growth parkin growth was statistically different from the control with a
P value ≤ 0.001 as determined from an unpaired T-test. ● (Black) - Vector; ● (Green) parkin (C) BY cells expressing parkin-YFP were grown in inducing liquid media for 8
hours and fluorescent images were captured using a Leica TCS SP5 II confocal microscope
at 63x magnification. The scale bar represents 5µm. (D) Thirty µg total protein of cell
extracts from wild type W303 and W303 expressing parkin were resolved by SDS-PAGE,
transferred to nitrocellulose membranes and expression of parkin was detected using
immunodetection and imaged using infrared conjugated secondary antibodies. PGK1 was
used to assess equal loading.
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Figure 3-2. Establishment of the parkin yeast model.
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3.3

Genetic Modulators of Parkin Toxicity and Localization
Yeast can be used to perform extremely powerful genetic screens that cannot be

carried out in any other model systems. These screens make use of the exhaustive overexpression and deletion libraries that have been generated in yeast. Based on previous
descriptions of parkin’s involvement in degradation of damaged proteins and turnover of
damaged mitochondria (mitophagy), we decided to perform a genetic screen with parkin
in a select library of 17 yeast deletions strains of genes involved in managing oxidative
stress and protein misfolding which are described in Table 3-1.
Parkin and parkin-YFP expressing yeast plasmids were transformed into the
selected yeast strains. Deletion strains expressing untagged parkin were spotted onto
inducing media and growth was assessed against a wild-type control strain expressing
parkin (Figure 3-3 A). This screen revealed three deletion strains that show reduced growth
due to the over-expression of human parkin: 1) deletion of SOD2, encoding a
mitochondrial superoxide dismutase that protects against toxicity caused by superoxide
radicals (115, 116); 2) deletion of YAP1, encoding a transcription factor required for
oxidative stress tolerance that is activated by H2O2 (117); and 3) deletion of BTN2,
encoding a v-SNARE binding protein that facilities protein retrieval from a late endosome
to the Golgi and contributes to prion curling (118). Deletion strains expressing parkin-YFP
were used for fluorescent microscopy to assess changes in parkin localization. Only two
strains, deletion of SOD2 and SGT2, showed changes in parkin localization, showing
subcellular accumulation of parkin into bright puncta; all other strains showed diffuse
parkin localization as seen in wild-type yeast cells. SGT2 is a cytoplasmic co-chaperone
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that is part of a protein complex required to mediate post-translational insertion of tailanchored proteins into the endoplasmic reticulum (ER) membrane (119), suggesting that
altered capability of cells to undergo proper protein trafficking and folding affects parkin
localization. These results indicate that genetic interactions can cause growth retardation
and parkin accumulation, but these phenotypes are not necessarily dependent on one
another. The results from this limited pilot screen built a strong rational to conduct a highthroughput screen using the entire deletion and over-expression yeast libraries. A highthroughput screen may uncover novel genetic interactions with parkin and elucidate
pathways that modulate parkin localization and parkin function that have not been
described previously.
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Figure 3-3. Pilot screen for genetic modulators of parkin toxicity and localization.
Parkin or parkin-YFP was transformed into a selected set of BY deletion strains of genes
involved in managing oxidative stress and protein misfolding. (A) BY deletion strains
expressing parkin were spotted to assess the effects of parkin expression on BY deletion
strains. (B) BY deletion strains expressing parkin-YFP were grown in inducing liquid
media for 8 hours and fluorescent images were captured using a Leica TCS SP5 II confocal
microscope at 63x magnification to detect changes in parkin localization. The scale bar
represents 5 µm.
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Figure 3-3
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Table 3-1. List of yeast deletions and corresponding gene function used to screen for
parkin genetic interactions. Cellular functions and phenotypes associated with gene
deletions. Modified from the Saccharomyces Genome Database.
Gene

Function

Null Phenotype

Reference(s)

HSP12

Plasma membrane protein involved in
maintaining
membrane
organization;
involved in maintaining organization during
stress conditions; induced by heat shock,
oxidative stress, osmostress, stationary phase,
glucose depletion, oleate and alcohol.

Slow growth phenotype,
increased sensitivity to cellwall affecting drugs, and
increased flocculation.

(120, 121)

HSP30

Negative regulator of the H(+)-ATPase
Pma1p; stress-responsive protein.

No growth phenotype.

(122)

HSP31

Methylglyoxalase
that
converts
methylglyoxal to D-lactate; involved in
oxidative stress resistance.

No growth phenotype;
increased sensitivity to
oxidative stress and
accumulation of ROS.

(121)

TRX2

Cytoplasmic thioredoxin isoenzyme; part of
thioredoxin system which protects cells
against oxidative and reductive stress.

Increased heat sensitivity
and decreased resistance to
hydrogen peroxide.

(123, 124)

UBI4

Ubiquitin; becomes conjugated to proteins,
marking them for selective degradation via the
ubiquitin-26S proteasome system; essential
for the cellular stress response.

Increased sensitivity to
elevated temperature, zinc
deficiency, nitrogen
starvation, and oxidative
stress.

(125, 126)

YAP1

Basic leucine zipper (bZIP) transcription
factor; required for oxidative stress tolerance;
activated by H2O2 through the multistep
formation of disulfide bonds.

Increased mutation
frequency, decreased
resistance to oxidizing and
reducing agents.

(117)

TRX1

Cytoplasmic thioredoxin isoenzyme; part of
thioredoxin system which protects cells
against oxidative and reductive stress.

Decreased chromosome and
plasmid maintenance.

(123, 124)

TSA1

Thioredoxin peroxidase; acts as both
ribosome-associated and free cytoplasmic
antioxidant; self-associates to form highmolecular weight chaperone complex under
oxidative stress.

Hypersensitive to oxidative
stress and shows decreased
anaerobic growth rate.

(127, 128)

TSA2

Stress inducible cytoplasmic thioredoxin
peroxidase; cooperates with Tsa1p in the
removal of reactive oxygen, nitrogen and
sulfur species using thioredoxin as hydrogen
donor.

Decreased growth rate in
exponential phase.

(129, 130)
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BTN2

v-SNARE binding protein; facilitates specific
protein retrieval from a late endosome to the
Golgi; modulates arginine uptake, possible
role in mediating pH homeostasis between the
vacuole and plasma membrane H(+)-ATPase.

Decreased resistance to
acidic pH.

(118, 131)

CTA1

Catalase A; breaks down hydrogen peroxide
in the peroxisomal matrix formed by acylCoA oxidase (Pox1p) during fatty acid betaoxidation.

Decreased resistance to
oxidative stress and
decreased superoxide
accumulation.

(132, 133)

CUR1

Sorting factor, central regulator of spatial
protein quality control; physically and
functionally interacts with chaperones to
promote sorting and deposition of misfolded
proteins into cytosolic compartments.

Increased prion formation
and abnormal protein
distribution.

(11, 131)

SRX1

Sulfiredoxin; contributes to oxidative stress
resistance by reducing cysteine-sulfinic acid
groups in the peroxiredoxin Tsa1p, which is
formed upon exposure to oxidants.

Decreased oxidative stress
resistance and increased
sensitivity to hydrogen
peroxide.

(134)

SGT2

Glutamine-rich cytoplasmic co-chaperone;
serves as a scaffold bringing together TRC
complex members required to mediate
posttranslational insertion of tail-anchored
proteins into the ER membrane; plays a role in
targeting chaperones to prion aggregates.

Increased heat sensitivity
and decreased resistance to
hygromycin B.

(119)

PRX1

Mitochondrial peroxiredoxin with thioredoxin
peroxidase activity; has a role in reduction of
hydroperoxides.

Decreased resistance to
oxidative stress.

(135)

SOD2

Mitochondrial
manganese
superoxide
dismutase; protects cells against oxygen
toxicity.

Increased apoptosis, and
decreased chronological and
replicative lifespan.
Increased sensitivity to
oxidative stress, heat, and
ionic stress

(115, 116)

SNO4

Possible chaperone and cysteine protease;
required for transcriptional reprogramming
during the diauxic shift and for survival in
stationary phase

Decreased oxidative stress
resistance and increased
accumulation of ROS.

(136)
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3.4

Oxidative Stress and Parkin Accumulation
Before testing the effects of stress inducing treatments on parkin expressing cells,

we tested to see if parkin is modified from naturally occurring stress inducing chemicals,
such as reactive oxygen or nitrogen species that can be by-products of normal cellular
processes (137, 138). Based on the high cysteine content of parkin, we hypothesized that
parkin would be highly susceptible to oxidative modification in vivo. Western blots were
performed with protein lysates from yeast cells expressing parkin (Figure 3-4 A). Before
resolving by SDS-PAGE, samples were prepared in loading buffer either with or without
reducing agents (βME/DTT). In the absence of reducing agents, parkin migrated through
the gel at a faster pace than parkin treated with reducing agents. N-Ethylmaleimide (NEM)
irreversibly modifies cysteine residues by adding an alkyl group to the sulphur atom on
their side chains. When protein lysates from yeast cells expressing parkin were treated with
50 mM NEM, the molecular weight shift of parkin observed by Western blot with nonreducing buffer was eliminated (data not shown). A closer analysis of the parkin signal of
under non-reducing conditions (Figure 3-4 A lane 2) revealed a predominant species
around 50kDa with a smeared signal above and below the predominant band. These results
suggest that parkin is modified by oxidative damage under normal growth conditions in
yeast.
To test if this result was an artefact caused by the non-native environment of a yeast
cell, similar experiments were performed with three human cell lines expressing different
forms of parkin. HeLa and HEK 293 cells were chosen as simple model mammalian
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Figure 3-4. Parkin is oxidatively modified in vivo.

Figure 3-4. Parkin is oxidatively modified in vivo. Cell lysate from W303 (A) or various
mammalian cells (B) expressing parkin (W303), transiently transfected parkin (HeLa),
endogenous parkin (SH-SY5Y), or stably transfected FLAG-parkin (HEK 293) were used
to perform western blots and probe for parkin. 30µg (A) or 80µg (B) of total protein from
cell extracts were prepared in loading buffer with or without reducing agents (1% BME
and 100mM DTT). Samples were resolved by SDS-PAGE, transferred to nitrocellulose
membranes and expression of parkin was detected using immunodetection and imaged
using infrared conjugated secondary antibodies. PGK1 and tubulin were used to assess
equal loading for yeast or mammalian extracts respectively.
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systems, and SH-SY5Y cells were selected based on their neuron-like characteristics. HeLa
cells used were transiently transfected with human parkin. HEK 293 cells stably expressing
parkin tagged amino (N)-terminally with the FLAG epitope (FLAG-parkin) were provided
by Dr. Rylett (Robarts, Western University) and SH-SY5Y cells used express endogenous
parkin. Western blots were performed with protein lysates from these three cell lines
(Figure 3-4 B) which showed that there is a similar molecular weight shift for parkin in
mammalian cells in the absence of reducing agents. This trend occurred with varying
degrees of intensity, which is likely due to the various levels of parkin expression in the
different cell lines and different levels of ROS. The HeLa and HEK 293 cell lines, which
constitutively express parkin, showed the most significant shift in molecular weight,
whereas SH-SY5Y lysates expressing endogenous parkin at lower levels showed a less
significant shift.
We next sought to test the effects of adding additional stress inducing chemicals on
parkin. Spotting assays and fluorescent microscopy were performed with yeast cells
expressing parkin in the presence of various stress inducing chemicals (Figure 3-5 A). At
the concentrations used in these experiments, no significant changes were seen in the
growth rate of parkin expressing yeast cells, but treatment with H2O2 and L-Azetidine-2carboxylic acid (AZC) caused parkin-YFP to accumulate into subcellular puncta. Western
blot analysis of lysates of cells expressing parkin grown in the presence of stress inducing
chemicals (Figure 3-6) showed no noticeable difference in parkin’s migration patterns, as
parkin extracted from stress-treated cells showed the same shift in molecular weight in the
absence of reducing agents as seen in untreated yeast and mammalian cells (Figure 3-4).
Treatment with two oxidative stress inducing reagents, Antimycin A and peroxynitrite,
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Figure 3-5. Stress treatment alters parkin localization in yeast. (A) W303 cells used for
spotting growth assays and BY cells used for fluorescent microscopy were transformed
with parkin and parkin-YFP, respectively. W303 expressing parkin were spotted onto
inducing media containing 500 µM AZC, 10 µM peroxynitrite, 100 µM H2O2, 2 mM DTT,
25 µM radicicol, or 50 µM antimycin A. BY cells expressing parkin-YFP were grown in
inducing liquid media for 8 hours containing the above drug concentrations and fluorescent
images were captured using a Leica TCS SP5 II confocal microscope at 63x magnification.
The scale bars represents 5 µm. (B) W303 expressing parkin were grown in media
containing 1 mM, 0.1 mM, or 0.05 mM H2O2 and incubating at 30°C. OD600 measurements
were taken every 15 minutes and plotted to generate a growth curve. Standard deviations
did not exceed a maximum OD600 = 0.05. At mid-log growth all samples were statistically
different from the control with a P value ≤ 0.0001 as determined from a One-way ANOVA.
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Figure 3-5
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Figure 3-6. Stress treatment does not alter oxidative modification of parkin in yeast.

Figure 3-6. Stress treatment does not change oxidative modification of parkin in yeast.
Cell extracts from W303 expressing parkin grown in the presence of 100µM H2O2, 10µM
peroxynitrite, or 50µM antimycin A were prepared in loading buffer with or without
reducing agents (1% BME and 100mM DTT). Samples were resolved by SDS-PAGE,
transferred to nitrocellulose membranes and expression of parkin was detected using
immunodetection and imaged using infrared conjugated secondary antibodies.
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appear to cause and increase in overall parkin levels, but the experiment would need to be
repeated in order to determine if this trend is statistically significant.
H2O2 was chosen for subsequent experiments based on its relevance to disease
associated cell damage. Growth curves with increasing concentrations of H2O2 showed that
up to a concentration of 100 µM, H2O2 had no effect on cell growth in the presence or
absence of parkin (Figure 3-5 B). Increasing the concentration of H2O2 to 1 mM caused a
slowed entry in logarithmic growth phase as well as a slower growth rate during
exponential growth as indicated by the maximum slope of the curve for both control cells
and cells expressing parkin. Although cell growth is affected by the increased H2O2
concentration, the difference between wild-type cells and cells expressing parkin did not
seem to change when compared to untreated cells.
Next we tested if stress treatment would cause similar changes to parkin
localization in mammalian cells. HeLa cells transiently transfected with parkin were treated
with stress inducing chemicals and parkin localization was assessed using
immunofluorescence microscopy (Figure 3-7 A). In contrast to the results found in yeast,
HeLa cells treated with stress chemicals showed no change in parkin localization as we
observed the same diffuse parkin localization seen in untreated cells. Western blots (Figure
3-7 B) showed that parkin also undergoes a molecular weight shift in the absence of
reducing agents and this effect seems unchanged by the presence of stress inducing
chemicals. Overall, there were only minor effects caused by stress treatment that seemed
mostly exclusive to yeast. The lack of observed effects in HeLa cells could be a result of
the increased capability of mammalian cells to cope with various types of cellular stress.
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Figure 3-7. Parkin is unaffected by stress treatment in HeLa cells. HeLa cells
transiently transfected with parkin were used to assess the effects of stress treatment on
parkin in mammalian cells. After transfection, cells were given 24 hours to recover in full
media before treating for 8 hours with 75 µM H2O2, 10 µM MG132, 10 µM peroxynitrite,
or 10 mM AZC. Following treatment (A) cells were passaged to 8 chamber microscopy
slides and prepared for immunofluorescence imaging. Parkin was visualized using an
AlexaFluor-488 conjugated secondary antibody and nuclei were stained with DAPI.
Images were captured a Zeiss Axio Vert A1 Inverted fluorescent microscope using a 40x
objective. Scale bars represent 10 µm. Parkin is stained green and nuclei are stained blue.
(B) Cells lysates (30 µg total protein) were analyzed by Western blotting detecting parkin
in the presence or absence of reducing agent in the loading buffer.
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Figure 3-7.
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3.5

Subcellular Localization of Parkin Truncations and Point

Mutations
Extensive experimentation has been performed to structurally characterize each of
the functional domains of parkin and to determine how different domains interact and move
within the entire parkin protein while executing its enzymatic activity (63, 65). Based on
this knowledge, we generated functional truncation variants of parkin that we used to
characterize and map changes to specific domains of the protein. Four truncation variants
were generated and transformed into yeast. These variants include: 1. 141C, which has a
N-terminal truncation of the first 140 residues that include the autoinhibitory Ubl domain
and an unstructured linker region of approximately 70 amino acids; this parkin variant has
increased activity compared to the wild-type protein and can be used to monitor how
dysregulation of parkin affects misfolding and toxicity; 2. 141-409, which is similar to
141C with an additional 56 residue C-terminal truncation of the catalytic C-terminal
Rcat/RING2 domain. This variant is unable to perform the catalytic transfer of ubiquitin
from E2 to substrate proteins; 3. 321C, which has a 320 residue N-terminal truncation
leaving only the two most C-terminal domains (Brcat/IRB and Rcat/RING2) intact. This
variant is capable of ubiquitination activity, albeit with reduced efficiency; and 4. Ubl,
which only has the most N-terminal 76 residues that make up the ubiquitin-like (Ubl)
domain; this domain performs an autoinhibitory function within the parkin protein.
Furthermore, we employed a set of four point mutants selected based on structural
and functional features of parkin. Two of these point mutants were used previously by
Wen-Jie et. al (71). C289G and C418R, and have been identified as AR-JP causing
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mutations. These parkin variants contain amino acid changes of cysteine residues that
coordinate Zn2+ ions required for proper parkin folding (60). By altering these residues,
parkin is unable to properly bind Zn2+ ions and loses its structural integrity, and thus has
an increased propensity to misfold. These mutants were used to compare oxidative stress
induced misfolding to aggregation caused by pathogenic AR-JP mutants. The other two
mutations were to S65, the serine residue in parkin’s Ubl domain, which is phosphorylated
by PINK1 (88). The S65A mutant was used to monitor how parkin aggregation and toxicity
changes in the absence of PINK1-mediated phosphorylation. The S65E mutant was used
as a phospho-mimic to determine whether aggregation and toxicity was caused by S65
phosphorylation.
We first developed yeast models of all the truncation variants, testing toxicity,
localization and expression. Spotting assays and growth curves revealed that all of the
truncation variants caused a mild growth retardation that was identical to that caused by
wild-type full-length parkin (Figure 3-8 A and B). Localization studies were performed
with C-terminally YFP-tagged parkin truncation variants (Figure 3-8 C and D).
Fluorescent microscopy showed that like parkin, Ubl and 321C were diffusely spread
throughout the cytosol, but 141C and 141-409 had altered subcellular localization (Figure
3-8 E). 141C formed small subcellular puncta, similar in size and distribution to those
caused by AZC or H2O2 treatment on parkin-YFP expressing cells (Figure 3-5 A) with
some diffuse staining. 141-409 caused more severe changes, forming either several large
or many small puncta with no diffuse staining occurring in any cells. These findings
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Figure 3-8. Truncations cause subcellular accumulation of parkin without altering
growth in yeast. W303 transformed with parkin truncation variants (A/B) or C-terminally
YFP tagged parkin truncation variants (C/D) were used to perform growth assays. Spotting
assays (A/C) were performed by growing liquid cultures of W303 to stationary phase in
non-inducing selective media. Cultures were diluted to OD600 = 1.0 and serial diluted 1:5
before spotting on selective inducing agar media and incubated at 30°C for 2-4 days before
imaging to assess the effects of parkin truncations with and without C-terminal YFP tags
compared to wild type parkin. Growth curves (B/D) were performed by growing liquid
cultures to stationary phase in non-inducing selective media. Cultures were washed twice
with sterile H2O and resuspended in inducing selective media before diluting to OD600 =
0.2 and incubating at 30°C. OD600 measurements were taken every 15 minutes and plotted
to generate a growth curve. Standard deviations did not exceed a maximum OD600 = 0.02.
At mid-log growth all samples were statistically different from the control with a P value
≤ 0.001 as determined from a One-way ANOVA ● (Black) – Vector; ■ (Green) – Parkin or
Parkin-YFP; ▲ (Purple) – 141C or 141C-YFP; ▼ (Blue) – 141-409 or 141-409-YFP; ♦
(Orange) – 321C or 321C-YFP; ● (Teal) – Ubl or Ubl-YFP. (E) BY transformed with Nterminally YFP tagged parkin truncation variants were grown in inducing liquid media for
8 hours and fluorescent images were captured using a Leica TCS SP5 II confocal
microscope at 63x magnification. The scale bars represents 5µm.
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Figure 3-9. Parkin 141C truncation is expressed at higher levels than wild type parkin
in yeast. (A) Schematic representation of parkin and its domains. Thirty µg total protein
were used for Western blots detecting parkin. Primary antibodies with epitopes specifically
recognizing various domains were used to detect parkin and the various truncation variants
and compare relative expression. A RING2 specific antibody was used to detect parkin,
141C, and 321C (B), a RING 1 specific antibody was used to detect parkin, 141C, and 141409 (D), and a Ubl specific antibody was used to detect parkin and Ubl (F). Signal
intensities were measured and quantified, setting the value of wild-type parkin expression
to 1. Means were compared using a one-way ANOVA (C and E) or an unpaired T-test (G).
Two asterisks (**) indicates a statistical difference with a p value ≤ 0.01. . Black – Parkin;
Green – 141C; Purple – 321C; Blue – 141-409; Orange – Ubl.
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Figure 3-9
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suggest that the Rcat/RING2 domain removed in the 141-409 variant plays a role in
maintaining proper parkin folding and localization.
We next tested expression levels of the parkin truncation variants in yeast. Because
it was not possible to compare all variants using the same antibody, three different primary
anti-parkin antibodies were used to quantify the expression of the different truncation
variants. In each case, the level of wild-type full length parkin expression was arbitrarily
set to one, and the relative intensity of the truncation variants was compared to wild-type
parkin (Figure 3-9). Although the α-Rcat/RING2 1° antibody (Cell Signalling) yielded
approximately a three-fold stronger signal than the α-RING1 1° antibody (Abcam) for
wild-type parkin using the same lysates (data not shown), in both cases, nearly three times
more 141C was expressed than wild-type parkin (Figure 3-9 C and E). The three
remaining truncation variants were expressed at relatively similar levels to wild-type fulllength parkin (Figure 3-9 C, E, and G).
We then performed the same set of experiments to test the four parkin point
mutants. All four point mutants had the same growth phenotypes as wild-type parkin in the
presence or absence of C-terminal YFP tags, showing only mild growth restriction (Figure
3-10 A, B, C, and D). Fluorescent microscopy revealed that the C289G and C418R
mutants formed subcellular aggregates (previously shown in mammalian cells (71)), but
both S65 mutants showed diffuse cytosolic localization (Figure 3-10 E). The aggregates
formed by the C289G and C418R mutants resemble those formed by the 141C variant
(Figure 3-8 E), forming one or more small puncta per cell with some diffuse staining still
occurring. Analysis of expression levels showed that all four point mutants had similar
expression levels compared to wild type parkin (Figure 3-11 A and B). Only
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Figure 3-10. Parkin point mutants are non-toxic but alter parkin localization and
expression levels in yeast. W303 cells expressing parkin point mutants (A and B) or Cterminally YFP tagged parkin point mutants (C and D) were used for growth assays.
Spotting assays (A and C) were performed to assess the effects of parkin truncations with
and without C-terminal YFP tags compared to wild type parkin. Growth curves (B and D)
were performed by growing in inducing selective at 30°C. OD600 measurements were taken
every 15 minutes and plotted to generate a growth curve. Standard deviations did not
exceed a maximum OD600 = 0.05. At mid-log growth all samples were statistically different
from the control with a P value ≤ 0.01 as determined from a One-way ANOVA. Samples
tested were; ● (Black) Vector, ■ (Green) Parkin/Parkin-YFP, ▲ (Purple) Parkin
S65A/Parkin S65A-YFP, ▼ (Blue) Parkin S65E/Parkin S65E-YFP, ♦ (Orange) Parkin
C289G/Parkin C289G-YFP; and ● (Teal) Parkin C418R/Parkin C418R-YFP. (E) BY cells
expressing C-terminally YFP tagged parkin point mutants were grown in inducing liquid
media for 8 hours and fluorescent images were captured using a Leica TCS SP5 II confocal
microscope at 63x magnification. The scale bars represents 5µm.
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Figure 3-11. Point mutations change parkin levels in yeast.

Figure 3-11. Point mutations change parkin levels in yeast. (A) 30µg total protein of
cell extracts from W303 transformed with parkin or parkin point mutants were resolved by
SDS-PAGE, transferred to a nitrocellulose membrane and expression was detected using
immunodetection and imaged using infrared conjugated secondary antibodies. Samples
were run in triplicate, quantified, and graphed (B) setting the value of wild type parkin
expression to 1. Means were compared using a one-way ANOVA. An asterisk (*) indicates
statistical difference with a p value ≤ 0.05. Black – Parkin; Green – Parkin S65A; Purple –
Parkin S65E; Blue – Parkin C289G; Orange – Parkin C418R.
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the decreased level of the S65A mutant and the increased amount of the S65E, C289G and
C418R mutants were statistically significant.
We next tested the expression of the parkin truncation variants and point mutants
in mammalian cells to test if any of these results were artefacts caused by parkin expression
in yeast, as shown for chemical stress treatment of parkin (Figure 3-7). Due to technical
issues with strong background signals, the 141-409, 321C, and Ubl truncation variants
could not be detected though immunofluorescence microscopy in transfected HeLa cells.
Despite extensive testing and protocol adjustments, all four different parkin antibodies
tested here showed significant background staining in untransfected HeLa cell that express
no endogenous parkin (Appendix 3). Additionally, only the Rcat/RING2 primary antibody
was able to detect parkin in Western blots, so the following experiments were performed
with only the parkin point mutants and the 141C variant. Immunofluorescence microscopy
staining revealed that 141C, S65A and S65E, like wild type parkin, were cellular diffuse,
and the C289G and C418R mutants formed subcellular aggregates as previously shown
(71) (Figure 3-12 A). Western blots of transfected cell lysates showed that, in contrast to
results in yeast, 141C is expressed at significantly lower levels than parkin (Figure 3-12 B
and C). Similarly, the S65A point mutant, that had lower expression in yeast, was
expressed at nearly four-fold higher levels than wild-type parkin in transfected HeLa cells
(Figure 3-12 D and E). Similarly, the S65E point mutant was expressed at even higher
levels than S65A, suggesting that modification of the Ubl domain plays a significant role
in parkin expression and stability in mammalian cells. In contrast, the expression levels of
the two parkin cysteine mutants were similar to wild-type parkin (Figure 3-12 D and E).
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Figure 3-12. Parkin point mutants and truncations have altered expression and
cellular localization in Hela cells. HeLa cells transiently transfected with parkin, parkin
truncation variants, or parkin point mutants were used to assess the effects of parkin
alterations in mammalian cells. After transfection, cells were given 24 hours to recover in
full media before further treatment. (A) Transfected Hela cells were passaged to 8 chamber
microscopy slides and prepared for immunofluorescence imaging. Parkin, 141C, and four
parkin point mutants were immunodetected with a RING2 specific primary antibody and
subsequently visualized using an AlexaFluor-488 conjugated secondary antibody. Cell
nuclei were stained with DAPI. Images were captured a Zeiss Axio Vert A1 Inverted
fluorescent microscope using a 40x objective. Scale bars represent 10µm. Parkin, 141C,
and parkin point mutants are stained green, nuclei are stained blue. (B and D) Cells used
for Western blotting were washed and lysed before resolving 30µg total protein by SDSPAGE. Samples were run in triplicate and signal intensities were quantified relative to the
tubulin loading control and graphed (C and E), setting wild-type parkin levels to 1. Means
were compared using an unpaired T-test (C) or a one-way ANOVA (E). Two, three, or four
asterisks (**/***/****) indicates a statistical difference with a p value ≤ 0.01, ≤ 0.001, or
≤ 0.0001, respectively. Tubulin was used to assess equal loading. . Black – Parkin; Green
– 141C; Purple – Parkin S65A; Blue – Parkin S65E; Orange – Parkin C289G; Teal – Parkin
C418R.
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Figure 3-12
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In summary, modification of key cysteine residues involved in zinc ion
coordination (C289G and C418) significantly affected parkin solubility in both yeast and
mammalian cells. Modification of S65 did not seem to affect parkin localization but had
variable effects on expression in yeast and mammalian cells. 141C caused parkin
aggregation and increased expression in yeast but had no effect on localization and showed
reduced expression in HeLa cells.

3.6

PINK1 Modulates Parkin Localization, Toxicity, and Stability
With the recent explosion of literature focused on the relationship between parkin

and PTEN-induced putative kinase 1 (PINK1), we next decided to study the effects of coexpressing these two proteins in yeast. Most of the parkin/PINK1 related literature focuses
on how PINK1 activates parkin and the ensuing ubiquitination and turnover of damaged
mitochondria (mitophagy). In contrast, our study aimed to explore PINK1 as a modifier of
parkin folding and stability, and thereby determine how the addition of PINK1 affects
parkin localization, expression, degradation, and toxicity.
Unlike most proteins, expression of the human form of PINK1 in yeast would not
allow for proper function of the protein because human PINK1 appears to be degraded
rapidly in yeast. Many studies suggest that PINK1 is anchored to the mitochondria via an
N-terminal leader sequence that directs the protein to the mitochondrial membrane after
translation (77). Unfortunately, this leader sequence is human-specific, and would not
properly transport PINK1 to the mitochondria in yeast. A modified PINK1 clone containing
a yeast specific N-terminal outer mitochondrial protein (OMP) leader sequence and a Cterminal FLAG tag was generously provided to us by our collaborator Dr. Endo (Kyoto
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Sangyo University). This template was used to clone PINK1 into yeast vectors for
expression in our model system. Also, the kinase activity of PINK1 was eliminated by
mutating two key aspartic acid residues to alanine (D3682A and D384A). We used these
mutations to create a kinase dead (KD) PINK1 mutant by mutagenic PCR and subsequently
cloned into yeast expression vectors as a control.
3.6.1

Co-expression of PINK1 and Parkin in Yeast
These yeast specific PINK1 and KD PINK1 clones were co-expressed with parkin

and the parkin truncation variants to test for toxicity (Figure 3-13). Interestingly, in yeast,
PINK1 expression caused a mildly toxic phenotype on its own (Figure 3-13 A lane 2)
which does not occur with the KD PINK1 mutant (Figure 3-13 E lane 2). When coexpressed with PINK1, wild-type parkin caused a severe toxic phenotype, almost
completely inhibiting growth (Figure 3-13 A lane 3). Although parkin and PINK1 on their
own caused only mild or slightly more severe growth inhibition, respectively, the coexpression of both had drastically increased (i.e. synergistic) growth inhibition.
Interestingly, co-expression of PINK1 with the parkin truncation variants still exhibit
artificial toxicity, even when expressed with variants lacking S65, including 141C, which
is the site of PINK1 mediated phosphorylation of parkin (Figure 3-13 A and B).
PINK1 was then co-expressed with parkin-YFP and C-terminally YFP-tagged
truncation variants (Figure 3-13 C and D) which showed a similar growth phenotype as
their untagged counterparts with PINK1 and parkin-YFP causing the most significant
toxicity, and reduced toxicity when PINK1 is co-expressed with 141C-YFP. In all cases,
the addition of a C-terminal YFP tag slightly reduced the growth defect compared to their
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Figure 3-13. Co-expression of parkin and PINK1 causes toxicity in yeast. W303
expressing PINK1-FLAG (A, B, C, and D) or kinase dead (KD) PINK1-FLAG (E and F)
and parkin truncation variants (A, B, E, and F) or C-terminally YFP tagged parkin
truncations (C and D) were used to perform growth assays. Spotting assays (A/C/E) were
performed to assess the effects of parkin truncations with and without C-terminal YFP tags
compared to wild type parkin in the presence of PINK1 or KD PINK1. Growth curves (B,
D, and F) were performed by growing in inducing selective media at 30°C. OD600
measurements were taken every 15 minutes and plotted to generate a growth curve.
Standard deviations did not exceed a maximum OD600 = 0.02. At mid-log growth all
samples were statistically different from the control with a P value ≤ 0.01 as determined
from a One-way ANOVA The constructs tested were; ● (Black) Vector, ■ (Green)
PINK1/KD PINK1, PINK1/KD PINK1 with ▲ (Purple) Parkin/Parkin-YFP, ▼ (Blue)
141C/141C-YFP, ♦ (Orange) 141-409/141-409-YFP, ● (Teal) 321C/321C-YFP, and ■
(Red) Ubl/Ubl-YFP.
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Figure 3-14. Co-expression of parkin and PINK1 causes yeast cell death. (A) Western
blot using 30µg total protein of cell extracts from W303 expressing parkin, parkin and
PINK1-FLAG, or parkin and KD PINK1-FLAG were probed with an anti-parkin antibody.
PGK1 was used to assess equal loading. (B) SYTOX Green cell death assay was used to
assess cell death from the co-expression of parkin with wild-type or KD PINK1 based on
the dye’s inability to enter live cells. After 8 hour of induction, cultures were incubated
with SYTOX Green dye and emission was measured that was correlate to cell death. Values
were corrected to culture density. Samples were run in triplicate, quantified, and graphed
setting a boiled control to 100% cell death. Two, three, or four asterisks (**/***/****)
indicate a statistical difference with a p value ≤ 0.05, ≤ 0.001, or ≤ 0.0001 respectively.
Black – Vector; Green – Parkin; Purple – PINK1; Blue – PINK1 + Parkin; Orange – KD
PINK1; Teal – KD PINK1 + Parkin; ■ Red – Boiled.
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untagged counterparts. Co-expression of parkin and the parkin truncation variants with KD
PINK1 were all non-toxic (Figure 3-13 E and F), suggesting that this toxic effect is
dependent on the kinase activity of PINK1. We then ensured that wild-type (WT) and KD
PINK1 were expressed properly in yeast. Western blots of yeast cell expressing WT or KD
PINK1 in the absence and presence of parkin showed that PINK1 was stably expressed in
yeast, but the KD mutant seemed to be expressed at lower levels than WT PINK1 (Figure
3-14 A).
To test whether the toxic effects caused by PINK1/parkin co-expression were based
on growth inhibition or cell death, a SYTOX® Green based assay was used (Figure 3-14
B). SYTOX® Green is a nuclear stain that is membrane impermeable and can only enter
dead cells. As shown above (Figure 3-2 A and B and Figure 3-13 A and B), parkin and
PINK1 independently cause mild growth defects. The SYTOX® assay revealed that this
defect is actually cell death, each resulting in approximately 75% viability compared to the
control. The co-expression of the two proteins caused even more cell death showing
approximately 45% viability compared to the control. Given that parkin and PINK1
independently cause about 25% cell death each, these results suggest that the amount of
cell death caused by their co-expression is proportional to the combinatorial effects of the
two. This contrasts our result seen in Figure 3-13 A and B in which PINK1/parkin toxicity
appears to be synergistic, almost completely inhibiting growth. These findings would
suggest that PINK1/parkin co-expression causes cell death while simultaneously inhibiting
growth of viable yeast cells. As expected, expression of KD PINK1 causes no additional
cell death compared to the control, but its co-expression with
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Figure 3-15. PINK1 causes parkin accumulation in yeast. BY cells expressing parkinYFP or C-terminally YFP tagged parkin truncations in the absence (As shown above in
Figure 3-8) and presence of (B) PINK1 or (C) KD PINK1. Cells were grown in inducing
liquid inducing media for 8 hours and fluorescent images were captured using a Leica TCS
SP5 II confocal microscope at 63x magnification. The scales bar represent 5µm.
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Figure 3-15
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parkin eliminated the cell death caused by parkin alone, suggesting that KD PINK1 protects
yeast from parkin toxicity.
We next performed fluorescent microscopy to test if PINK1 co-expression caused
changes to parkin localization (Figure 3-15). The addition of PINK1 caused parkin-YFP
to form subcellular aggregates and almost completely eliminated any diffuse parkin
staining from the cytosol. Since 141C-YFP and 141-409-YFP already formed subcellular
aggregates on their own, co-expression with PINK1 did not have an effect on their
localization. 321C-YFP localization was also unaffected from the co-expression with
PINK1 which is not surprising because PINK1 does not interact with or phosphorylate any
residues within this parkin truncation. However, the co-expression of PINK1 did cause a
subtle change to Ubl-YFP localization, causing the formation of extremely small
fluorescent foci in a small number of cells.
Since PINK1 caused such a significant change in parkin localization, we next tested
if parkin aggregates caused by the introduction of PINK1 had amyloid-like biophysical
properties, such as robust insolubility in the presence of potent detergents. To test this,
semi-denaturing detergent agarose gel electrophoresis (SDD AGE) was used (Figure 316). This technique utilizes mild lysis conditions in attempts to preserve subcellular
aggregates. Protein samples are run through agarose with low sodium dodecyl sulfate
(SDS) content, instead of polyacrylamide gel, where large amyloid-like complexes remain
intact and run through the gel very slowly. This results in a high molecular weight species
for insoluble, amyloid-like protein aggregates, as seen with the polyQ-expanded huntingtin
protein (72Q) which was used as a positive control.
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Figure 3-16. PINK1 induced parkin aggregates are not amyloid-like.

Figure 3-16. PINK1 induced parkin aggregates are not amyloid-like. 30µg total protein
of cell extracts from W303 expressing parkin, or parkin and PINK1 were resolved by semidenaturing detergent agarose gel electrophoresis (SDD AGE), transferred to nitrocellulose
membranes via capillary force and expression of parkin was detected using
immunodetection and imaged using infrared conjugated secondary antibodies. 25Q and
72Q huntingtin lysates were used as controls to show non amyloid-like and amyloid-like
aggregation respectively.
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In contrast, soluble, non-amyloid-like proteins run migrate through the gel as a monomer
and show a single band at the expected molecular weight, as seen with the non-expanded
huntingtin protein (25Q) which was used as a negative control. Despite testing several
lysis and running conditions, as well as H2O2 treated parkin samples (data not shown), we
did not detect amyloid-like protein aggregates composed of parkin in cells co-expressing
parkin and PINK1.
We next tested how point mutations within parkin would affect PINK1 induced
growth phenotypes in yeast. Growth assays were performed using WT and KD PINK1 coexpressed with the four parkin point mutants. All four of the point mutants showed
significantly reduced toxicity compared to wild-type parkin (Figure 3-17 A and B). The
results from spotting assays and growth curve assays were somewhat contradictory, as
spotting assays performed on solid agar media showed strong reduction of toxicity (Figure
3-17 A), whereas growth curves performed in liquid media showed that the point mutants,
when co-expressed with PINK1, are still more toxic than PINK1 alone (Figure 3-17 B).
This discrepancy might be caused by the different growth patterns of yeast in liquid and on
solid media. Results from spotting assays typically represent a later time point in the yeast
growth cycle where the point mutants co-expressed with PINK could have caught up to
cells expressing PINK1 alone. In both cases, wild-type parkin was significantly more toxic
than all of the point mutants when expressed with PINK1, implying that the interaction of
PINK1 and parkin is altered by parkin point mutations. Again, co-expression of the point
mutants with the KD PINK1 abolished all toxicity (Figure 3-17 C and D).
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Figure 3-17. PINK1/parkin toxicity is rescued by parkin point mutations. W303 cells
expressing PINK1-FLAG (A and B) or kinase dead (KD) PINK1-FLAG (C and D) and
parkin point mutants (A, B, C, and D) were used to perform growth assays. Spotting assays
(A/C) were performed by growing on selective inducing agar media to assess the effects of
parkin truncations with and without C-terminal YFP tags compared to wild type parkin in
the presence of PINK1 or KD PINK1. Growth curves (B and D) were performed by
growing liquid cultures in inducing selective media at 30°C. OD600 measurements were
taken every 15 minutes and plotted to generate a growth curve. Standard deviations did not
exceed a maximum OD600 = 0.02. At mid-log growth all samples were statistically different
from the control with a P value ≤ 0.05 as determined from a One-way ANOVA. Samples
tested were; ● (Black) Vector, ■ (Green) PINK1/KD PINK1, PINK1/KD PINK1 with ▲
(Purple) Parkin,▼ (Blue) Parkin S65A, ♦ (Orange) Parkin S65E, ● (Teal) Parkin C289G,
and ■ (Red) Parkin C418R.
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Figure 3-17.
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Figure 3-18. PINK1 mildly affects localization of mutant forms of parkin in yeast. BY
cells expressing parkin-YFP or C-terminally YFP tagged parkin point mutants in the
absence (As shown above in Figure 3-10) and presence of (B) PINK1 or (C) KD PINK1
were grown in inducing liquid media for 8 hours and fluorescent images were captured
using a Leica TCS SP5 II confocal microscope at 63x magnification. The scales bar
represent 5 µm.
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Figure 3-18
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Figure 3-19. Parkin levels are decreased upon co-expression with PINK1 in yeast.

Figure 3-19. Parkin levels are decreased upon co-expression with PINK1 in yeast. (A)
30µg total protein of cell extracts from W303 expressing parkin or parkin and PINK1 were
resolved by SDS-PAGE, transferred to nitrocellulose membranes and expression of parkin
was detected using immunodetection and imaged using infrared conjugated secondary
antibodies. (B) Parkin signal intensities from n=11 samples were measured and quantified
relative to the PGK1 loading control and parkin levels in cells not co-expressing PINK1
was set to 1. Means were compared using an unpaired T-test and two asterisks (**)
indicates a statistical difference with a p value ≤ 0.001. PGK1 was used to assess equal
loading. Black – Parkin; Green – PINK1 + Parkin.
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Florescent microscopy was also performed with cells co-expressing the parkin
point mutants and WT or KD PINK1 (Figure 3-18). We observed mild changes in the
localization of parkin S65A and S65E mutants, which formed one to two puncta in a small
proportion of cells. The drastically reduced effects on parkin localization caused by point
mutations also suggest the PINK1/parkin interaction is modified by parkin point mutations.
While testing the effects of co-expressing parkin and PINK1, we noticed that the
levels of parkin being expressed in the presence of PINK1 seemed to be reduced compared
to cells expressing parkin alone. Western blots were performed with protein lysates from
yeast cells expressing parkin and co-expressing parkin and PINK1 using different
combinations of protease inhibitors, and run in the presence and absence of reducing agents
(Figure 3-19 A). The levels of parkin in cells co-expressing parkin and PINK1 were
reduced by almost two and a half fold compared to cells expressing parkin alone (Figure
3-19 B).
3.6.2

Co-expression of PINK1 and Parkin in Mammalian Cells
Since the expression of wild type parkin with PINK1 had the most drastic effects

in yeast, we decided to focus on this interaction in mammalian cells. HeLa cells transfected
with parkin, co-transfected with parkin and PINK1, or co-transfected parkin and KD
PINK1

were

analyzed for parkin localization and stability (Figure

3-20).

Immunofluorescence microscopy revealed that the co-expression of parkin with WT
PINK1 caused no changes in parkin localization, as parkin staining remained diffuse
(Figure 3-20 A). This result is consistent with the literature which shows that cells
endogenously expressing parkin and PINK1 do not show altered parkin localization
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Figure 3-20. Co-expression of PINK1/parkin in HeLa cells. HeLa cells transiently
transfected with parkin, parkin and PINK1, or parkin and kinase-dead (KD) PINK1 were
used to assess the affects PINK1 on parkin localization and stability in mammalian cells.
After transfection, cells were given 24 hours to recover in full media before further
treatment. (A) Transfected HeLa cells were passaged to 8 chamber microscopy slides and
prepared for immunofluorescence imaging. Parkin was visualized using an AlexaFluor-488
conjugated secondary antibody and nuclei were stained with DAPI. Images were captured
a Zeiss Axio Vert A1 Inverted fluorescent microscope using a 40x objective. Scale bars
represent 10µm. Parkin is shown in green and nuclei are shown in blue. (B) Cell lysates of
HeLa transfected with the indicated constructs were used for Western blotting detecting
parkin and tubulin as a loading control (C) Parkin signal intensities were measured and
quantified relative to the tubulin loading control and graphed. Parkin levels in non-cotransfected cells was set to 1. Means were compared using a one-way ANOVA. Black –
Parkin; Green – PINK1 + Parkin; Purple – KD PINK1 + Parkin.
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Figure 3-20.
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unless they are treated with the mitochondrial uncoupling agent CCCP (83) which causes
the production of excessive amounts of ROS. Western blots were performed with lysates
from these cells and quantification yet again revealed no changes in response to coexpression of parkin and PINK1 (Figure 3-20 B and C).
Our next goal was to test whether PINK1/parkin co-expression caused toxicity in
mammalian cells. For these experiments, both HeLa and HEK 293 cell lines were used.
Initially, HeLa cells were transfected with all possible combinations of parkin, wild-type
PINK1 and KD PINK1. Following the transfection period, cells were given 24 hours to
recover in full media (10% FBS and 4.5 g/L glucose) before testing cell viability (Figure
3-21 A). We observed no significant difference in cell viability for any combination of
proteins. We speculated that the 24 hour recovery period was not long enough for the cells
to accumulate sufficient amounts of the toxic species potentially caused by co-expressing
PINK1 and parkin. To test this, HeLa cells were transfected with the same combination of
proteins, but following the transfection period, cells were given four days to recover in
either full media or minimal media (1% FBS and 1 g/L glucose) (Figure 3-21 B).
Incubating cells in minimal media reduces their division rate and could allow for more
accumulation of a toxic species.
Yet again, the co-expression of PINK1 and parkin was not detrimental to cell
viability, but in fact, had the highest cell viability in both the full and minimal media
recovery conditions. This would suggest that the co-expression of PINK1 and parkin
actually plays a protective role in mammalian cells. Lastly, HEK 293 cells stably
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Figure 3-21. PINK1 and parkin co-expression in mammalian cells is non-toxic. (A)
HeLa cells transiently transfected with all permutations of parkin, PINK1, kinase dead
(KD) PINK1, and GFP as a control were given 24 hours to recover in full media (4.5 g/L
glucose and 10% FBS) before analyzing cell viability using an ATP based luminescence
assay. (B) HeLa cells transfected in an identical manner as in A were given four days to
recover in either full media or minimal media (1 g/L glucose and 1% FBS) before analyzing
cell viability using an ATP based luminescence assay. (C) HEK 293 cells stably expressing
FLAG-parkin were transfected with vectors for PINK1 or KD PINK1 expression and given
four days to recover in either full media or minimal media before analyzing cell viability
using an ATP based luminescence assay. For all data sets samples were run in triplicate,
quantified and graphed. Means were compared using a one-way ANOVA. One, two, three,
or four asterisks (*/**/***/****) indicates a statistical difference with a p value ≤ 0.05, ≤
0.01, ≤ 0.001, or ≤ 0.0001 respectively. Black – No DNA; Green – GFP; Purple – Parkin;
Blue – PINK1; Orange – PINK1 + Parkin; Teal – KD PINK1; Red – KD PINK1 + Parkin.
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Figure 3-21
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expressing FLAG-parkin were used to test how cells that are constantly expressing parkin
are affected by the introduction of PINK1. Again cells were transfected to combine parkin
expression with wild-type or KD PINK1 and allowed to recover for four days in full or
minimal media (Figure 3-21 C). Again, cells expressing parkin and PINK1 were equally
as viable as cells co-expressing parkin and KD PINK1, suggesting that the co-expression
of parkin and PINK1 does not exhibit the same toxicity in mammalian cells as it does in
yeast. These results suggest that the changes in parkin localization and stability caused by
PINK1 are yeast-specific and could be due to their inability to cope with phospho-parkin
as they do not inherently express orthologues of either of these two proteins.

3.7

Parkin Proteolysis and Degradation in Yeast
Throughout our investigations, we noticed that Western blots of parkin expressing

yeast lysates showed multiple highly reproducible bands of a lower molecular weight than
the expected 52 kDa size of the full-length protein. These additional banding patterns also
seemed to be specific depending on the epitope of the 1° antibody used (Figure 3-22 B).
When using the α-Ubl antibody (Figure 3-22 B panel 3) or the α-Rcat/RING2 antibody
(Figure 3-22 B panel 1), which correspond to the most N and C-terminal domains of
parkin, respectively, multiple bands were visualized between the range of 50 and 10 kDa
with an additional band of high intensity running close to the dye front at around 5-10 kDa.
Alternatively, using an α-RING1 antibody (Figure 3-22 B panel 2), which is specific to a
domain near the middle of parkin, showed fewer low molecular weight bands, and instead,
showed two to three bands greater than 25 kDa. Given that these bands were clearly
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Figure 3-22. Parkin is degraded into distinct proteolytic fragments in vivo.

Figure 3-22. Parkin is degraded into distinct proteolytic fragments in vivo. (A)
Schematic representation of parkin and its domains. (B) Thirty µg total protein of cell
extracts from wild type W303 and W303 expressing parkin were analyzed by Westernblotting using three different primary antibodies with epitopes specific for distinct regions
of parkin. (C) To assess if proteolytic cleavage products were being produced during or
after cell lysis an alternate technique was used to prepare cell lysates. One W303 culture
expressing parkin was equally split and lysed using two different techniques. The left lane
used the standard glass bead lysis technique where cell are lysed in the presence of multiple
different protease inhibitor. The right panel was lysed by boiling in a NaOH based lysis
buffer and loading directly to the gel following neutralization, which does not allow postlysis proteolysis. After lysis samples were resolved by SDS-PAGE and imaged in an
identical manner as described in B.
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parkin specific as they did not appear in wild type yeast cells, we believe that parkin is
naturally undergoing proteolytic cleavage in vivo. To eliminate the possibility that this
cleavage was occurring after lysis of the yeast cells, a NaOH based lysis technique was
used, where cells were boiled in a NaOH based buffer, which would immediately denature
all proteins and deactivate all proteases. After boiling, the samples were pH-neutralized
and loaded directly into acrylamide gels, where they were resolved by SDS-PAGE next to
a lysate that was prepared by glass bead lysis with protease inhibitors in the buffer (Figure
3-22 C). Western blots of these samples showed nearly identical size bands at
approximately 30, 25 and 10 kDa in both lysates, suggesting that this proteolytic cleavage
is occurring pre-lysis.
Next we tested if parkin was degraded in yeast cells by the 26S proteasome.
Because yeast efficiently export many small molecules, including the proteasome inhibitor
MG132, a yeast strain with deletions of the genes encoding PDR1 and PDR3, cell
membrane transport proteins, were used to allow effective proteasome inhibition by
MG132. Δpdr1,3 yeast cells transformed with parkin were grown in inducing liquid media
for ten hours to allow for parkin accumulation. Then expression of the galactose inducible
GAL1 parkin promoter was quenched with the addition of glucose to a final concentration
of 2%. Simultaneously, samples were treated with either 50 µM MG132 to inhibit 26S
proteasome dependent degradation or an equivalent volume of dimethyl sulfoxide (DMSO)
as a control. Aliquots of the cultures were taken every four hours for twelve hours. Western
blots were performed with these lysates and parkin levels were quantified relative to PGK1,
which is a highly abundant stable protein in yeast. After setting the values of parkin at time
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Figure 3-23. Inhibiting the 26S proteasome increases parkin stability in yeast. (A)
After 8 hours of induction in selective media W303 Δpdr1,3 cells expressing parkin were
washed twice in sterile water and resuspended in non-inducing selective media (to prevent
further parkin expression) with either 50 µM MG132 or an equivalent volume of DMSO
added. Aliquots of the cultures were taken every four hours for twelve hours. (C) Cultured
HEK 293 cells stably expressing FLAG-parkin and (D) SH-SY5Y cells expressing
endogenous parkin were treated with cycloheximide (Cx) and DMSO or 10 µM MG132.
Similar to the technique described in panel A, samples were harvested at various time
points and frozen until all time points had been collected. (B/C/D) samples were lysed and
30 µg of total protein was resolved by Western blotting for parkin (B) Samples were run in
triplicate and parkin levels were quantified and normalized relative to the PGK1 loading
control. (C and D) Sample were run in triplicate and parkin levels were quantified without
normalization to a loading control. (B, C, and D) Parkin levels were independently set to 1
at time zero for the DMSO and MG132 treated samples. Means of the same time points
were compared using a two-way ANOVA. Three or four asterisks (***/****) represent
statistically significant differences with a p value ≤ 0.001 or ≤ 0.0001 respectively. Black
– DMSO treated; Green – MG132 treated.
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Figure 3-23.
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0 to 100%, the relative parkin intensities showed a decrease in overall parkin over the
course of 12 hour for both the MG132 and DMSO treated controls, with significantly less
degradation in the MG132 treated samples (Figure 3-23 A and B). After twelve hours
about 30% of the original parkin remained in control cells whereas MG132 treated cells
retained nearly double the amount of parkin. In these experiments only the predominant
band representing the full length protein was quantified, although samples did exhibit lower
molecular weight bands as described in Figure 3-22 as well as high molecular weight
smears that could represent poly-ubiquitinated parkin (data not shown). These data suggest
that in yeast grown under normal conditions, parkin undergoes significant proteasomedependent degradation.
Similar experiments were performed with HEK 293 cells stably expressing FLAGparkin and SH-SY5Y cells expressing endogenous parkin. In these systems expression of
all proteins was quenched using cycloheximide and samples were again treated with either
MG132 or DMSO as a control (Figure 3-23 C and D). Cells were followed for either 16
or 20 hours before lysis and Western blotting. The results showed no statistical difference
between MG132-treated or untreated samples in either cell line.
We next tested the effect on proteasome inhibition on parkin degradation without
inhibiting protein expression. HeLa cells transfected with parkin-expressing vectors were
treated to test the effects of decreased protein degradation. Following treatment with 10
µM MG132 for 8 hours, proteins were extracted, and parkin stability was analyzed by
Western blotting. We noticed an increase in parkin levels in MG132 treated cells compared
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to untreated controls (Figure 3-24 A and B). This result indicates that transfected parkin
is degraded by the 26S proteasome in HeLa cells.
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Figure 3-24. Parkin stability is mildly increased by MG132 in Hela cells.

Figure 3-24. Parkin stability is mildly increased by MG132 in Hela cells. Cell lysates
of HeLa cells transfected with parkin were analyzed by Western blotting (A) to detect
parkin. (B) Steady state levels of parkin were compared to cells treated with MG132 and
parkin levels were quantified relative to the tubulin loading control. Parkin levels in
untreated cells was set to 1. Means were compared using an unpaired T-test and an asterisk
(*) indicates a statistical difference with a p value ≤ 0.05. Tubulin was used to assess equal
loading. Black – untreated; Green – MG132 treated.
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Chapter Four: Discussion
4.1 Introduction – Parkin in PD
The E3 ubiquitin ligase parkin is essential for maintaining neuronal health in the
substantia nigra and the dysfunction of parkin has been associated with familial and
sporadic forms of PD (139). Parkin prevents the accumulation of damaged cellular
proteins, particularly mitochondrial proteins, thus regulating the homeostasis of
mitochondria, and consequently diminishing oxidative stress caused by ROS (140).
PINK1, a serine/threonine kinase, has been implicated as a key regulator of parkin through
two interrelated mechanisms: PINK1-mediated phosphorylation of parkin and PINK1mediated phosphorylation of ubiquitin, which activates parkin (77, 78). In addition to
insufficient phosphorylation of parkin by PINK1, damage to parkin by oxidative stress,
loss of function mutations, and gain of function mutations resulting in parkin misfolding
have also been associated with parkin dysfunction in PD (114, 139, 141, 142). Yet the
cellular and molecular mechanisms by which parkin damage and misfolding contribute to
PD remain poorly understood.
The overall goal of this thesis was to decipher how parkin regulation by
PINK1, parkin misfolding and subsequent stress on the cellular protein quality
control machinery, and oxidative damage to parkin contribute to parkin
dysregulation and dysfunction in PD.
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4.2

Summary of Findings and Significance

4.2.1

Sequence Analysis
Analysis of parkin’s amino acid sequence demonstrated that the structurally and

functionally determined catalytic triad consisting of C431, H433, and E444 located in
parkin’s Rcat/RING2 domain (112) is highly conserved across multiple different
evolutionary distant species (Figure 3-1). Importantly, this analysis also revealed an
unusually high level of conserved cysteine residues throughout the entire parkin protein
with the exception of the N-terminal Ubl domain that contains only one cysteine. Thirty
five of human parkin’s 465 total amino acid residues are cysteines, giving it an overall
cysteine content of 7.52%, which is nearly three times higher than the average for other
human proteins (2.26% according to (7)). Structural studies have determined that 28 of
these cysteine residues are required for coordination of eight Zn2+ ions in four distinct
parkin domains (59). Accordingly, Zn2+ coordination does not account for all 31 of the
conserved cysteines within parkin.
Cysteine residues are inherently sensitive to oxidative and nitrogenous
modifications, and they can be essential for sensing and regulating levels of stress-inducing
chemicals in the cell. For example, the Kelch-like ECH-associated protein 1 (Keap1) is an
oxidative stress sensing protein that regulates the transcription factor Nuclear factor
(erythroid-derived 2)-like 2 (Nrf2, (143)). Under normal cellular conditions Keap1
facilitates ubiquitination of Nrf2 in the cytosol, thus inducing rapid degradation of Nrf2.
This prevents Nrf2 from entering the nucleus where it is transcriptionally active (143).
Under condition of oxidative stress, C151 of Keap1 is oxidatively modified, causing a

117

conformational shift that releases Nrf2 and allows it to enter the nucleus and promote
transcription of antioxidant genes.
Increased oxidative stress is a hallmark of PD (144, 145) and is closely associated
with cellular damage. Additionally, oxidative stress induced by CCCP-mediated
uncoupling of the electron transport chain causes a change in parkin localization, recruiting
it to the mitochondria to activate its role in mitophagy (76, 78, 81). Also, Chung et al. have
shown that parkin can be S-nitrosylated by nitric oxide (NO) and that this modification
reduces its activity (146). In a similar manner, parkin could be modified in response to
increased levels of oxidative stress, diminishing its E3 activity. A decrease in parkin
activity could result in an increased load on the protein quality control machinery and
activate one of many protective cellular stress responses programs.
In essence, parkin could act as a cellular sensor to detect and preemptively respond
to oxidative stress and activate an anti-oxidant response. However, no previous studies
have directly addressed oxidative damage to parkin and its ensuing misfolding. This would
present a previously unknown function of parkin in stress homeostasis and in PD.
4.2.2

Parkin Yeast Model
Following successful examples of PD yeast models in the literature (99–109), we

established a parkin yeast model, which we used as an experimental platform for further
experimentation (Figure 3-2). In our model, parkin was diffusely localized throughout the
yeast cytosol as previously observed in mammalian cells, including human neurons (113,
114, 147). We also showed that parkin is stably expressed and that it only slightly decreased
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the growth rate of yeast. This effect can be attributed specifically to expression of parkin
since expression of a similar sized protein in yeast does not inhibit growth (Appendix 5).
4.2.3

Genetic Interactions of Parkin
Using our parkin yeast model, we performed a small scale genetic screen with 17

yeast deletion strains deficient in genes required for oxidative stress management and
protein quality control to unravel genetic interactions with parkin (Figure 3-3). In this
screen one gene deletion (SGT2) was identified that significantly altered parkin
localization and two gene deletions (YAP1 and BTN2) were identified that significantly
reduced growth of yeast cells expressing parkin. Notably, only one gene deletion (SOD2)
altered both parkin localization and reduced the growth of cells expressing parkin
simultaneously.
Deletion of SOD2, encoding the mitochondrial superoxide dismutase, which
prevents the accumulation of superoxide radicals, does not have a growth phenotype under
regular conditions. Yet the expression of parkin caused a significant reduction in the
growth rate of SOD2 deleted yeast. SOD2 deletion also altered parkin localization, causing
small subcellular inclusions of parkin in addition to the diffuse localization pattern
observed in wild-type cells. This result supports our idea that parkin acts as an oxidative
stress sensor. The yeast SOD2 deletion strain accumulates excessive amounts of ROS
(148), which may oxidatively damage parkin, result in parkin misfolding, and alter parkin’s
subcellular localization, thus inhibiting growth.
In order to confirm that these changes are indeed a result of increased levels of
ROS, future experiments would need to test for increased levels of ROS and compare these
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results to wild-type cells and cells exposed to chemically-induced oxidative stress. If parkin
were properly functioning in wild-type yeast cells to degrade damaged proteins, the
increase in ROS may modify parkin causing its aggregation, thereby inhibiting its
protective function. This decrease in protective parkin activity could cause an increased
burden on the protein quality control machinery, leading to growth inhibition.
Alternatively, the rise in ROS levels may not damage parkin itself. Instead, ROS
may modify and damage other cellular proteins, increasing the number of proteins that
require processing and degradation. The juxtaneuclear quality-control compartment
(JUNQ) and perivacuolar insoluble protein deposit (IPOD) were first described by
Kaganovich et. al in yeast as intracellular compartments that sequester misfolded cytosolic
proteins (33). This research showed that when ubiquitinated, soluble misfolded proteins
are directed to JUNQ, which contains a high concentration of proteasomes. JUNQ has been
described as a site where misfolded proteins are sequestered when proteasome activity is
impaired, often in response to cellular stress including heat shock. Following recovery from
stress conditions, proteins sequestered to JUNQ can either be refolded via molecular
chaperones or degraded by the proteasome. In contrast, proteins that were not ubiquitinated
were directed to IPOD which is speculated to permanently sequester toxic amyloid-like
proteins, thus preventing their toxic interaction with cytosolic proteins.
In the SOD2 deletion strain, parkin may be recruited to areas with increased need
for UPS activity, like JUNQ, which would account for our observation of subcellular
puncta with some remaining diffuse signal. In this scenario, an increased burden on the
protein quality control machinery could also prevent normal growth by directing more

120

resources towards eliminating damaged proteins. Whether parkin or other cellular proteins
are damaged by ROS in the SOD2 deletion strain, our data suggest that parkin responds to
increased ROS in the cell. The relationship between SOD2 and parkin has not been
thoroughly characterized in the literature but our findings present an enticing basis to
further study this genetic interaction.
Deletion of YAP1, and deletion of BTN2 both caused a decrease in growth rate of
yeast cell expressing parkin compared to wild-type cells, yet neither deletion caused a
change in parkin localization. Yap1 encodes a transcription factor required for oxidative
stress tolerance (117) and BTN2 encodes a v-SNARE binding protein that facilities protein
retrieval from the late endosome to the Golgi and contributes to prion curling (118).
Decreased growth in the YAP1 deletion strain closely relates to the effects of the SOD2
deletion strain, in that an inadequate cellular response to oxidative stress causes parkinrelated growth defects. This further supports the notion that oxidative stress is a major
contributor to parkin modification.
Our data for the BTN2 deletion, however, suggests a role of parkin associated with
inadequate protein quality control beyond oxidative stress. Yeast deficient in BTN2 show
increased propensity to accumulate prions (149), and have altered protein trafficking and
localization. Therefore parkin toxicity in the BTN2 deletion strain could imply that parkin’s
E3 activity is required to degrade accumulating prion proteins. Here, an increased burden
on the protein quality control machinery caused by increased UPS activity of parkin could
induce cellular stress and inhibit growth.
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This may seem counter-intuitive as it is also plausible that parkin expression in
these cells would eliminate prion accumulation, thus playing a protective role. The
accumulation of potentially toxic proteins, such as prions, into benign aggregates has been
suggested to prevent additional damage to the cell (33). It is possible that parkin
ubiquitinates the sequestered prions and releases them into the cell, causing toxicity and
inhibiting growth. This could be tested by assessing parkin ubiquitination activity on prion
or prion-like proteins in the absence of BTN2 in future experiments.
Finally, deletion of SGT2, encoding a cytoplasmic HSP90 co-chaperone required
to mediate post-translational insertion of tail-anchored proteins into the ER membrane
(119), altered parkin localization. In this strain, we observed the formation of large puncta
in addition to diffuse cytosolic parkin staining. Without SGT2, yeast cells may accumulate
unprocessed proteins in the cytosol that normally require processing and insertion into the
ER membrane. The observed change in parkin localization suggests that parkin is recruited
to areas of the cell with an increased need for protein degradation, including JUNQ as
described above, and may play a protective role to eliminate damaged or misfolded proteins
and prevent cell damage. Notably, SGT2 deletion strains do not exhibit decreased growth
in the absence of parkin, even though they have impaired insertion of tail-anchored proteins
into the ER membrane. Apparently, the cellular protein quality control machinery
adequately processes these mislocalized proteins and prevent growth defects. The
expression of parkin in this strain may act as an additional support for UPS-mediated
degradation of mislocalized proteins and therefore alters parkin localization without
causing toxicity.
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Figure 4-1. Parkin genetic interaction network.

Figure 4-1. Parkin genetic interaction network. Network of genetic interactions of
parkin showing two degrees of separation. Genetic interactions with parkin identified in
this thesis are shown in blue and previously established genetic associations with
interactors of parkin are shown in yellow.
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To test this concept, we would need to examine parkin expression in a SGT2
deletion strain that has additional gene deletions of yeast E3 ligases or other genes involved
in protein turnover and UPS. If parkin expression in these cells rescues growth defects
caused by the buildup of misfolded proteins, it will support our claim that parkin is essential
for protein folding homeostasis.
Overall, our pilot screen identified interesting and rather unexpected genetic
interactions with parkin that implicate a role for parkin in both oxidative stress management
and protein quality control as shown in Figure 4-1. Importantly, this provides a strong
rationale to proceed with large scale genetic screens using deletion and over-expression
libraries encompassing the entire yeast genome. This will further elucidate the parkin
interaction network and identify previously unknown roles for parkin and potential
therapeutic targets for treating PD. This is supported by previous findings from large scale
genetic screens that identified toxic modifiers of mutant Htt and α-synuclein in yeast (150).
4.2.4

Oxidative Damage to Parkin
We next assessed the state of parkin oxidation. When performing Western blots on

cellular protein lysates, the convention is to use reducing conditions (151). Although this
often improves the quality and analyses of results, artificially reducing proteins eliminates
oxidative modifications to proteins (151). In Figure 3-4, we compared protein lysates of
yeast and mammalian cells prepared in reducing and non-reducing conditions by Western
blot. We found that, under non-reducing conditions, parkin migrates in SDS-PAGE at a
faster rate and produces a less defined signal. This suggests the presence of intramolecular
disulfide formation between any of the 35 cysteine residues within parkin.
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Furthermore, we observed a large shift in the apparent molecular weight of parkin
expressed in HeLa and HEK293, and to a lesser extent in SH-SY5Y cells (Figure 3-4 B).
In these experiments, unmodified SH-SY5Y cells were used to analyze endogenous levels
of parkin, whereas HeLa and HEK293 cells used constitutively expressed transfected
parkin at higher levels, as indicated by the strong signal intensity. Excess parkin
accumulation caused by constitutive over-expression in HeLa and HEK293 cells may not
be turned over as efficiently as lower levels of endogenous parkin in SH-SY5Y. As a result,
excess parkin may be subjected to increased oxidative damage, thus increasing the number
of disulfides formed and enhancing the shift in molecular weight seen in non-reducing
Western blots for HeLa and HEK293 cells.
To further test the effects of parkin oxidation, we performed experiments in yeast
with the addition of stress inducing chemicals to mimic the conditions potentially found in
aging and PD patient cells (Figures 3-5, 3-6 and 3-7). We found that treatment with H2O2
and AZC elicited drastic changes in parkin localization causing the formation of multiple
small puncta throughout cells. Treatment with these chemicals thus resembled aberrant
parkin localization as observed in our pilot yeast deletion screen (Figure 3-4). H2O2
treatment is reminiscent of the oxidative stress in the SOD2 deletion strain as both caused
the accumulation of parkin. Furthermore, impaired protein folding by AZC treatment and
the ensuing induction of the heat shock response (152) mimic the effects of SGT2 deletion
which lead to increased levels of damaged or misfolded proteins which also affects parkin
localization.
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Both AZC and H2O2 altered parkin localization, which suggests that different types
of cellular stress conditions affect the cellular localization and accumulation of parkin.
Also, treatment with H2O2 and AZC generally causes the accumulation and mislocalization
of damaged and misfolded proteins, which may recruit a significant proportion of parkin.
Alternatively, stress treatment could cause damage to parkin itself, leading to its
sequestration for processing by molecular chaperones or the protein degradation
machinery. However, Western blot analysis did not reveal any significant change in parkin
migration patterns in the presence of H2O2 and other stress inducing chemicals (Figure 36), which does not clarify whether parkin is directly modified as a result of chemical stress.
Further experiments will be required to decipher whether these chemicals are indeed
modifying parkin itself or whether they indirectly affect parkin localization in yeast. The
use of antibodies that specifically recognize oxidatively modified cysteine residues could
clarify if parkin directly undergoes oxidative modification.
Growth curve assays in the presence of increasing concentrations H2O2 in yeast
were used to elucidate a role of parkin under high levels of oxidative stress (Figure 3-5 B).
Only at a concentration of 1 mM did the addition H2O2 have an effect on cell growth. At
this concentration, H2O2 caused a delayed entry in logarithmic growth phase and caused
slower growth during exponential growth phase. Although cell growth was affected by the
increased H2O2 concentration, the difference between wild-type cells and cells expressing
parkin was unaffected compared to untreated cells, suggesting that parkin is neither playing
a protective nor a detrimental role in the presence of H2O2 in yeast.
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We performed similar experiments in HeLa cells where H2O2, AZC, and other
stress inducing chemicals were added before assessing parkin localization by
immunofluorescence microscopy and parkin modification via Western blot (Figure 3-7).
None of these stress treatments showed changes in parkin localization or migration
compared to untreated cells. Although they are derived from human cells, the rapid rate of
division of HeLa cells may act to effectively dilute toxic misfolded proteins induced by
chemical stress, thus preventing changes to parkin localization or oxidative modification.
4.2.5

Parkin Mutants and Truncations Alter Parkin Localization
We used several truncation variants of parkin and specific parkin point mutants

(Figure 1-6) to study the effect of parkin misfolding and map these effects to specific
parkin domains. When expressed in wild-type yeast cells, none of the parkin variants or
point mutants had any effect on cell growth. Furthermore, expression of the parkin S65A
and S65E mutants as well as the 321C parkin variant did not alter parkin localization.
Several parkin variants did, however, cause drastic changes in parkin localization and
stability (Figures 3-8, 3-9, 3-10, and 3-11).
The AR-JP causing C289G and C418R mutants affecting residues required for Zn2+
coordination caused parkin to accumulate into subcellular foci (Figure 3-10) as shown
previously (71). This change in parkin localization was similar to changes observed upon
treatment with AZC and H2O2, and the SOD2 and SGT2 gene deletions from our pilot
screen, where parkin formed multiple small inclusions while additionally maintaining
some diffuse cytosolic localization. Expressing the overactive 141C mutant (Figure 3-8)
also showed a similar localization pattern. The C289G and C418R mutants are structurally
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unstable and misfold and thus may form aggregates. However, our Western blot analysis
revealed that these mutants were expressed at the same level as wild-type parkin, which
would suggest that they are not being degraded more than wild-type parkin. These mutants
might simply relocate to specific subcellular locations, such as IPOD or JUNQ, to prevent
their interference with normal cellular functions as discussed in section 4.2.3.
In contrast, the 141-409 mutant caused a more drastic change to parkin
localization. Truncation of both the Ubl and Rcat/RING2 domains eliminated all diffused
cytosolic parkin, and instead, caused parkin to form either two to three larger, or multiple
smaller puncta. Evidently, the regulation of parkin by the Ubl domain and linker alters its
localization as shown with the 141C variant. The additional truncation of the Rcat/RING2
domain in the 141-409 parkin variant, however, seems to further decrease parkin stability.
This effect may be caused by the loss of the two structurally required Zn2+ ions found in
the Rcat/RING2 domain, or destabilization of the entire C-terminus of parkin since
Rcat/RING2 is adjacent to the RING0 domain when properly folded (63).
Our experiments did not directly test the solubility of these parkin aggregates.
Future work should therefore include experiments that directly assess the solubility of
parkin and its mutants, which could determine whether parkin mutations and truncations
form insoluble protein aggregates or if they simply change parkin localization. These
experiments will include Triton X-100 based solubility assays that can differentiate
between soluble and insoluble fractions of cell lysates (153).
We selected only the 141C variant and the four point mutants for our experiments
in HeLa cells (Figure 3-12). Localization studies showed that neither S65A nor S65E
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parkin mutants altered parkin localization, but the AR-JP causing C289G and C418R
mutants formed subcellular inclusions while maintaining some diffuse cytosolic
localization. Western blots showed similar expression levels of the cysteine mutants
compared to wild-type parkin. This supports our previous claim that these mutants are
being sequestered to JUNQ-like compartments, and are not degraded as discussed in
section 4.2.3.
In contrast to the results seen in yeast, the N-terminal truncation of the Ubl domain
and linker region in the 141C variant did not alter parkin localization in HeLa cells. Also,
experiments testing the stability of 141C in mammalian cells similarly did not resemble
our result in yeast. In Hela cells, 141C is expressed at approximately 50% of the level of
wild-type parkin (Figure 3-12 B and C), whereas in yeast, 141C is expressed at nearly
three times higher levels than wild-type parkin (Figure 3-9 B, C, D and E). Human cells
endogenously express parkin, and likely contain pathways that require parkin activity.
However, 141C is not normally expressed in mammalian cells and may therefore not be
recognized and subsequently degraded. Alternatively, yeast cells do not endogenously
express parkin or 141C, suggesting that they may be processed differently in yeast than in
mammalian calls which could account for the difference in stability observed in these
experiments. The discrepancies between our yeast and mammalian systems are further
discussed below in section 4.3.1.
4.2.6

PINK1 Modulates Parkin Localization and Toxicity
The regulation of parkin by PINK1 has emerged as an important concept in parkin

activation. Our next experiments addressed the PINK1-parkin interaction using our yeast
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and mammalian cell models and we further characterized this interaction with parkin point
mutants and parkin truncation variants.
4.2.6.1 Co-expression of PINK1 and Parkin Truncation Variants Cause Toxicity in Yeast
When expressed alone in yeast, human PINK1, containing a yeast-specific
mitochondrial targeting sequence, exhibited a slightly more pronounced growth defect than
that seen when expressing parkin alone (Figure 3-13 A and B). In contrast, the coexpression of PINK1 and wild-type parkin caused a severe growth inhibition. Experiments
with a kinase dead mutant form of PINK1 showed that this effect is dependent on the kinase
activity of PINK1. Of all variants used in this study, only the wild-type parkin and the two
cysteine mutants contain intact S65 and thus can be phosphorylated by PINK1. It was
therefore unexpected to find that the co-expression of PINK1 with 141C also exhibited a
severe growth inhibition that was only slightly less toxic than the co-expression of PINK1
and wild-type parkin.
Our results suggest that the toxicity caused by the co-expression of PINK1 and
parkin can at least partially be attributed to PINK1-mediated parkin phosphorylation. Yet
the toxicity observed from co-expression of PINK1 cannot be attributed to phosphorylation
of 141C, since it lacks the PINK1 phosphorylation site located in parkin’s Ubl domain.
Here, PINK1 may interact with and phosphorylate other proteins, which could be
particularly toxic in yeast cells expressing 141C.
PINK1 has previously been shown to phosphorylate not only parkin (81, 142), but
also mitochondrial proteins including TOM20 and mitofusin (86, 87) and, importantly,
ubiquitin. Additionally, it has been postulated that phospho-ubiquitin strongly contributes
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to parkin activation (154). Given that the 141C variant that lacks the auto-inhibitory Ubl
domain, phosphorylation of ubiquitin in yeast by PINK1 may act to even further activate
141C. This may result in UPS overloading and cellular stress. Figure 4-2 presents a model
for PINK1 activity that involves phosphorylation of ubiquitin, mitochondrial, and
cytoplasmic proteins causing increased activity of the 141C variant leading to increased
UPS activity and degradation of essential cellular proteins. This can explain the observed
growth inhibition that occurred independently of PINK1-mediated phosphorylation of
parkin.
When co-expressing all of our parkin variants with PINK1, wild-type parkin, 141C
and the independently expressed Ubl domain all exhibited PINK1-dependent changes in
localization (Figure 3-15 B). Since PINK1 can phosphorylate ubiquitin and considering
the structural similarity between the Ubl domain and ubiquitin, PINK1 may phosphorylate
S65 of parkin’s Ubl domain, even when it is detached from the rest of parkin. The Ubl
domain might thus mimic phospho-ubiquitin and its function in the UPS. Only a fraction
of the Ubl appears to be affected by PINK1 because the majority of the Ubl remains
diffusely localized and small bright foci are formed in a small proportion of cells.
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Figure 4-2. Model of PINK1-mediated increase of parkin ubiquitination activity in
yeast causing toxicity. A) Under normal conditions, parkin or 141C is located in the
cytosol and exhibits standard levels of ubiquitination activity. B) Following the
introduction of PINK1 1) ubiquitin, 2) cytosolic proteins, or 3) mitochondrial proteins are
phosphorylated by PINK1. 4) In response to 1, 2, or 3, parkin or 141C becomes overactive,
which leads to 5) uncontrolled ubiquitination and 6) degradation of essential cellular
proteins causing toxicity. 7) Alternatively, an increase in parkin activity increases parkin
auto-ubiquitination leading to its degradation.
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To test if parkin’s Ubl domain can at least partially function as ubiquitin future
experiments could use yeast strains expressing Ubl in place of the standard ubiquitin fusion
genes and test their viability. Yeast cells contain four genes encoding ubiquitin, and yeast
cells remain viable when up to three of these genes are deleted. By deleting these ubiquitin
fusion genes while simultaneously expressing parkin’s Ubl domain, we would be able to
test cell viability and determine whether the Ubl domain can function in place of ubiquitin
in yeast cells.
When independently expressed in yeast, the 141C parkin variant exhibited an
altered localization compared to wild-type parkin as we have previously discussed in
section 4.2.5. However, when we co-expressed 141C with PINK1, the formation of
subcellular 141C puncta was exacerbated, causing a decrease in the amount of diffusely
localized protein. This finding supports our model presented in Figure 4-2 where PINK1
increases the activity of the already overactive 141C variant of parkin indirectly by
phosphorylating ubiquitin or other cellular proteins.
Most parkin variants used here maintained some level of diffuse localization when
expressed in yeast. The co-expression of PINK1, however, eliminated all diffuse wild-type
parkin from the cytosol and formed similar puncta as seen with the 141-409 variant. In
combination with the results from our growth assays, this could suggest that in the presence
of PINK1, parkin is activated, as documented by several groups (142, 154–156). Yet parkin
may also undergo a conformational change that causes its misfolding into a species that is
toxic to the cell. Further testing would be required to determine the composition and
structure of the parkin inclusions caused by its interaction with PINK1.
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In addition, PINK1 expression could create phospho-ubiquitin in yeast. This could
explain the toxicity associated with PINK1 expression, as yeast may not normally express
a kinase that efficiently phosphorylates ubiquitin. Therefore phospho-ubiquitin may disturb
UPS function and cause toxicity. In any case, the co-expression of parkin with PINK1 adds
complexity to this scenario.
We did not assess the presence of phospho-parkin or phospho-ubiquitin in our yeast
model, but future work could clarify the cause of these significant changes in parkin
localization and toxicity. Experiments to test the presence of phospho-parkin or phosphoubiquitin using phospho-specific antibodies in localization studies and Western blot could
establish that PINK1 acts to phosphorylate parkin or ubiquitin in yeast. Coimmunoprecipitation of parkin substrates while inhibiting protein degradation with
proteasome inhibitor would be followed by Western blot analysis probing for ubiquitin and
phospho-ubiquitin in the presence and absence of PINK1. These experiments would
indicate if parkin activity is increased in the presence of PINK1, if phospho-ubiquitin is
created by PINK1, and if phospho-ubiquitin is incorporated into poly-ubiquitin chains built
on parkin substrates.
Growth assays testing PINK1 co-expression with parkin-YFP supports our notion
that PINK1 induces parkin misfolding. When co-expressing C-terminally YFP tagged
wild-type parkin and parkin variants with PINK1, we observed similar toxicity as with
untagged parkin and parkin variants co-expressed with PINK1. In all cases, the expression
of YFP fusion forms of parkin reduced growth inhibition compared to untagged forms of
the protein. Fluorescent protein fusions have been shown to increase the solubility of
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normally insoluble proteins (157, 158) thus reducing the toxicity associated with protein
misfolding. Our results suggest that PINK1 causes parkin to misfold and form a toxic
insoluble species and subsequently the YFP fusion solubilizes parkin and reduces its
toxicity.
We also tested if parkin formed amyloid-like aggregates in yeast using SDD-AGE
(Figure 3-16), yet our experiments showed that parkin does not form amyloid-like
conformers. This does not, however, disprove that parkin misfolds and forms soluble
aggregates. Future experiments will include sedimentation assays to assess if parkin
changes its three-dimensional conformation or misfolds when co-expressed with PINK1,
when mutated, or when exposed to stress conditions.
4.2.6.2 Toxicity Associated with Co-expression of PINK1 and Parkin is Reduced by
Parkin Point Mutations in Yeast
As discussed above, the co-expression of PINK1 with parkin induced severe growth
inhibition in yeast. However, when co-expressing our four parkin point mutants with
PINK1, we observed a significant decrease in PINK1-parkin dependent toxicity that only
slightly differed depending on the parkin mutant being expressed (Figure 3-17).
The expression of all four point mutants caused similarly reduced levels of toxicity.
However, the parkin S65E mutant, which to some extent mimics PINK1 phosphorylated
parkin, caused a more severe growth defect than the other parkin point mutants, including
the S65A mutant which cannot be phosphorylated by PINK1. This finding again may
indicate that PINK1 alters parkin activity indirectly by phosphorylation of other cellular
proteins including ubiquitin, which only additional experiments can clarify.
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The increased toxicity caused by the phospho-mimic S65E parkin suggests that
PINK1-mediated phosphorylation of parkin also contributes to parkin regulation. The use
of aspartic and glutamic acid residues to mimic phosphorylation of proteins is a widely
used technique but many studies have suggested that these substitutions can only partially
recapitulate effects caused by phosphorylation (154, 159). The addition of a negatively
charged residue mimics the effects of phosphate addition to a protein, but phosphate groups
have a significantly a different shape than the carboxyl group of aspartic or glutamic acid
residues. Additionally, phosphates carry two negative charges compared to the single
negative charge on an acidic residue. These differences between phosphates and phosphomimics may explain the decreased toxicity caused by the expression of the S65E parkin
mutant compared to PINK1 co-expression with wild-type parkin.
The co-expression of the C289G and C418R parkin mutants with PINK1 also
reduced toxicity compared to wild-type parkin. Although these parkin mutants still contain
the S65 site of PINK1-directled phosphorylation and can be phosphorylated, they are
structurally unstable (71). The misfolding of these parkin mutants caused by the loss of
structurally required Zn2+ ions may cause a conformational shift that renders S65 partially
inaccessible to PINK1 and prevent their phosphorylation. Alternatively, the structural
instability of C289G and C418R may expose the Ubl domain to more efficient PINKmediated phosphorylation. In any case, C289G and C418R are loss of function mutations
(57), suggesting that PINK1-mediated phosphorylation of these mutants or other cellular
proteins do not have the capacity to affect their already compromised functional state.
Phosphorylation of parkin and C289G and C418R, may induce parkin misfolding, which
is toxic to yeast cells. This would account for the toxicity observed in these experiments
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co-expressing PINK1 with C289G and C418R parkin. Additionally, this would explain part
of the toxicity caused by co-expression of PINK1 with wild-type parkin as discussed in
section 4.2.6.1.
Co-expression of PINK1 (Figure 3-18) with C289G and C418R resulted in
unaltered localization patterns. S65 parkin mutants exhibited slightly altered localization
upon co-expression with PINK1, where both S65A and S65E parkin formed one or two
small puncta in a small proportion of cells. Since neither of these S65 parkin mutants can
be phosphorylated by PINK1, this suggests that the change in localization is due to the
phosphorylation of ubiquitin to activate these parkin mutants and alter their localization.
4.2.6.3 PINK1 Co-expression with Parkin in HeLa Cells Increases Viability
Following these findings in yeast we performed similar localization and viability
experiments in mammalian cells co-expressing wild-type parkin and PINK1. Neither
toxicity associated with co-expression of PINK1 and parkin, nor changes in parkin
localization were observed in HeLa cells. Viability assays showed an increase in cell
viability by approximately 25% (Figure 3-21 B). These findings support the model
currently accepted in the literature that parkin and its regulation by PINK1 are protective
(88, 160, 161). As discussed in sections 4.2.5. and 4.3.1., the absence of endogenously
expressed PINK1 and parkin and subsequent lack of processing or function in yeast may
account for the discrepancies between our yeast and mammalian models.
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4.2.7

Parkin Turnover and Degradation
In some of our experiments, we showed that parkin undergoes oxidative

modification in vivo. Additionally, our results suggested that parkin undergoes proteolytic
degradation (Figure 3-22 B). We also determined that parkin is degraded in yeast via
degradation by the UPS (Figure 3-23). We propose that parkin misfolding under normal
conditions and, by extension, conditions of oxidative stress, affect parkin activity, stability,
and misfolding.
We also showed that when co-expressed with PINK1, parkin is less stable than
when expressed alone in yeast (Figure 3-19). Similar experiments found that parkin
stability was increased in HeLa cells following inhibition of the proteasome, albeit to a
small extent. This suggests that parkin also undergoes proteasome-dependent degradation
in mammalian cell but at a slower rate than in yeast. Future experiments could include
testing the degradation and relative stability of the parkin point mutants and truncation
variants used in this study to determine if AR-JP causing mutations can lead to altered
parkin stability and potentially map which domains of parkin are essential for maintaining
stability.
Ultimately, more work is required to further clarify the involvement of the protein
quality control machinery in parkin degradation, and if this contributes to PD pathogenesis.
Nevertheless, these results give an interesting basis for studying parkin post-translational
processing and degradation and its effects on protein function and longevity.
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4.3

Experimental Limitations

A thorough discussion of technical problems and limitations can be found in Appendix 1.
4.3 Modelling Parkinson’s Disease in Yeast – Opportunities and Limitations
Studying human proteins and diseases in model organisms is a commonly used
strategy in biomedical research, but there are inherent limitations with every model system.
During our investigation, we discovered several interesting results regarding parkin
misfolding, altered localization, toxicity, degradation, and oxidative modification in our
yeast model. Notably, most of these findings did not replicate in mammalian cells. Unlike
human cells, yeast cells do not endogenously express parkin, PINK1, or related orthologues
of either protein. This allowed us to monitor the effects of co-expressing these proteins in
yeast using it as a simple living test tube. Our approach to studying parkin and PINK1 in
yeast relied mainly on analyzing phenotypic changes caused by the expression of one or
both of these proteins; these phenotypic analyses included changes in growth rate, protein
localization, and levels of protein expression.
One limitation of using yeast to study these proteins is that it is difficult to assess
the functional state of parkin or PINK1 in vivo using these methods of analysis. It is
possible that parkin expressed in yeast has altered function compared to parkin expressed
in human cells. For example, parkin could have increased or decreased activity, or even be
completely inactive. This could be due to differences is in the subcellular environment of
yeast cells, which may render parkin unable to recognize substrates for ubiquitination.

140

Alternatively, yeast E2s may not interact with parkin, rendering it unable to carry out
ubiquitination and protein degradation.
It is also possible that the introduction of a non-native E3 to yeast disrupts normal
cellular protein quality control and causes adverse effects. This circumstance seems
unlikely, as expression of parkin alone did not noticeably affect yeast in any of our
experiments. This could, however, occur upon co-expression of parkin with PINK which
caused drastic changes to parkin toxicity, localization, stability, and potentially, activity.
Nevertheless, without a bona fide parkin substrate, it is nearly impossible to definitively
determine if parkin activity is altered in yeast.
Similarly, it is difficult to assess the phosphorylation activity of PINK1 in yeast. In
attempts to ensure normal PINK1 localization, a modified mitochondrial targeting
sequence was used in our experiments to direct PINK1 to yeast mitochondria. Most
evidence suggests that PINK1 predominantly acts to phosphorylate parkin or ubiquitin (88,
142, 154, 155). PINK1 has also been shown to phosphorylate mitochondrial proteins such
as TOM20 and mitofusin (86, 87). As discussed above, the foreign environment of yeast
could expose PINK1 to different substrates and yeast mitochondrial proteins may not be
recognized by PINK1, preventing their phosphorylation. All these scenarios may
contribute to the toxic effects caused by the co-expression of PINK1 and parkin in yeast,
which do not directly translate to human cells.
Additionally, results from our yeast model may not have been replicated in
mammalian system due to poor transfection efficiency. When optimizing transfection
protocols, a GFP expressing plasmid was used to determine transfection efficiency, which

141

was calculated to be 68.7% based on fluorescence. However, when examining cells
transfected with parkin in the presence or absence of PINK1, immunofluorescence showed
an estimated 20-25% of cells expressing transfected parkin. Based on this low transfection
efficiency, the lack of change to parkin localization and toxicity in the presence of PINK1
could be due to an insufficient proportion of cells expressing the transfected proteins. As a
result, any phenotypic changes potentially occurring would have been masked by the large
majority of untransfected cells.
Generally, the discrepancy observed between yeast and mammalian cells suggests
that our results may not directly address how dysfunction of parkin and PINK1 cause cell
death in human brain cells in PD. Nevertheless, our findings lead to a better understanding
of the interactions of parkin and PINK1 and cellular processing of parkin. In future, it
would be advantageous to expand other conditions established in our yeast model into
mammalian cells, using the truncation variants and point mutants in attempts to
characterize and map the PINK1/parkin related effects and perform structure-function
analyses to assess misfolding altered the activity of PINK1 or parkin.

4.4

Future Directions
We have outlined several experiments above that will be completed in the future to

address questions directly raised from our results. These experiments include: 1)
characterizing the genetic interaction of parkin and SOD2, 2) assessing the ability of parkin
to ubiquitinate prions or prion-like proteins, 3) expression of parkin in an SGT2 deletion
strain containing additional deletions of yeast E3s to determine if parkin acts to assist
normal yeast UPS, 4) perform large scale genetic screens with the entire yeast deletion and
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overexpression libraries to elucidate previously undescribed genetic interactions of parkin
and potentially, cellular functions, 5) test for direct oxidative modification of parkin, 6)
determine the solubility and conformation of parkin puncta caused by mutations,
truncations, oxidative stress, or co-expression with PINK1, 7) determine is parkin’s Ubl
domain can function in place of ubiquitin in yeast, 8) perform assays to test the activity of
PINK1 and parkin in yeast to determine their functional status, 9) test for the presence of
phospho-ubiquitin in yeast and determine if is incorporated into K63 poly-ubiquitin chains
build on substrates of the UPS, and 10) pulse-chase experiments to assess the degradation
of parkin in mammalian cells.
Looking beyond, expanding research on parkin oxidation, misfolding, and
degradation into other model systems could be extremely advantageous for understanding
these effects in humans. C. elegans has been used previously to study PD, in particular
parkin (54–57), and their eight defined dopaminergic neurons present a simplistic system
to study parkin activity in PD-relevant neuronal cell types. Fruit fly (D. melanogaster)
models have also proven to be useful for studying PD given that there are several fruit fly
models of PD genes, including parkin (166–170), and that the relationship of PINK1 and
parkin was first studied in fruit flies (171). Rodent models may also be useful to study
parkin degradation and altered localization in a complex brain system that can be used to
study and compare different brain regions that have different levels of neuronal cell death
in PD patients. Ultimately, studying these aspects of parkin regulation and modification in
post mortem PD patient brain samples will help to determine if findings from these models
translate into humans and can be attributed to parkin-mediated PD.
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4.5

Significance
The implication of parkin in both familial and idiopathic PD and the limited

understanding of the mechanisms underlying parkin dysfunction in PD present a strong
rationale for continued research on parkin oxidation, misfolding, and degradation. This
thesis repeatedly provides evidence that oxidative stress, regulation by PINK1, protein
misfolding, UPS-mediated degradation, and the protein quality control machinery work in
tandem to regulate both parkin function and dysfunction. Future research based upon our
findings and using our yeast model will further determine the underlying genetic, cellular,
and molecular mechanisms by which parkin contributes to PD and may also establish
parkin misfolding as a promising therapeutic target for PD treatment.
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Appendices
Appendix 1. Discussion of technical limitations.
Immunofluorescence Microscopy
The use of immunofluorescence microscopy to visualize subcellular localization of
proteins is powerful tool that eliminates the need to genetically modify the cells or cellular
proteins with fluorescent protein fusions. One limitation of immunofluorescence
microscopy is the availability of specific and effective antibodies required for proper
protein recognition. Parkin is a widely studied protein and there are several commercially
available antibodies recognizing different epitopes within parkin. In this study, four
different parkin antibodies were used that mapped to three different domains of the protein.
HeLa cells were chosen to transfect wild-type human parkin as the literature
suggests that they do not express any endogenous parkin. Untransfected HeLa cells were
used to test the specificity of these four parkin antibodies. These experiments showed that
all four of these parkin antibodies resulted in significant background staining. (Appendix
3). While the RING1 and Rcat/RING2 specific antibodies caused diffuse staining
throughout the cytosol of HeLa cells with varying degrees of intensity, the Ubl specific
antibody caused strong staining in the nucleus and weaker staining in the cytosol. It is
possible that the Ubl specific antibody, given the structural similarities of the Ubl domain
to ubiquitin, could be binding to ubiquitin or the ubiquitin-like protein SUMO in HeLa
cells which would account for the strong nuclear and weaker cytosolic staining (172).
Alternatively, HeLa cells might express parkin-like proteins or proteins with structurally
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similar epitopes to parkin, which may include other E3s. This would result in non-specific
binding of parkin antibodies in fixed HeLa cells. This speculation is supported by the fact
that Western blots performed with these antibodies did not elicit non-specific staining,
suggesting that these antibodies are not suitable for immunofluorescence microscopy.
Several attempts were made to decrease or eliminate non-specific signals. These
strategies included increasing blocking periods, increasing concentrations of BSA in the
blocking solution, adding goat serum to blocking solutions to prevent non-specific binding
of the secondary goat-derived antibodies, and decreasing primary and secondary antibody
incubation times. Despite all these efforts, the non-specific staining persisted even when
using all of the techniques described above in combination. This could bring into question
the specificity of these antibodies when probing for non-denatured proteins. Due to time
constrains, we were unable to rectify this problem and immunofluorescent images were
taken of cells expressing parkin at high enough levels to overcome the background staining.
To address this problem in the future, our protocol would need to be further optimized.
Additionally, the use of other commercially available parkin antibodies or a home-made
parkin antibody would be tested to determine if this issue was due to the specific antibodies
used in this study.
Parkin Protein Fusions
The use of fluorescent fusions or peptide epitope tags is an invaluable technique
that enables simple and easy identification of protein localization. Protein fusions can be
cloned onto proteins onto either the N- or C-terminus.
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Fluorescent protein fusions are used to visualize proteins in living cells. A concern
regarding using recombinant proteins with fluorescent fusions is the effects the fluorescent
fusion has on protein folding and stability. GFP is significantly larger than most peptide
epitope tags as it is a 238 amino acid protein and must adopt a proper three dimensional
fold in order to function. The beta barrel fold of GFP is also an extremely stable
conformation and can remain in cells for extensive periods of time after translation, even
if it is cleaved from a recombinant protein. The addition of stable fluorescent fusions like
GFP can also affect the stability of recombinant proteins. For these reasons the use of
fluorescent fusion proteins can raise concerns regarding the validity of results acquired
using these recombinant proteins when assessing protein function, folding and stability.
These concerns are particularly important when studying parkin. Structural studies
have shown that the C-terminal residue of parkin is buried within the hydrophobic core of
the Rcat/RING2 domain (60, 112) and the addition of large protein fusions at the Cterminal end of the protein may likely disrupt the fold of the Rcat/RING2 domain that is
required for parkin’s E3 ligase function. For this reason, many groups have chosen Nterminal fluorescent fusions when studying parkin localization in order prevent misfolding
and subsequent loss of function of the C-terminal domain. However, recently structural
findings have shown that the N-terminal Ubl domain of parkin is highly mobile and plays
a major role in regulating parkin activity (63) rendering N-terminal fusions problematic
regarding effects on parkin function.
For these reasons, in this study, we used unmodified parkin wherever possible to
avoid concerns regarding effects of protein fusions. All of our growth experiments were
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performed using both wild-type parkin and parkin-YFP which showed no difference in
growth with the exception of co-expression of PINK1 and parkin discussed in section
4.2.6.1. Although immunofluorescence can be done in yeast, due to time constrains of this
project, we chose to use fluorescently fused parkin, parkin point mutants, and parkin
truncation variants for localization studies in yeast. In our experiments, we observed drastic
changes in parkin localization caused by various parkin point mutations, truncations and
PINK1 co-expression. Notably, when assessing parkin localization using parkin point
mutants and truncation variants with C-terminal YFP fusions, our results were always
compared to a C-terminally YFP fused wild-type parkin as a control to ensure all changes
were due to changes to parkin itself or co-expression with PINK1. However, we cannot
definitively rule out that the fluorescent tags did not have an effect on parkin localization,
and may have stabilized mutant or truncated forms of the protein. To validate these results,
immunofluorescence would need to be performed to assess if point mutants, truncations,
and PINK1 co-expression have the same effects on untagged parkin.
Inhibiting Protein Degradation in Mammalian Cells
Before treating yeast cells with the proteasome inhibitor MG132 to test parkin
degradation and stability we first had to quench parkin expression. In yeast, this was
achieved by engineering parkin expression constructs under control of the galactoseinducible GAL1 promoter. Thus, by switching yeast cells to a glucose based media, parkin
transcription was attenuated. In mammalian cells however, inhibiting transcription of
parkin using cycloheximide also prevents translation of other cellular proteins. Therefore,
experiments testing parkin stability in mammalian cells probably did not yield the same
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results as those performed in yeast, which are likely due to alterations to many cellular
processes and potential cell death following prolonged exposure to cycloheximide. It is
also possible that the treatment with cycloheximide alters general cellular protein
expression so severely that the protein degradation machinery is stressed to a point that it
can no longer facilitate the same rate of parkin degradation that would occur under normal
conditions. This concern could be addressed by performing pulse chase experiments using
radio-labelled atoms that would eliminate the need to inhibit protein production while still
allowing the assessment of parkin degradation.
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Appendix 2. Comprehensive parkin sequence alignment.
SP|O60260|PRKN2_HUMAN
TR|Q7KTX7|Q7KTX7_DROME
SP|Q9WVS6|PRKN2_MOUSE
SP|Q9JK66|PRKN2_RAT
TR|F1NWU0|F1NWU0_CHICK
TR|H2QU08|H2QU08_PANTR
TR|F6U1L3|F6U1L3_MACMU
TR|I3N341|I3N341_ICTTR
TR|U3KCF7|U3KCF7_FICAL
TR|Q561U2|Q561U2_DANRE
TR|W4YQE2|W4YQE2_STRPU
TR|Q7Q591|Q7Q591_ANOGA
TR|C3Z502|C3Z502_BRAFL
TR|H3D789|H3D789_TETNG
TR|M3ZNV3|M3ZNV3_XIPMA
TR|A0A087XI83|A0A087XI83_POEFO
TR|A0A0A9XSY6|A0A0A9XSY6_LYGHE
TR|E0VIU9|E0VIU9_PEDHC
TR|T1H7C6|T1H7C6_MEGSC
TR|L7M1N2|L7M1N2_9ACAR
TR|V5GZV6|V5GZV6_IXORI
TR|V5IIZ0|V5IIZ0_IXORI
TR|H0ZGE3|H0ZGE3_TAEGU
TR|Q1WDP3|Q1WDP3_PIG
TR|H0X3U6|H0X3U6_OTOGA
TR|I3JJF6|I3JJF6_ORENI
TR|B8YGJ6|B8YGJ6_MACFA
TR|Q5J4W3|Q5J4W3_TAKRU
TR|U3FQA1|U3FQA1_CALJA
TR|G3N0R1|G3N0R1_BOVIN
TR|Q17DC3|Q17DC3_AEDAE
TR|G3PFJ2|G3PFJ2_GASAC
TR|E2BWM9|E2BWM9_HARSA
TR|A0A067RG71|A0A067RG71_ZOONE
TR|A0A0L0CIZ3|A0A0L0CIZ3_LUCCU
TR|A0A0F7Z269|A0A0F7Z269_CROAD
TR|A0A0B2UTN0|A0A0B2UTN0_TOXCA
TR|Q9XUS3|Q9XUS3_CAEEL

-------------------------------------MIVFVRFNSSHGFPVEVDSDTSI
-----MSFIFKFIATFVRKMLELLQFGGKT---LTHTLSIYVKTNTGKTLTVNLEPQWDI
-------------------------------------MIVFVRFNSSYGFPVEVDSDTSI
-------------------------------------MIVFVRFNSSYGFPVEVDSDTSI
-------------------------------------MIVFVRFNSSHGFPVELGLDASI
-------------------------------------MIVFVRFNSSHGFPVEVDSDTSI
--------------------------------------SVFVRFNSSHGFPVEVDSDTSI
---------------------------------------VFVRFNSSHGFPVEVDSDTSI
---------------------------------------VFVRFNSSHGFPVEVGLDSSI
-------------------------------------MIVFVRFNSSHGFPVELEQGASV
-------------------------------------------------MTVHINPSQNG
-----MFDLFGFIRQLIGSMLAIFSFGKKK---LSNSLSVYVKTNTGNTLAVDLEPHMDI
----------------------------------MSTFQVMVRFNSNHSFLVTVHTSWTI
-------------------------------------VPVIVRYNLGPEVVVEVQEEATV
-------------------------------------AAVFVRFNRGPGVAMELSAAARV
-------------------------------------VAVFVRFNRGPGVAVELSAAAHV
------MFLFDFFWSLWESLVHIMTFSRNP---QNNKLSIHVKSNTGNSVDVDLDPQWDI
------MSILEWFWNILCGMAQYLTFSKNL--TNDNLVNIYVKSNVGGTISVNLDPKSDI
-----MEFIFEFFRSFLNAMLALLSFGKKT---VKNTLNINVKTNDQ-VLNIELQKSRNL
-MAGALRSFLDALALFLWRRLAFLSFRLRQPETPMNEITINVRFSADLVIPLRLERDATA
MAASFLRWLLYVLASTFQRPLAFLRRGWPPPHVAMDEVTINVQFSTNLAISVTVKRDCTV
MAASFLRWLLYVLASTFQRPLAFLRRGWPPPHVAMDEVTINVQFSTNLAISVTVKRDCTV
---------------------------------------VFVRFNSSHGFPVEVGSDSSI
-------------------------------------MIVFVRFNSSHGFPVEVDSDTSI
---------------------------------------VFVRFNSSHGFPVEVDSDTSI
-------------------------------------FLPFLQFNLGPGVPVELQEEASV
-------------------------------------MIVFVRFNSSHGFPVEVDSDTSI
-------------------------------------MIVFVRYNLGPEVVVELQEEATV
-------------------------------------MLVFVRFNSSHGFPVEVDSDTSI
-------------------------------------MKVFVRFNSNHGFPVEVDSDTSI
-----MFDIVNFFKNLIYNMLAIFSFGRKK---LSNTLSIYVKTNTGNTLSVDLEPHMDI
-------------------------------------MIIYVRYNLGPCVPVELQEEASV
----------------------------------------------------------------MSFIINFIRKILQTMLQLVSVGKRT---ISNSLNVYIKTNTGCTLSVDLDPKWYI
-----MSFLINLIKAFIDKMLALLSFGSKT---ITNTLSIYVKTNTGRTLSVNLEPKWDI
-------------------------------------MIVFVRFNSSHGFPVEVDSDTSI
-------------------M-QLLVSVRNR------SQKHYAHLDRSMNLHIDVPSEGTI
---------------MSDEI-SILIQDRKT------G--------QRRNLTLNINITGNI

23
52
23
23
23
23
22
21
21
23
11
52
26
23
23
23
51
52
51
59
60
60
21
23
21
23
23
23
23
23
52
23
52
52
23
34
30
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SP|O60260|PRKN2_HUMAN
TR|Q7KTX7|Q7KTX7_DROME
SP|Q9WVS6|PRKN2_MOUSE
SP|Q9JK66|PRKN2_RAT
TR|F1NWU0|F1NWU0_CHICK
TR|H2QU08|H2QU08_PANTR
TR|F6U1L3|F6U1L3_MACMU
TR|I3N341|I3N341_ICTTR
TR|U3KCF7|U3KCF7_FICAL
TR|Q561U2|Q561U2_DANRE
TR|W4YQE2|W4YQE2_STRPU
TR|Q7Q591|Q7Q591_ANOGA
TR|C3Z502|C3Z502_BRAFL
TR|H3D789|H3D789_TETNG
TR|M3ZNV3|M3ZNV3_XIPMA
TR|A0A087XI83|A0A087XI83_POEFO
TR|A0A0A9XSY6|A0A0A9XSY6_LYGHE
TR|E0VIU9|E0VIU9_PEDHC
TR|T1H7C6|T1H7C6_MEGSC
TR|L7M1N2|L7M1N2_9ACAR
TR|V5GZV6|V5GZV6_IXORI
TR|V5IIZ0|V5IIZ0_IXORI
TR|H0ZGE3|H0ZGE3_TAEGU
TR|Q1WDP3|Q1WDP3_PIG
TR|H0X3U6|H0X3U6_OTOGA
TR|I3JJF6|I3JJF6_ORENI
TR|B8YGJ6|B8YGJ6_MACFA
TR|Q5J4W3|Q5J4W3_TAKRU
TR|U3FQA1|U3FQA1_CALJA
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FQLKEVVAKRQGVPADQLRVIFAGKELRNDWTVQNCDLDQQSIVHIVQRPWRKGQEMNAT
KNVKELVAPQLGLQPDDLKIIFAGKELSDATTIEQCDLGQQSVLHAIRLRPPVQR----LQLKEVVAKRQGVPADQLRVIFAGKELPNHLTVQNCDLEQQSIVHIVQRPRRRSHETNAS
FQLKEVVAKRQGVPADQLRVIFAGKELQNHLTVQNCDLEQQSIVHIVQRPQRKSHETNAS
LQLKEAVAQRQGVPADQLRVIFAGRELSNDLTLQNCDLVQQSIVHIVQNLQKNSD-KDET
FQLKEVVAKRQGVPADQLRVIFAGKELRNDWTVQHCDLDQQSIVHIVQRPWRKGQEMNAT
FQLKEVVAKRQGVPTDQLRVIFAGKELRNDWTVQNCDLDQQSIVHIVQRPRRKGQEMNAT
FQLKEVVAKRQGVPAGQLRVIFAGKELQNDLTVQNCDLEQQSIVHIVQRPRR-GPEADAP
LQLKEAVAQRQGVPADQLRVIFAGRELSNDLTLQNCDLAQQSIVHIVQSPQ-NSQNKEKT
SELKEAVGRLQGVQSDQLRVIFAGRELCNESTLQGCDLPEQSTVHVVLPPSTSAHRSELI
GELRSEVARLSGQSPADIRLVFAGKLIDDVQIMEDLRICENTMIHAVPAQRIQCHSDGPK
KDVKEMVAPRLGLEPQELKIIFAGRELSDTTTISECDLGQQSIIHVVKSRPTAITTPQKR
ARFKQEVGRTQGVPSGQIHILFAGRDLSDSLRIEDCQLGQQTVIHAISGLPQLSVDA--AELKEVVARQQGVQPERLRVLFAGRELKSTSTLQDCDLPEQSTVHVLVPPPAASSSKVHL
AELKEIVASQQGVPAQELRVLFAGRELQSSASLQGCDLPEHSTVHVVLPPPGSLHLPPPQ
AELKEIVGRQQGVPAQALRVLFAGRELQSSDSLQGCDLPDQSTVHVVLPPPGSIHLLPLGTLKEAIAPKIGLPADDMEIILAGKSLDDSTTIADCDLGEQSVLHAVKSHGQRQRRSRPL
KNVKELVAPKLGLEPDDVKIIFAGKELLDSTVIEVLDFFS-DILHAVKVNKKI------KK----SLLLLGITVEEIKIIFAGKELTDSTTIAECDLGNMSFLHAIKPRRNVQGQG--KDVKERLAEQLSLPVQEIRIIFAGKELLDHIAIKDYNVEEQTTVHAVRSANDGA-----Y
KAMKERLASQLDVPVQELRVIFAGKELRDDAYFKDCNIEEYTTVHAVRSAACATPGAEPV
KAMKERLASQLDVPVQELRVIFAGKELRDDAYFKDCNIEEYTTVHAVRSAACATPGAEPV
LQLKEAVAQRQGVPADQLRVIFAGRELSNDLTLQNCDLAQQSIVHIVESPQKNSQDKEKT
FQLKEVVAKRQGVPADQLRVIFAGKELRNDLTVQRCDLDQQSIVHVVLRPQRNGQERGVA
FQLKEVVAKRQGVPADQLRVIFAGKELRNDWTVQNCDLDQQSIVHIVQKPWRKGHEMAAT
AQLKEVVGSQQGVRPERLRVLFAGRELQSTATLQGSDLPEQSTVHVVLPPSGASSFQQLM
FQLKEVVAKRQGVPTDQLRVIFAGKELRNDWTVQNCDLDQQSIVHIVQRPRRKGQEMNAT
AELKEVVGQQQGVQPDLLRVLFAGRELKSTSTLQGCDLPEQSTVHIIVPSPASSSYKTLL
FQLKEVVAKRQGVPADQLRVIFAGKELRNDWTVQNCDLDQQSIVHIVQRPWRKGQESNAT
FQLKEVVARRQGVPADQLCVIFAGKELRNDWTVQSCDLDQQSIVHIVLRPRRKGPE---KDVKEIVAPQLGLAPGELKIIFAGKELSDTITISECDLGQQSIIHAVKARTIPKKVN--ADLQQLVGSQQGVHAELLRVLFAGRELKSSFTLQGCDLPEQSTVHVVLPKSAPTPGHLLL
----------MGMAAEDIKIIFAGKELHNSIVIEECDLGQQSTLHAVRNPHKKLKNQC-KDVKELVAPRLGLSPEEVKIIFAGKELHDSIVIEECDLGQQSILHAVRSHASHRKKP--KNVKEIVAPQLGLQPEEVKIIFAGKELSDATTIEECDLGQQSILHAIQARPVQQR----FQLKEAVAKRQGVPADQLHVIFAGKELRNDLTLKNCDLPQQSIVHIVQNRQKSENENPRSDVIEVLARRIKVSPNSFKIILCGKVLGGATSLHSLLLGPQTSLAAVVVDVSASDDKSAN
EDLTKDVEKLTEIPSDELEVVFCGKKLSKSTIMRDLSLTPATQIMLLRPKFNSHN-ENGA
. :::.*: :
.
.
: :
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83
82
83
82
80
80
83
71
112
83
83
83
82
111
104
104
114
120
120
81
83
81
83
83
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79
109
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48
109
107
82
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89
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GGDDPRNAAGGCEREPQSLTRVDLSSSVLPGDSVGLAVILHTDSRKDSPP------------QKI---QSATLEEEEPSLSDEASKPLNETLLDLQLESEER-L--------------GGDEPQSTSEGSIWESRSLTRVDLSSHTLPVDSVGLAVILDTDSKRDSEA---------GGDKPQSTPEGSIWEPRSLTRVDLSSHILPADSVGLAVILDTDSKSDSEA---------EDNHAGGILKTLERVPESLTRIDLSSSILPSLSAGLAVILDTKEPNISPP---------GGDDPRNAAGGCEREPQSLTRVDLSSSVLPGDSVGLAVILHTDSRKDSPP---------GGDNARNTAGGCEREPQSLTRVDLSSSVLPGDSVGLAVILHTDSRNDSPP---------GGDEPRTVLGGPEREPRSLTRVDLSSSVLPADSVGLAVVLDTGSRRDSTA---------EDSCIGGVPKTLKREPESLTRIDLSTSILPSVSAGLAVILDPGKNSVSLP---------Q-------QRRLGSGMESLTRLDLSSSRQTTASEGLAVILETEASRREDT---------------T-IKDEGVKPQPVH------------VLMESRIIDEDQRSPET----------QAKPAL---NATISEEPSPEEQQQHNKPLSETMSELTVLDERN-------------------------RSSAAAPRSLSDVQLNVRP-------------------------------L---QEHQARGEEEDHDSLTRLDLSSSRLTTTTSGLAVILERNGLGGVGATAGGGEAG-E-----H----LAASVTRLTRLDLSSSRLAAVATAAVQTT---------VLEGGGGDED------------AARGTRLTRLDLSSSRLAVLEG-----------------GRGGGDED---NQI---MSDLVEE---------NDALPATVSEIDEN-HDT-VQ---------------------------------KNVIPDKPLCETLEELHQLNDQK-NV------------------I---------STLTKKEDQPSKPLCETLPDLKLVNM------------------M-------------------DAEVQC-PLGEGII--TSQ--------------------V-------------------SAEMCCAPLGGSLAKGTRG--------------------V-------------------SAEMCCAPLGGSLAKA--Q--------------------EYSCVGGVPKALKREPESLTRIDLSTSILPSVSAGLAVILDPGKNSVSLP---------AGHR----PGRAGREPASLTRVDLSGSVLPGDAVGLAVILQDDSADGAAP---------GGDGPRSTTGGPGREPQSLTRVDLSSSLLPADSVGLAVILDTESRSDPPR---------Q-----E----H-RAEGSLTRLDLSSSRLPASSE-----------------GGGGGAEGGGDNARNTAGGCEREPQSLTRVDLSSSVLPGDSVGLAVILHTDSRNDSPP---------L---PEHLSQGEEENHDSLTRLDLSASRLPTTSSTLGVILERNDSEGVGATAGGGGAEAA
GGDNPRNAAGGCEREPQSLTRVDLSSSVLPGDSVGLAVILHTESRDDSPP----------GHSPRPAWGRSDREPESLTRVDLSSSMLPADSVGLAVILQDGEESGASS---------NGKTLL---ESPISEETL--EESTSTKPLCETLTDLQMTEVNE----------------L---RERLAGGGQEEGNSLARLDISSSRFPCTPPGLDGS------------NGGGG-EGA
-ASSSI---EE--YKSESSDLNESGSKPMNETLTDLSLDSSDQ-H-------------------------------GSESPSEGSKPLNETLMDLQLSDHER-RS----------------KRL---YSTVAEE-EP-SEEQPSKPLCETLVDLQLLSEER-S--------------------LLLSSNGREPTSLTRVDLSTNLLPSDSLGLAVILDNRIPI-------------A----------------------------------------------------------T-----------------------------------------------------------
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130
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140
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---------------AGSPAGRSIYNSFYVYCKGPCQ-----------RVQPGKLRVQCS
--------------NITDEERVRAKAHFFVHCS-QCD-----------KLCNGKLRVRCA
---------------ARGP-VKPTYNSFFIYCKGPCH-----------KVQPGKLRVQCG
---------------ARGPEAKPTYHSFFVYCKGPCH-----------KVQPGKLRVQCG
---------------SEK-SGAASYNSFYVFCKNFCQ-----------AVKPGKLRVRCN
---------------AGSPAGRSIYNSFYVYCKGPCQ-----------RVQPGKLRVQCS
---------------AGSPADRPIYNSFYVYCKGPCQ-----------RVQPGKLRVQCS
---------------ARGP-GRPTYNSFYVYCKGPCQ-----------GVQPGKLRVRCG
---------------SEKSAGAASYNSFYVFCKNFCQ-----------AVKPGKLRVRCS
---------------A-GHTGAKAHSSFYVFCKTVCK-----------AIQPGKLRVRCK
---------------PDVDLASSLHPSFYVYCKSHCR-----------SVQPGKLRVCCQ
--------------GDQSIPIGRTKAHFFVYCS-QCE-----------KVCTGKLRVRCG
---------------EGADTAAGSLPSYFVFCKRPCK-----------AVRPGKLRVRCG
NDGATPESGGEVQAAGVKGHSVHPRSTFFVYCKS-CK-----------SIQPGKLRVRCR
------QR--T---EQQAAAPKGVCSTFFVYCKR-CS-----------SIQSGKLRVRCR
------QR--T---EQQAAAPKG---TFFVYCKR-CS-----------SIQSGKLRVRCR
----------PSPADSDGKPQKPQQAHFYVYCA-TCMTNNLGNPTLPLKPKEGKLRVRCS
----------ESIEESNLKNEGKNKAHFFIYCANPCK-----------KINTGKLRVCCS
-----------------------RKAHFFVYC--QCK-----------KLCKGKLRVRCF
----------LTEEEHLARKTEADKALFFVYCKQPCD-----------RVLPGKLRVCCA
----------YTEEERLASTAEVDKTLFFVYCKSPCG-----------RVEPGKLRVRCA
----------LTEEERLASTAEVDKTLFFVYCKSPCG-----------RVEPGKLRVRCA
---------------SEKSAGAASYNSFYVFCKNFCQ-----------AVKPGKLRVRCS
---------------AGRPADRPTNKSFYVYCKGPCQ-----------RVQPGKLRVRCS
---------------AAGPAGRPVYNSFYVYCKGPCH-----------RVQPGKLRVQCN
------ES--LEEVQAVAHSSVRACSTFFVFCKS-CC-----------SIEPGKLRARCQ
---------------AGSPADRPIYNSFYVYCKGPCQ-----------RVQPGKLRVQCS
LGGDSADDRAVLQSAGAKDHSVRPRSTFFVYCKS-CK-----------LVQPGKLRVRCR
---------------AGSAAGRPVYNSFYVYCKGPCQ-----------KVQPGKLRVQCG
---------------ARRPAGRPTYNSFYVYCKGPCQ-----------GVQPGKLRVRCS
--------------KPGSPARERRKAHFFVYCS-QCE-----------KVCTGKLRVRCG
EGG----DREQVQAASLKVLCVRTCSTFFVYCKR-CK-----------SIQPGKLRVCCS
--------------NLSTEEQQDNRAHFYIYCPGPCK-----------IVTAGKLRVKCA
--------------VRTDEDRERKRAHFYVYCAWPCK-----------EMKLGKLRVRCA
--------------NIPEENRERSKAHFYVHCS-QCN-----------KLCKGKLRVRCS
----------------PPNNSEVKYSSFYVFCKSFCQ-----------AVKPGKLRVRCK
--------------SSSIDSNRTDVPSFHVFCKG-CN-----------SLAKGKLRVYCA
--------------TAKITTDSSILGSFYVWCKN-CD-----------DVKRGKLRVYCQ
:.: *
*
****. *

167
179
166
167
165
167
166
163
164
159
135
186
136
186
161
146
189
168
155
170
179
177
165
163
165
155
167
188
167
162
181
171
121
172
177
155
129
124

168

SP|O60260|PRKN2_HUMAN
TR|Q7KTX7|Q7KTX7_DROME
SP|Q9WVS6|PRKN2_MOUSE
SP|Q9JK66|PRKN2_RAT
TR|F1NWU0|F1NWU0_CHICK
TR|H2QU08|H2QU08_PANTR
TR|F6U1L3|F6U1L3_MACMU
TR|I3N341|I3N341_ICTTR
TR|U3KCF7|U3KCF7_FICAL
TR|Q561U2|Q561U2_DANRE
TR|W4YQE2|W4YQE2_STRPU
TR|Q7Q591|Q7Q591_ANOGA
TR|C3Z502|C3Z502_BRAFL
TR|H3D789|H3D789_TETNG
TR|M3ZNV3|M3ZNV3_XIPMA
TR|A0A087XI83|A0A087XI83_POEFO
TR|A0A0A9XSY6|A0A0A9XSY6_LYGHE
TR|E0VIU9|E0VIU9_PEDHC
TR|T1H7C6|T1H7C6_MEGSC
TR|L7M1N2|L7M1N2_9ACAR
TR|V5GZV6|V5GZV6_IXORI
TR|V5IIZ0|V5IIZ0_IXORI
TR|H0ZGE3|H0ZGE3_TAEGU
TR|Q1WDP3|Q1WDP3_PIG
TR|H0X3U6|H0X3U6_OTOGA
TR|I3JJF6|I3JJF6_ORENI
TR|B8YGJ6|B8YGJ6_MACFA
TR|Q5J4W3|Q5J4W3_TAKRU
TR|U3FQA1|U3FQA1_CALJA
TR|G3N0R1|G3N0R1_BOVIN
TR|Q17DC3|Q17DC3_AEDAE
TR|G3PFJ2|G3PFJ2_GASAC
TR|E2BWM9|E2BWM9_HARSA
TR|A0A067RG71|A0A067RG71_ZOONE
TR|A0A0L0CIZ3|A0A0L0CIZ3_LUCCU
TR|A0A0F7Z269|A0A0F7Z269_CROAD
TR|A0A0B2UTN0|A0A0B2UTN0_TOXCA
TR|Q9XUS3|Q9XUS3_CAEEL

TCRQATLTLTQGPSCWDDVLIPNRMSGECQSPHC----------PGTSA-EFFFKCGAHP
LCKGGAFTVHRDPECWDDVLKSRRIPGHCESLEVACV--DNAAGDPPFA-EFFFKCAEHV
TCKQATLTLAQGPSCWDDVLIPNRMSGECQSPDC----------PGTRA-EFFFKCGAHP
TCRQATLTLAQGPSCWDDVLIPNRMSGECQSPDC----------PGTRA-EFFFKCGAHP
ECKQGTLTLARGPSCWDDVLIPNRITGVCQSPDC----------SGNVA-EFYFKCGAHP
TCGQATLTLTQGPSCWDDVLIPNRMSGECQSPHC----------PGTSA-EFFFKCGAHP
TCRQATLTLTQGPSCWDDVLIPNRMSGECQSPHC----------PGTTAVRFFLRCGEHG
TCRQATLTLAQGPSCWDDVLIPNRMSGKCQSPGC----------PGTRA-EFFFKCGAHP
VCKQGTLTLARGPSCWDDVLIPNRIGGVCQSRGC----------TGNVA-EFYFKCGAHP
DCKQGTLTLSRGPSCWDDVLLPNRIHGVCQSQGC----------NGRLA-EFYLKCASHP
TCKDNAFIVKEDPVCWDDVILSNRISGSCFVPGC----------QGQKA-EFFFKCSSHA
ICGSGAFTVHRDPTCWDDVLKRKRITGHCENYEVPCV--ENDEGEPPFT-EFYFKCSEHS
TCRQTTLTLSRDPNCWEDVLVPGKIQGRCLSRGC----------PGTVA-EFYFKCADHH
SCRQTTLTLSRGPSCWDDVLLRNRLHGVCHSDGC----------HGTEA-EFYMKCARHP
RCRQMTLTLCRGPSCWDDVLLPGRIHGVCQFEGC----------HGNEA-EFYMKCASHP
RCRQMALTLSRGPSCWDDVLLPGRIHGVCQFEGC----------HGNEA-EFYMKCASHP
SCKSGAIQLDSDPASWSDVLERTRITGDCQEQGCS-------DGPVAWA-EFYFKCAEHV
ECKHGAFTVDTDPQSWADVLDKNKITGVCNNVG----------CEGLYA-KFYFKCASHP
KCKSGAFTVYKDPECWDDVLKPQRIHGLCEGNEESPC--TGNDNGLPYA-EFYFKCAEHS
SCGEGSFILQKDPSCWKDVLEPGRLLGQCQICH-----------QVRAA-RFFFKCTG-TCGQGCFLLDREPSCWPDVLERGRLGGRCEQEG----------CGGRLA-DFFFKCASSN
TCGQGCFLLDREPSCWPDVLERGRLGGRCEQEG----------CGGRLA-DFFFKCASSN
VCKQGTLTLARGPSCWDDVLIPNRIGGVCQSQGC----------NGNVA-EFYFKCGAHP
TCQQATLTLTQGPSCWDDVLIPNRMSGECQSPNC----------PGTTA-EFFFKCGAHP
TCKQATLTLAQGPSCWEDVLIPNRMSGECQSPNC----------PGTTA-EFFFKCGAHP
SCKQTTLTLSRGPSCWDDVLLPGRIHGICQSEGC----------QGNEA-EFYMKCASHP
TCRQATLTLTQGPSCWDDVLIPNRMSGECQSPHC----------PGTTA-EFFFKCGAHP
SCRQATLTLSRGPSCWDDVLLQSRVHGVCHSDGC----------HGTEA-EFYMKCASHP
TCRQATLTLTQGPSCWDDVLIPNRMSGECQSPNC----------PGTSA-EFFFKCGAHP
TCQQATLTLAQGPSCWEDVLIPNRMSGECQSPNC----------PGTRA-EFFFKCGAHP
ICKSGAFTVHRDPACWDDVLKKKRITGHCENYEIPCV--ENELGDPPFT-EFYFKCSEHS
SCRETTFTLSRGPSCWDDVLLPGRVHGFCQSDAC----------VGNEA-EFYMKCASHP
KCNSGAVTVDRDPQCWSDILEPNRITVHCENDFCPASSLSEEEFQVTYA-HFYFKCTRHV
SCRSGAFTVDRDPQCWDDVLEGRRITGDCQNDS---C--IGSDDGPKFA-EFYFKCFEHT
LCKGGAFTVHRDPECWDDVLKSRRIRGHCESLEIACV--DNDIGDPPFA-EFYFKCAEHI
TCKQGTLTLARDPSCWEDVLIPNSILGVCHYQNC----------SGEIA-EFYFKCGAHP
RCLSSSVVLKRDPEKWSDVLSSRAINAECEDCE-----------EETFA-KFCFKCVICD
KCSSTSVLVKSEPQNWSDVLKSKRIPAVCEECCT----------PGLFA-EFKFKCLACN
*
. :
* * *::
:
*
: * ::*
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T--SDKE-TSVALHLIATNSRNITCITCTDVRSPVLVFQCNSRHVICLDCFHLYCVTRLN
S-GGEKD-FAAPLNLIKNNIKNVPCLACTDVSDTVLVFPCASQHVTCIDCFRHYCRSRLG
T--SDKD-TSVALNLITSNRRSIPCIACTDVRSPVLVFQCNHRHVICLDCFHLYCVTRLN
T--SDKD-TSVALNLITNNSRSIPCIACTDVRNPVLVFQCNHRHVICLDCFHLYCVTRLN
T--TDSE-TSVALNLVTTNSRGITCITCTDIRSPVLVFQCMHRHVICLDCFHLYCVTMLN
T--SDKE-TSVALHLIATNSRNITCITCTDVRSPVLVFQCNSRHVICLDCFHLYCVTRLN
A--EDKS-LGHGLHLLPTKLRNVRNIFLSLCRSPVLVFQCNSRHVICLDCFHLYCVTRLN
T--SDKE-TSVALNLITTNSRDISCITCTDTRSPVLVFQCTHRHVICLDCFHLYCVTRLN
T--ADSE-TSVALNLVTTNSRCITCITCTDIRSPVLVFQCVHRHVICLDCFHLYCVTMLN
T--CDND-TSVALDLIMPNTRRVPCIACTDIMTPVLVFQCAERHVICLECFHLYCVSRLN
S--SVND-QFTVLPLVKTNTRRVICITCADILTSVLVFPCSASHVMCLDCFRQYCRLCLD
S-GGEKD-FAAPLSLIKTNHKNIPCIACTDTSETILVFPCVAGHVSCLDCFRQYCVTRLL
T--SEDD-TSVALPLVKSNTQSVDCLGCTDVRTPVMVFECADGHVMCLDCFARYCVTKLN
T--SDSD-HSVALDLIMTNSRDVPCIACADVVDVVLVFQCLERHVICLECFRHYCQVRVN
T--SEDD-VSVALDLVLSNTRSVPCIGCTDIRDVVLVFQCSDRHVICLDCFQRYCQTRLN
T--SEDD-VSVALDLVLSNTRGVPCIGCTDIRDVVLVFQCSDRHVICLDCFQRYCQTRLN
P-KSENESEAVPLYLIRANSRSTPCLACMDIMDTVIVFSCA--HTICLDCFNDYITSKIR
S-QGEND-TAVPLNLIKRNHKKIPCLACTDICDPVLVFSCDNRHVTCLECFKNYCGSRLK
L-GMEDD-FAAPLKLIRINEQNVPCLACMDVSETILVFPCELRHVTCLDCFLQYCRSRLL
KIGSHDDQVPIVLQLIRYNYLQVPCLACLDVSRLVLVFKCA--HVICLDCFRAYCRSRLD
RLEGHDQRGSTVLPLVRCNFLGVPCLSCTDVSRIVLVFPCTSSHVICLECFGTYCRSRLD
RLEGHDQRGSTVLPLVRCNFLGVPCLSCTDVSRIVLVFPCTSSHVICLECFGTYCRSRLD
T--TDSE-TSVALNLVTTNSRCITCITCTDIRSPVLVFQCVHRHVICLDCFHLYCVTMLN
T--SDKE-TSVALNLITTNSRDITCITCTDIRSPILVFQCNCRHVICLDCFHLYCVTRLN
T--SNKD-TSVALNLITTNSRDISCITCTDVRSPVLVFQCNYRHVICLDCFHLYCVTRLN
T--SDDD-FSVALDLIMTNTRGVPCIACTDVMGVVLVFQCLERHVICLDCFQRYCQTRLN
T--SDKE-TSVALHLIATNSRNITCITCTDVRSPVLVFQCNSRHVICLDCFHLYCVTRLN
T--SDND-HSVALDLIMTNSRDVPCIACTDVMDVVLVFECLERHVICLECFRHYCQVRLN
T--SDKE-TSIALHLIATNSRNITCITCTDVRSPVLVFQCNSRHVICLDCFHLYCVTRLN
T--SDKE-TSVALNLITTNSRDISCITCTDIRSPVLVFQCTHRHVICLDCFHLYCVTRLN
S-GGEKD-FAAPLNLIKTNHKDIPCIACTDTSDTVLVFPCEAGHVTCLDCFRQYCVSRLL
T--PEDE-VSVALDLIMTNSREVPCMACSDTTELVLVFQCAERHVICLHCFHRYCQTRLN
S-LGEDD-KVIPLYLIRANLRNVPCLACTDVRETVLVFPCEAHHVTCLDCFCEYCIVRLQ
S-QGEDD-QAVPLYLIKSNVRDVPCLACTDVSDPVLVFPCDLAHVTCLECFRAYCVARLR
S-GGEKD-FAAPLNLIKINIKDIPCLACTDVSDTVLVFPCESKHVTCIECFLHYCRSRLM
T--SDSE-TSVPLNLITTNTRYISCITCTDVRSPVLVFPCIHHHVICLDCFHLYCVTMLN
E-------VAVPLTHVRGYRGEGECSICGETALR-AVVDVGCHHETCVDCFTAYMETAFT
D-------PAAALTHVRGNWQMTECCVCDGK-EK-VIFDLGCNHITCQFCFRDYLLSQLE
* :
:.
* * ** *
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DRQFVHDP-QLGYSLPCVAGCPNSLIKELHHFRILGEEQYNRYQQYGAEECV-LQMGGVL
ERQFMPHP-DFGYTLPCPAGCEHSFIEEIHHFKLLTREEYDRYQRFATEEYV-LQAGGVL
DRQFVHDA-QLGYSLPCVAGCPNSLIKELHHFRILGEEQYTRYQQYGAEECV-LQMGGVL
DRQFVHDA-QLGYSLPCVAGCPNSLIKELHHFRILGEEQYNRYQQYGAEECV-LQMGGVL
DRQFIYDP-DLGYSLPCVAGCPDSLIKEVHHFRILGEEQYNRYQRYGAEECV-LQMGGLL
DRQFVHDP-QLGYSLPCVAGCPNSLIKELHHFRILGEEQYNRYQQYGAEECV-LQMGGVL
DRQFVHDP-QLGYSLPCVAGCPNSLIKELHHFRILGEEQYNRYQQYGAEECV-LQMGGVL
DRQFLHDP-QLGYSLPCVAGEQGEERFE-LHFRLLGQLQYNRYQQYGAEECV-LQMGGVL
DRQFIHDP-ELGYSLPCVAGCPDSLIKELHHFRILGEEQYGRYQRYGAEECV-LQMGGVL
ERQFTQET-LLGYSLPCAAGCPDSLIKEVHHFRVLGEEQYERYQRYAAEECV-LQMGGVL
ERRFIQSP-ELGYTLPCPAGCEDSLIKDTHHFLVLGKEQYARYKRFGTEEYL-LSEGGVL
ERQFVEHP-TGGYTLQCPAGCDNSFIEDVHHFKLLNKEQYERYQRFATEEFV-LKNGGVL
DRQFVQHA-SLGYTLPCPGGCDNSLIKEVHHFRMLGDEQYDRYQRFGAEECV-LQMGGVL
ERQFVYDA-AIGYSLPCAAGCTNSLIKEVHHFRILGENQYERYLQYGAEECL-LRNGGLM
ERQFIYDA-VIGYSLPCAAGCENSLIRELHHFRILGDNQYGRYQQYGAEECL-LTAGGVL
ERQFIYDA-VIGYSLPCAAGCENSLIRELHHFRILGDDQYGRYLQYGAEEFL-LTAGGVL
ERKFVLDD-DVGYSLLCPVGCEGSLITEIHHFRLLAPHLYNMYQQFATEDFV-LKSGGVL
DRQFLSHP-DFGYTLPCPAGCSNSFIEEVHHFRLLTDAQYEQYHRFATEEFI-LQAGGVL
ERQFMPHP-DIGYTLQCPTGCPDSFIDEIHHFKLLTPEEYDRYQMYATEEYV-LQAGGVL
ERAFVQHP-TLGWTLPCPVGCADSLIEESHHFYLLGSEQYQRYQRFAAEEWV-LQAGGVL
ERGFVQHP-QLGSTLPCPVGCDDSFIQETHHFCLLGPEQYQRYQRFAAEEFV-LQAGGVL
ERGFVQHP-QLGSTLPCPVGCDDSFIQETHHFCLLGPEQYQRYQRFAAEEFV-LQAGGVL
DRQFIHDP-ELGYSLSCVAGCPDSLIKELHHFRILGEEQYNRYQHYGAEECV-LQMGGVL
DRQFVHDP-QLGYSLPCVAGCPNSLIKELHHFRILGEEQYNRYQQYGAEECV-LQMGGVL
DRQFVHDP-QLGYTLPCVAGCPNSLIKELHHFRILGEEQYSRYQQYGAEECV-LQMGGVL
DRQFVYHP-VIGYSLPCAVGCDDSLIKEVHHFRILGDEQYGRYLQYGAEECL-LITGGMM
DRQFVHDP-QLGYSLPCVAGCPNSLIKELHHFRILGEEQYNRYQQYGAEECV-LQMGGVL
ERQFVYDP-DVGYSLPCAAGCINSLIKEVHHFRILGEHQYDRYLQYGAEECL-LRSGGLM
DRQFVHDP-QLGYSLPCVAGCPNSLIKELHHFRILGEEQYNRYQHYAAEECV-LQMGGVL
DRQFVHDP-QLGYSLPCVAGCPNSLIKELHHFRILGEEQYNRYQQYGAEECV-LQLGGVL
ERQFLEHP-SGGYTLQCPVGCESSYIEDVHHFKLLSKEQYERYQRFATEEFV-LRNGGVL
DRRFFSHP-VIGYSLPCAAGCADSLIKELHHFRILGDDQYGRYQKYGAEECL-LMNGGLM
ERQFQFDSVEGYYTLPCPAGCPDSFISEVHHFHLLNAELYNKYQRFGTEEYV-LRSGGFL
DRQFWSHP-EHGYTLPCPAGCKDSLITEVHHFRLLTPAQYAQYQRFATEEYV-LQAGGVF
ERQFMPHP-DIGYTLACPAGCENSFIEEIHHFKLLTREEYERYQRFATEEYV-LQAGGVL
NRQFVHDP-IFGYSLSCVASCPDSLIKELHHFRILGEEQYNRYQSYGAEEYV-LQMGGVL
QQQFFIRP-PYGYTLSCPVYGCRGCVTDVHLFYLLGKQRYSNYQTQATEKFVSLENEGIF
RFGFVNQP-PHGFTIFCPYPGCNRVVQDVHHFHIMGQTSYSEYQRKATERLIAVDDKGVT
*
:: *
:
* ::
* *
.:* : :
*.
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CPRPGCGAGLLP----------EPD--QRKVTCEGG-NGLGCGFAFCRECKEAYHEGECS
CPQPGCGMGLLV----------EPD--CRKVTCQ-----NGCGYVFCRNCLQGYHIGECL
CPRPGCGAGLLP----------EQG--QRKVTCEGG-NGLGCGFVFCRDCKEAYHEGDCD
CPRPGCGAGLLP----------EQG--QKKVTCEGG-NGLGCGFVFCRDCKEAYHEGECD
CPTPSCGAGLLP----------EPE--VRKIVCEPG-NGIGCGFVFCRECKEEYHEGECS
CPRPGCGAGLLP----------EPD--QRKVTCEGG-NGLGCGFAFCRECKEAYHEGECS
CPRPGCGAGLLP----------ESD--QRKVTCEGG-NGLGCGFAFCRECKEAYHEGECS
CPRPGCGAGLLP----------EAG--QRKVTCEAG-NGLGCGFVFCRDCKEEHHEGSCS
CPSPGCGAGLLP----------EPG--LRRIVCEPG-NGIGCGSVFCRECKEEFHEGECN
CPAPGCGAGLLP----------PDE--ERRVCCEPGNNGLGCGFVFCRDCKEEFHEGPCR
CPSPGCGAGILP----------ESD-GESRVECLQE-EGFGCGFVFCRNCHEAYHEGECG
CPQPGCGMGLLV----------DPE--CRRIQCQ-----NGCGYVFCRSCLQGYHIGECF
CPGRGCGVGLLP----------EGS--SNMVECVRQ-AGSGCGFVFCKLCKEAYHNGPCG
CPSPGCGAGLVP----------PDG--ARRVECDRQ---VGCGFVFCRNCREGYHEGVCP
CPSPGCGAGLLP----------PEG--SRKVECDRR--LLGCGFVFCRDCREGFHEGPCE
CPSPGCGAGLLP----------PEG--SRRVECDRR---LGCGFVFCRDCREGFHEGPCE
CPHPNCGMGIYP----------DDD--CDAVRC-------TCGYVFCKKCLQGNHIGDCD
CPQPGCGQGILI----------DQN--CNRVQC-------SCGYVFCGKCLEGFHLGECL
CPRPDCGMGLLI----------EPD--CKKVVCQ-----NGCGFVFCRDCLQGYHIGECN
CPRPGCGQGLLP----------EPG--CDRVKCD-----RGCGFVFCRLCLQGHHLGPCT
CPQPGCGQGILV----------DLG--CTRVTCEAA--TQGCGFVFCRLCLQGHHLGPCI
CPQPGCGQGILV----------DLG--CTRVTCEAA--TQGCGFVFCRLCLQGHHLGPCI
CPTPGCGAGLLP----------EPD--LRRIVCEPG-NGIGCGSVFCRECKEEFHEGECN
CPRPGCGAGLLP----------EPG--QRKVTCEGG-NSLGCGLVFCRDCKESYHEGECS
CPRPGCGAGLLP----------EPG--QRRVACERD-SGLGCGFVFCRECKEADHDGECS
CPSPGCGAGLVP----------PDG--SRKVECDRR---LGCGFVFCRLCRGEYHEGPCQ
CPRPGCGAGLLP----------ESD--QRKVTCEGG-NGLGCGFAFCRECKEAYHEGECS
CPSPGCGAGLVP----------PDD--SRRVECDRQ---IGCGFVFCRICREGYHEGGCL
CPRPGCGAGLLP----------EPD--QRKVTCEGG-NGLGCGFAFCRECKEAYHEGECS
CPGPGCGAGLLP----------EPG--QRKVSCEPG-HGLGCGFVFCRDCKEPYHEGDCG
CPQPGCGMGLLV----------DPE--CKRVQCQ-----NGCGFVFCRNCLQGYHIGECL
CPSPGCGAGLIP----------PDD--SRRVTCDRH---LGCGFVFCKCCREGYHEGACL
CPMPDCGMGIIPPTIEEQAEKDDDQ--RRRIQCI-----GGCGYVFCRLCLQGYHTGKCE
CPQPGCGMGIIA----------EPE--CRRITCT-----NGCGFVFCRQCLQGYHLGECV
CPQPGCGMGLLV----------EPD--CKKVTCQ-----NGCGYVFCRNCLQGYHLGDCL
CPTPGCGAGLLP----------ESE--MRKIVCEPR-NGLGCGFVFCRECKEEYHEGECH
CPYSGCGAAFLW----------EQDVTSPKVLCP------ECHRLFCGVCRREHCVC--CPNVSCGQSFFW----------EPYDDDGRSQCP------DCFFSFCRKCFERNCVC--**
** .:
*
*
** *
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AVFEAS---GTTT-QAYRVDERAAEQARWEA-AS-KETIKKTTKPCPRCHVPVEKNGGCM
PEGTGA---SATNSCEYTVDPNRAAEARWDE-AS-NVTIKVSTKPCPKCRTPTERDGGCM
SLLEPS---GATS-QAYRVDKRAAEQARWEE-AS-KETIKKTTKPCPRCNVPIEKNGGCM
SMFEAS---GATS-QAYRVDQRAAEQARWEE-AS-KETIKKTTKPCPRCNVPIEKNGGCM
SFLSTQ---GAVAQKGYVVDENAAMQARWEE-AS-KETIKKTTKPCPNCHIPVEKNGGCM
ALFEAS---GTTT-QAYRVDERAAEQARWEA-AS-KETIKKTTKPCPRCHVPVEKNGGCM
ALFEAS---GTTT-QAYRVDERAAEQARWEE-AS-KETIKKTTKPCPRCHVPVEKNGGCM
TLLEAS---AAAK-QAYRVDERAAEHARWEE-AS-KETIKRTTKPCPHCGVPVEKNGGCM
SLLSPQ---GAVA-QGYAVDEHAAMQARWEE-AS-RETIKKTTKPCPNCNIPVEKNGGCM
HTTSTA---SAGALQGYVVDEEAALRARWEQ-AS-QETITKTTHPCPKCQVPVEKNGGCM
QRIEEP---HGPRGSGSEVDMERERRARWESEES-KRTIGETSKPCPNCKVPVERNGGCM
ETPTPS---TPGNEQGYAIDPLRASEARWDE-AT-KIAIKVTTKPCPQCRTATERDGGCM
QTAPQP---SAPA-NNYRVDRDRARRARWER-RT-AATIERTTKACPGCKVRTEKNDGCM
TTQSQT---TAEASQDFVVDEEATLRARWDQ-AS-LLLLQESTKPCPKCSVPVERNGGCM
GPAAPP---PADACQGFVVEDEASQRGRWDR-AS-LQLILESTRRCPRCLVPVERNGGCM
GPAAPP---PGDACQGFVVGDEASQRGRWDL-AS-LQLIQESTRRCPRCLVPVERNGGCM
NAVDIL----TGLSPTYTIDPSRAAQSKWDE-AS-HRSIRAGTKPCPKCRTATERAGGCM
NPTDVP---FLSQNCDYPLDPEKLEKARWDE-AS-STVIKVLTKPCPKCRTSTERAGGCM
PEVNQI---DTTRSCEYSVNPNNAAEARWED-VSTAVTIKVSTKPCPKCRTPTERDGGCM
SSREAGEERAAGPRF------LAAQGSSWDE-AS-RLTVQATTKPCPKCRTPTERSGGCM
RDEEDEASAALGSVWAYPVDEAQARGSRWDE-AS-RLTVRSTTKPCPMCRTPTERDGGCM
RDEEDEASAALGSVWAYPVDEAQARGSRWDE-AS-RLTVRSTTKPCPMCRTPTERDGGCM
SLLSPP---GAMA-QGYVVDEHAAMQARWEE-AS-RETIKKTTKPCPNCNIPVEKNGGCM
ALFEAS---AAVA-QAYRVDQKAAEQARWEE-AS-KETIRKTTKPCPRCHVPVEKNGGCM
ALFEAS---GTVA-QAYRVDERAAEQARWEE-AS-KETIKQTTKPCPRCHVPVEKNGGCM
AVTAPP---TGEAAQGFVVGEEASLRGRWER-AS-LLVIAELTRRCPTCSVPVERNGGCM
ALFEAS---GTTT-QAYRVDERAAEQARWEE-AS-KETIKKTTKPCPRCHVPVEKNGGCM
ATQSQT---TAEGSQDFVVDEGASLRGRWDR-AS-LLLLQESTKPCPKCSAPVERNGGCM
ALSEAS---GTIP-QAYRVDERAAEQARWEE-AS-KETIKKTTKPCPRCHVPVEKNGGCM
AVIEAS---GTVT-QAYRVNEKAAEQARWEE-AS-KETIKKTTKPCPRCHVPVEKNGESG
ETPQPN---A-GAAPNYTIDPLRASEARWDE-AS-KIAIKVTTKPCPQCRTATERDGGCM
TEQAPP---IAESSQGFVVEEEASVKGRWDQ-AS-LLLLQETTKRCPQCSVPVERDGGCM
FQPLGAST-DVSSLRNYSVDPLRAKDAKWDE-AS-RKTIQVSTKPCPLCRTPTERDGGCM
HEGDGSGTSASTGDCQYNVDPGRAAQARWDE-AT-KVAIKVTTKPCPKCRTPTERAGGCM
PENGTG---NTTGSCEYAVDPNRAAEARWDE-AS-NVTIKVSTKPCPKCRTPTERDGGCM
SFFKCP---GATAQMGFEIDEHAAVRARWEG-AS-KETIKRTTKPCPKCHVPVEKDGGCM
-EEND---------------------------AT-ELTIKTTCHSCPTCGVPTERNGGCA
-QSED-------------------------D-LT-RTTIDATTRRCPKCHVATERNGGCA
:
:
: ** *
*:
.

432
450
431
432
431
432
432
427
429
426
403
457
401
450
426
410
451
429
427
427
450
448
430
428
430
419
432
452
432
427
451
435
407
443
448
421
360
356

173

SP|O60260|PRKN2_HUMAN
TR|Q7KTX7|Q7KTX7_DROME
SP|Q9WVS6|PRKN2_MOUSE
SP|Q9JK66|PRKN2_RAT
TR|F1NWU0|F1NWU0_CHICK
TR|H2QU08|H2QU08_PANTR
TR|F6U1L3|F6U1L3_MACMU
TR|I3N341|I3N341_ICTTR
TR|U3KCF7|U3KCF7_FICAL
TR|Q561U2|Q561U2_DANRE
TR|W4YQE2|W4YQE2_STRPU
TR|Q7Q591|Q7Q591_ANOGA
TR|C3Z502|C3Z502_BRAFL
TR|H3D789|H3D789_TETNG
TR|M3ZNV3|M3ZNV3_XIPMA
TR|A0A087XI83|A0A087XI83_POEFO
TR|A0A0A9XSY6|A0A0A9XSY6_LYGHE
TR|E0VIU9|E0VIU9_PEDHC
TR|T1H7C6|T1H7C6_MEGSC
TR|L7M1N2|L7M1N2_9ACAR
TR|V5GZV6|V5GZV6_IXORI
TR|V5IIZ0|V5IIZ0_IXORI
TR|H0ZGE3|H0ZGE3_TAEGU
TR|Q1WDP3|Q1WDP3_PIG
TR|H0X3U6|H0X3U6_OTOGA
TR|I3JJF6|I3JJF6_ORENI
TR|B8YGJ6|B8YGJ6_MACFA
TR|Q5J4W3|Q5J4W3_TAKRU
TR|U3FQA1|U3FQA1_CALJA
TR|G3N0R1|G3N0R1_BOVIN
TR|Q17DC3|Q17DC3_AEDAE
TR|G3PFJ2|G3PFJ2_GASAC
TR|E2BWM9|E2BWM9_HARSA
TR|A0A067RG71|A0A067RG71_ZOONE
TR|A0A0L0CIZ3|A0A0L0CIZ3_LUCCU
TR|A0A0F7Z269|A0A0F7Z269_CROAD
TR|A0A0B2UTN0|A0A0B2UTN0_TOXCA
TR|Q9XUS3|Q9XUS3_CAEEL

HMKCPQPQCRLEWCWNCGCEWNRVCMGDHWFDV--------------------------HMVCTRAGCGFEWCWVCQTEWTRDCMGAHWFG---------------------------HMKCPQPQCKLEWCWNCGCEWNRACMGDHWFDV--------------------------HMKCPQPQCKLEWCWNCGCEWNRACMGDHWFDV--------------------------HMKCPRPQCRFEWCWNCGLEWNRTCMGNHWFD---------------------------HMKCPQPQCRLEWCWNCGCEWNRVCMGDHWFDV--------------------------HMKCPQPQCRLEWCWNCGCEWNRVCMGDHWFDV--------------------------HMKCPQPQCRLEWCWNCGCEWNRTCMGDHWFDV--------------------------HMKCPRPQCRFEWCWNCGLEWNRTCMGDHWFD---------------------------HMVCPRPQCKFEWCWLCRVEWNRDCMGNHWFE---------------------------HMICSRTQCKYEWCWICGIEWNMGCLEDHWFGAGFLL----------------------HMVCTRSGCGFEWCWVCQTPWTRDCMAAHWFG---------------------------HMTCP--RCGFHWCWLCEREWGRNCQDRHWFGEGR------------------------HMQCP--LCKAEWCWLCGVFWNRECMGDHWFG---------------------------HMQCT--QCRAEWCWLCGAPWNRECMGNHWFG---------------------------HMQCT--QCRAEWCWLCGAPWNRECMGNHWFG---------------------------HMVCTR--CNFEWCWVCQISWTRSCMGSHWFG---------------------------HMICTRANCGFHWCWVCQGPWERDCMASHWFG---------------------------HMVCTRSGCDFEWCWICQTEWTRDCMGAHWFG---------------------------HMVCSRSQCGFQWCWLCQDEWTRQCMGAHWFG---------------------------HMICSRSQCGFQWCWLCQTEWSRNCMGAHWFG---------------------------HMICSRSQCGFQWCWLCQTEWSRNCMGAHWFG---------------------------HMKCPHPQCRFEWCWNCGLEWNRTCMGDHWFE---------------------------HMKCPQPQCQLEWCWNCGWEWNRDCMGDHWFDV--------------------------HMKCPQPQCRLEWCWNCGCEWNRVCMGDHWFDV--------------------------HMHCP--LCKAEWCWLCGVPWNRECMGNHWFGL--------------------------HMKCPQPQCRLEWCWNCGCEWNRVCMGDHWFDV--------------------------HMLCP--LCKAEWCWLCGVFWNRECMGDHWFG---------------------------HMKCPQPQCRLEWCWNCGCEWNRVCMGDHWFDV--------------------------LTEE----------RGCGGLSS---EGGREVGIYKGFLAGELSAGALGPSGQGLNLSTHV
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Appendix 3. Non-specific immunofluorescence signal in HeLa cells with parkin
antibodies. Untransfected HeLa cells were fixed and used for immunofluorescence with
A) a Cell Signaling parkin antibody B) an Abcam parkin antibody C) a Novus parkin
antibody or D) a Santa Cruz parkin antibody.
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Appendix 4. Supplementary figure data.
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Appendix 5. Growth curve of non-toxic protein expression in yeast.
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